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Megakaryoblastic	   Leukemia	   1	   (MKL1,	   MRTF-­‐A,	   MAL)	   is	   a	   transcriptional	   co-­‐activator	   of	  
Serum	   response	   factor	   (SRF)	   that	   promotes	   the	   expression	   of	   genes	   involved	   in	   cell	  
proliferation,	  motility,	  adhesion	  and	  differentiation-­‐processes.	   It	  thereby	  holds	  an	  essential	  
part	   in	   controlling	   fundamental	   biological	   processes	   like	   heart,	   cardiovascular	   system	   or	  
brain	  development.	  MKL1	  is	  inactive	  when	  bound	  to	  monomeric	  actin	  (G-­‐actin),	  thus	  nuclear	  
access	   is	   denied.	   However,	   signals	   that	   activate	   the	   small	   GTPase	   RhoA	   cause	   actin	  
polymerization	   (F-­‐actin)	   and	  MKL1	   dissociation	   from	   G-­‐actin,	   this	   way	   allowing	   successful	  
MKL1	  shuttling	  into	  the	  nucleus	  and	  conveying	  signals	  from	  RhoA	  into	  SRF	  activity.	  	  
Filamin	   A	   (FLNA)	   belongs	   to	   the	   group	   of	   actin-­‐binding	   proteins.	   It	   is	   indispensable	   for	  
filamentous	  F-­‐actin	  cross-­‐linking,	  thus	  contributes	  to	  cytoskeletal	  dynamics,	  cell	  mobility	  and	  
stability	  in	  a	  crucial	  way.	  	  
In	   this	   work,	   we	   found	   a	   new	   central	   mechanism	   of	   MKL1	   activation	   that	   is	   mediated	  
through	   its	   binding	   to	   FLNA	   as	   a	   novel	   interaction	   partner.	  We	  provide	   evidence	   that	   the	  
interaction	  of	  MKL1	  and	  FLNA	  is	  required	  for	  the	  expression	  of	  MKL1	  target	  genes	  and	  MKL1-­‐
dependent	  cell	  motility.	  We	  map	  MKL1	  and	  FLNA	  regions	  responsible	  for	  the	  interaction	  and	  
demonstrate,	   that	   cells	   expressing	   a	  MKL1	  mutant	   unable	   to	   bind	   FLNA	   showed	   reduced	  
expression	  of	  MKL1	   target	   genes	   and	   impaired	   cell	  motility.	   Furthermore	  we	   indicate	   that	  
induction	   and	   repression	   of	   MKL1	   target	   genes	   correlate	   with	   increased	   or	   decreased	  
quantity	   of	   the	  MKL1-­‐FLNA	   interaction.	  A	   dynamic	   flow	  was	   revealed,	   as	   lysophosphatidic	  
acid-­‐induced	   RhoA	   activity	   in	   primary	   human	   fibroblasts	   promoted	   the	   association	   of	  
endogenous	   MKL1	   with	   FLNA,	   whereas	   exposure	   to	   an	   actin	   polymerization	   inhibitor	  
dissociated	  MKL1	  from	  FLNA	  and	  decreased	  MKL1	  target	  gene	  expression	  in	  melanoma	  cells.	  	  
Thus	   FLNA	   binding	   to	   MKL1	   functions	   as	   a	   novel	   cellular	   transducer	   linking	   actin	  
polymerization	   to	   SRF	   activity,	   counteracting	   the	   known	   repressive	   complex	   of	  MKL1	   and	  
monomeric	  G-­‐actin,	  which	  advances	  to	  our	  mechanistic	  understanding	  of	  MKL1	  regulation.
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2.1	  Megakaryoblastic	  Leukemia	  1:	  A	  first	  look	  and	  brief	  history	  
Versatility	   and	   specificity	   in	   gene	   regulation	   is	   achieved	   with	   the	   association	   of	  
transcriptional	  co-­‐activators	  with	  specific	  DNA-­‐binding	  proteins.	  Megakaryoblastic	  Leukemia	  
1	  (MKL1,	  MRTF-­‐A,	  MAL)	   is	  a	  strong	  transcriptional	  co-­‐activator,	  which	  has	  been	  introduced	  
for	   the	   first	   time	   as	   a	   trigger	   for	   acute	   megakaryoblastic	   leukemia	   (AMKL),	   a	   rare	   and	  
aggressive	   form	   of	   childhood	   leukemia	   (Mercher	   T.,	   Coniat	   MB.	   et	   al,	   2001).	   AMKL's	  
signature	   trademark	   is	   the	   stoppage	   of	   thrombocytes	   development	   during	   the	   stage	   of	  
immature	   megakaryoblasts.	   Formation	   of	   a	   MKL1	   fusion	   protein	   (RBM15-­‐MKL1/	   RNA-­‐
binding	  motif	  protein	  15	  or	  OTT-­‐MAL/	  one-­‐twenty-­‐two-­‐myeloid	  acute	  leukemia)	  is	  expected	  
to	  be	   the	   cause.	   In	   contrast	   to	   regular	  MKL1,	  RBM15-­‐MKL1	  acts	   independently	  of	  G-­‐actin,	  
which	   naturally	   controls	  MKL1	   shuttling	  mechanism	   in	   and	   out	   of	   the	   nucleus.	   Therefore,	  
RBM15-­‐MKL1	   remains	   in	   the	   nucleus,	   resulting	   in	   a	   non-­‐stop	   stimulation	   of	   MKL1	   target	  
genes,	   thus	  promoting	   tumor	  progression	   (Descot	  A.,	   Rex-­‐Haffner	  M.	   et	   al,	   2008).	   Besides	  
the	   involvement	   of	   MKL1	   in	   acute	   megakaryoblastic	   leukemia,	   MKL1	   is	   also	   required	   for	  
tumor	   cell	   invasion	   and	   metastasis	   since	   knockdown	   of	   MKL1	   revoked	   cell	   invasion	   and	  
motility	  of	  human	  breast	  carcinoma	  and	  mouse	  melanoma	  cells	  (Medjkane	  S.,	  Perez-­‐Sanchez	  
C.	  et	  al,	  2009).	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Figure	  1:	  (Left)	  Thrombocytes	  development/stoppage	  at	  stage	  of	  immature	  megakaryoblastics	  (red	  circle)	  in	  
acute	  megakaryoblastic	  leukemia	  (AMKL).	  (Right)	  Formation	  of	  the	  RBM15-­‐MKL1-­‐fusion	  protein,	  which	  
remains	  in	  the	  nucleus.	  Taken	  from	  Mercher	  et	  al,	  2001;	  Posern	  et	  al,	  2008.	  
	  
2.2	   Serum	  Response	   factor	   (SRF):	   Engine	  of	   transcriptional	   activity	  
and	  director	  of	  elementary	  biological	  functions	  
Transcription	   factors	   mediate	   genetic	   execution	   in	   response	   to	   cellular	   signals,	   this	   way	  
playing	   major	   roles	   helping	   the	   cell	   adapting	   to	   changed	   demands.	   Serum	   response	  
transcriptional	  factor	  (SRF)	  which	  is	  activated	  by	  MKL1,	  directly	  regulates	  the	  transcription	  of	  
a	   large	   variety	   of	   genes	   involved	   in	   cell	   proliferation,	   cell	   motility,	   cell	   adhesion,	   cell	  
differentiation	   and	   organization	   of	   the	   cytoskeleton	   (Johansen	   FE.,	   Prywes	   R.,	   1995;	  
Treisman	  R.,	  1986).	  This	  way	  the	  MKL1/SRF	  complex	  obtains	  an	  essential	  part	  in	  controlling	  
fundamental	   biological	   processes	   like	   heart,	   muscle,	   cardiovascular	   system	   or	   brain	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development	  and	  its	  crucial	  necessity	   is	  strengthened	  by	  the	  early	  embryonic	  death	  of	  SRF	  
knockout	   mice	   (Arsenian	   S.,	   Weinhold	   B.	   et	   al,	   1998),	   malfunction	   in	   cardiac	   muscle	  
differentiation	  in	  transgenic	  mice	  containing	  dominant-­‐negative	  SRF	  mutants	  (Zhang	  X.,	  Chai	  
J.	  et	  al,	  2001;	  Zhang	  X.,	  Azhar	  G.	  et	  al,	  2001)	  and	  thin	  muscle	  fiber	  development	  in	  dominant	  
negative	  mutants	  of	  MKL1	  (Salvaraj	  A.,	  Prywes	  R.,	  2003).	  Furthermore,	  knockout	  of	  MKL1	  in	  
the	   brain	   caused	   morphological	   abnormalities	   and	   defects	   due	   to	   a	   failure	   of	   actin	  
polymerization	   and	   dysfunctional	   cytoskeletal	   organization	   resulting	   in	   impaired	   neuronal	  
migration	   (Mokalled	   MH.,	   Johnson	   A.	   et	   al,	   2010).	   The	   importance	   of	   the	   partnership	  
between	  MKL1	  and	  SRF	  is	  illustrated	  by	  the	  fact	  that	  SRF	  by	  itself	  is	  considered	  a	  rather	  weak	  
transcriptional	   factor	  not	  unfolding	   its	   full	   transcriptional	  diversity	   in	  before	  MKL1	  binding	  
(Spiegelman	  BM.,	  Heinrich	  R.,	  2004).	  	  
SRF	   belongs	   to	   the	   MADS-­‐box	   family	   of	   transcription	   factors,	   named	   after	   the	   founding	  
members	  MCM1,	  Agamous,	  Deficiens	  and	  SRF.	  As	  a	  unique	  characteristic,	  all	  members	  of	  the	  
MADS-­‐box	   family	   share	   the	   presence	   of	   a	  DNA	  binding	   domain	   (Pellegrini	   L.,	   Tan	   S.	   et	   al,	  
1995),	   mediating	   SRFs	   large	   variety	   of	   biological	   effects.	   Examining	   its	   evolution,	   the	  
importance	  of	  this	  sequence	  for	  SRF	  clarifies,	  reflected	  in	  a	  high	  degree	  of	  conservation	  in	  all	  
eukaryotic	   kingdoms.	   SRF	   conveys	   gene	   expression	   via	   binding	   to	   this	   highly	   conserved	  
sequence	  of	  nucleotides	  named	  serum	  response	  element	  (SRE)	  or	  CArG	  box	  (CC	  AT-­‐rich	  GG)	  
due	   to	   the	   conservation	   of	   the	   central	   A/T	   rich	   region	   and	   the	   flanking	   C-­‐G	   base	   pairs	  	  
(Pellegrini	  L.,	  Tan	  S.	  et	  al,	  1995).	  The	  CArG	  box	  is	  found	  within	  the	  promoters	  of	  known	  SRF	  
target	  genes.	  SRF	  target	  genes	  involved	  in	  cell	  growth	  can	  often	  be	  distinguished	  from	  those	  
involved	  in	  myogenesis	  by	  the	  degree	  of	  their	  CArG	  box	  binding.	  For	  example	  CArG-­‐boxes	  in	  
the	  promoters	  of	  several	  muscle	  genes	  differ	  more	  from	  the	  consensus	  sequence	  then	  those	  
which	  are	  involved	  in	  cell	  growth,	  resulting	  in	  a	  reduction	  in	  SRF-­‐binding	  affinity	  (Chang	  PS.,	  
Li	  L.	  et	  al,	  2001).	  	  
Representable	  and	  fine	  described	  SRF	  targets	  are	  the	  connective	  tissue	  growth	  factor	  (CTGF)	  
(Muehlich	   S.,	   Cicha	   I.	   et	   al,	   2007;	   Hinkel	   R.,	   Trenkwalder	   T.	   et	   al.,	   2014),	   Integrin	   alpha-­‐5	  
(ITGA5)	   (Muehlich	  S.,	  Hampl	  V.	  et	  al,	  2012)	  and	  Transgelin	   (SM22)	   (Olson	  E.,	  Nordheim	  A.,	  
2010).	   All	   three	   of	   them	  were	   frequently	   used	   in	   this	   work,	   showing	   prime	   examples	   for	  
MKL1	  activity.	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CTGF	  belongs	  to	  the	  family	  of	  subset	  ECM	  proteins,	  known	  as	  matricellular	  proteins.	  Besides	  
serving	  as	  a	  scaffold	  for	  arranging	  cells	  in	  tissue,	  the	  extracellular	  matrix	  (ECM)	  behaves	  as	  a	  
multifunctional	   cellular	   regulator.	   ECM	   proteins	   are	   able	   to	   modulate	   the	   activity	   of	  
extracellular	   signaling	   molecules	   such	   as	   growth	   factors	   or	   inflammatory	   cytokines.	  
Matricellular	   proteins	   in	   particular	   serve	   primarily	   regulatory	   rather	   than	   structural	   roles.	  
CTGF	   itself	   exercises	   important	   roles	   in	   lots	   of	   biological	   processes,	   for	   example	   cell	  
adhesion,	  migration	  or	  proliferation	  but	  also	  tissue	  wound	  healing	  and	  injury	  repair,	  where	  
its	   expression	   is	   highly	   increased	   (Chen	   C-­‐C.,	   Lau	   LF.,	   et	   al,	   2009).	   Deregulation	   of	   its	  
expression	  or	  activity	  contributes	  to	  inflammation	  and	  mediation	  of	  metastasis	  to	  the	  bone	  
in	   breast	   cancer,	   which	   makes	   it	   an	   interesting	   target	   for	   future	   therapeutic	   drug	  
administration	   (Muehlich	   S.,	   Cicha	   I.	   et	   al,	   2007),	   while	   expression	   levels	   are	   low	   under	  
physiological	  conditions.	  It	  also	  may	  enhance	  tumor	  growth	  through	  their	  potent	  angiogenic	  
activity	  (Shimo	  T.,	  Nakanishi	  T.,	  et	  al,	  2001).	  Accordingly,	  expression	  of	  CTGF	  in	  breast	  cancer	  
cells	  enhances	  microvessel	  density	  of	  xenograft	  tumor	  in	  mice	  (Yin	  D.,	  Chen	  W.	  et	  al,	  2010).	  
Consistently,	  xenograft	  tumor	  growth	  is	  inhibited	  by	  silencing	  CTGF	  expression	  in	  cancer	  cells	  
of	  prostate	  and	  pancreas	  (Bennewith	  KL.,	  Huang	  X.,	  et	  al,	  2009).	  
Integrins	   are	   transmembrane	   receptors	   that	   are	   bridges	   for	   cell-­‐cell	   and	   cell-­‐extracellular	  
matrix	   (ECM)	  attachment.	  They	  are	   found	   in	  multiple	   tissues	  and	  cells	  and	  when	  triggered	  
activate	  chemical	  pathways	  to	  the	  interior.	  This	  allows	  rapid	  and	  flexible	  response	  to	  events	  
at	  the	  cell	  surface.	  Similar	  to	  CTGF,	  raised	  ITGA5	   levels	  take	  place	  in	  a	  multitude	  of	  disease	  
patterns	  	  (Arosio	  D.,	  Casagrande	  C.	  et	  al,	  2012).	  
Transgelin	   (SM22)	   is	   an	   actin	   binding	   protein,	   which	   is	   plentifully	   expressed	   in	   smooth	  
muscle	  cells	   (SMC)	   (Sayar	  N.,	  Karahan	  G.	  et	  al,	  2015).	  Smooth	  muscle	  can	  be	   found	  within	  
the	  walls	  of	  blood	  vessels	  such	  as	  arteries	  and	  veins	  but	  also	  in	  the	  urinary	  bladder,	  uterus,	  
gastrointestinal	   tract	   and	   in	   the	   iris	  of	   the	  eye.	   In	   contrast	   to	   skeletal	   and	   cardiac	  muscle,	  
smooth	  muscle	  tissue	  tends	  to	  demonstrate	  higher	  elasticity.	  This	  ability	  to	  stretch	  and	  still	  
maintain	  contractility	  is	  important	  to	  organs	  like	  the	  urinary	  bladder.	  It	  has	  been	  shown,	  that	  
SM22	  is	  increased	  in	  gastric	  and	  colon	  cancer	  (Li	  N.,	  Zhang	  J.	  et	  al,	  2007;	  Lin	  Y.,	  Buckhaults	  PJ.	  
et	  al,	  2009).	  	  
In	  summary	  SRF	  acts	  as	  a	  docking	  platform	  for	  diverse	  signal	  regulated	  and	  cell	  type	  specific	  
cofactors	  triggering	  their	  distinct	  responses.	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2.2.1	  Serum	  Response	  factor	  (SRF):	  Two	  different	  pathways	  of	  activation	  
SRF	  stimulation	  is	  achieved	  via	  two	  parallel	  but	  independent	  signaling	  pathways	  that	  involve	  
mitogen-­‐activated	   protein	   (MAP)	   kinase/TCF	   on	   the	   one	   hand	   and	  Rho/actin	   dynamics	   on	  
the	  other.	  
2.2.1.1	  The	  ternary	  complex	  factor	  (TCF)	  dependent	  signaling	  pathway	  
First,	   stimulation	   with	   extracellular	   stimuli	   (serum,	   LPA,	   growth	   factors)	   leads	   to	   direct	  
phosphorylation	   of	   the	   ternary	   complex	   factors	   (TCFs)	   by	   the	   three	  major	   groups	   of	  MAP	  
kinase	   (Extracellular	   signal	  Regulated	  Kinase	   (ERK),	   c-­‐Jun	  N-­‐terminal	  Kinase	   (JNK)	   and	  p38)	  
(Sotiropoulos	  A.,	  Gineitis	  A.	  et	  al,	  1999).	  Next,	  phosphorylated	  TCFs	  bind	  SRF	  to	  trigger	  the	  
expression	  of	  target	  genes.	  The	  TCFs	  act	  as	  transcriptional	  co-­‐activators	  and	  are	  composed	  
of	  Elk-­‐1,	   SAP-­‐1	  and	  Net	  which	  belong	   to	   the	  Ets	  group	  of	   transcription	   factors,	  one	  of	   the	  
largest	  family	  of	  transcription	  factors	  (Sharrocks	  AD.,	  2001).	  Ets	  domain	  transcription	  factors	  
recognize	  an	  Ets	  Binding	  Site	  (EBS)	  which	  flanks	  the	  CArG	  boxes	  and	  which	  is	  required	  for	  the	  
ternary	  complex	  formation	  between	  TCFs	  and	  SRF	  (Treisman	  R.,	  1995).	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2.2.1.2	  The	  Rho-­‐actin	  signaling	  pathway	  and	  cytoskeleton	  actin	  dynamics	  
The	  second	  SRF	  activating	  pathway	  involves	  the	  small	  GTPase	  RhoA	  of	  the	  Rho	  family,	  which	  
belongs	  to	  the	  Ras	  superfamily	  of	  GTP-­‐binding	  proteins.	  Activation	  of	  growth	  factors	  as	  well	  
as	  G-­‐protein	  coupled	  receptors	  and	  integrins	  result	  in	  the	  activation	  of	  RhoA	  GTPase	  (Olson	  
EN.,	   Nordheim	   A.	   et	   al,	   2010).	   A	   fundamental	   characteristic	   of	   RhoA	   is	   the	   capability	   of	  
controlling	  actin	  assembly	  in	  response	  to	  extracellular	  signals	  (Vartiainen	  MK.,	  Guettler	  S.	  et	  
al,	   2007).	   RhoA	   has	   been	   described	   to	   be	   involved	   in	   plenty	   of	   cellular	   processes	   such	   as	  
cytoskeleton	  organization,	  gene	  transcription,	  cell	  migration	  and	  cell	  growth	  (Jaffe	  AB.,	  Hall	  
A.,	  2005).	  Rho/RhoA	  are	  able	  to	  act	  as	  a	  molecular	  switch	  by	  converting	  external	  indications	  
to	   intracellular	   signaling	  pathways.	  This	  happens	  due	   to	   shuttling	  between	  an	  active,	  GTP-­‐
bound	  and	  an	  inactive,	  GDP-­‐bound	  state.	  Rho/RhoA	  activation	  is	  promoted	  by	  GEF	  (guanine	  
nucleotide	  exchange	  factor),	  which	  catalyzes	  the	  exchange	  of	  GDP	  to	  GTP	  (Jaffe	  AB.,	  Hall	  A.,	  
2005).	  On	  the	  other	  hand,	  GAP	  (GTPase	  activating	  protein)	  stimulates	  Rho	  GTPase	  activity	  to	  
hydrolyze	  bound	  GTP.	  Thus,	  the	  activity	  of	  Rho	  GAP	  promotes	  the	  return	  of	  Rho	  GTPases	  in	  
their	  inactive	  GDP	  bound	  state	  (Jaffe	  AB.,	  Hall	  A.,	  2005).	  
First	  proof	  of	  a	  secondary,	  TCF-­‐independent	  activation	  of	  SRF	  was	  recorded	  by	  the	  findings	  
that	   mutation	   of	   the	   TCF-­‐binding	   site	   within	   target	   gene	   promoters	   did	   not	   completely	  
abolish	   the	   serum-­‐induced	   activation	   of	   the	   promoter	   (Hill	   C.,	   Wynne	   J.	   et	   al,	   1994).	  
Furthermore,	   SRF	   activation	   was	   blocked	   by	   Rho	   inhibition	   and	   activated	   upon	  
microinjection	  of	  active	  RhoA	  (Hill	  C.,	  Wynne	  J.	  et	  al,	  1995).	   In	  1999,	  Sotiropoulos	  A.	  et	  al.	  
brought	   up	   cytoskeleton	   actin	   dynamics	   and	   linked	   it	   successfully	   to	   Rho/RhoA	   signaling.	  
Actin	   is	  a	  highly	  conserved,	  42kDa	   large	  structure	  protein,	  which	   is	  ubiquitary	  expressed	   in	  
eukaryotic	   cells	   (Olson	   EN.,	   Nordheim	   A.	   et	   al,	   2010).	   Sotiropoulos	   et	   al	   showed	   that	  
Rho/RhoA	   signaling	   leads	   to	   the	   accumulation	   of	   filamentous	   actin	   (F-­‐actin)	   through	   both	  
filament	  stabilization	  and	  de	  novo	  polymerization.	  This	  led	  to	  stimulation	  of	  the	  SRF	  signaling	  
process.	   Combined	   with	   depletion	   of	   cellular	   monomeric	   G-­‐actin	   levels,	   first	   evidence	   of	  
direct	   influence	   of	   actin	   treadmilling	   to	   SRF	   activity	   was	   given,	   which	   was	   highlighted	   by	  
Posern	   G.	   et	   al	   (2002),	   who	   indicated	   that	   overexpression	   of	   non-­‐polymerizable	   actin	  
mutants	   showed	  no	   success	   in	   activating	   SRF.	   In	   general,	   the	   actin	   circuit	   is	   subject	   to	   an	  
ongoing	   process	   of	   polymerization	   and	   decay	   (Holmes	   KC.,	   Popp	   D.	   et	   al,	   1990).	   This	  
sensitive	  cycle	   is	  controlled	  by	  the	  ATPase	  activity	  of	  actin	   in	  a	  crucial	  manner.	  ATP-­‐bound	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monomeric	  actins	  are	  getting	  linked	  to	  actin	  filaments,	  followed	  by	  ATP	  hydrolysis,	  while	  in	  
contrast	  ADP-­‐bound	  actins	  remain	  in	  their	  monomeric	  state.	  	  
In	  variation	  to	  cytoplasmic	  actin,	  which	   is	   investigated	   in	  great	  detail,	  mystery	  still	   remains	  
about	   functions	  of	  nuclear	  actin.	  Recently	   it	  has	  been	  shown	  that	  nuclear	  and	  cytoplasmic	  
actin	  pools	  are	  in	  dynamic	  communication	  (Dopie	  J.,	  Skarp	  KP.	  et	  al,	  2012).	  On	  the	  one	  hand	  
Dopie	  J.	  et	  al	  used	  fluorescence	  loss	  in	  photobleaching	  (FLIP)	  to	  address	  nuclear	  actin	  export	  
and	  showed	  that	  most	  GFP-­‐actin	   is	  subject	   to	  rapid	  nuclear	  export,	   setting	  nuclear	  G-­‐actin	  
availability	   as	   a	   standard	   for	   export	   rate.	   On	   the	   other	   hand	   fluorescence	   recovery	   after	  
photobleaching	  (FRAP)	  indicated	  a	  rapid	  G-­‐actin	  import	  recovery	  phase	  followed	  by	  a	  slower	  
phase	   corresponding	   to	   reincorporation	   of	   actin	   into	   stable	   nuclear	   complexes.	   In	   2013,	  
Baarlink	  C.	  et	  al	  expanded	  the	  current	  actin	  paradigm	  by	  presenting	  an	  new	  model	  in	  which	  
the	   formin	   mDia,	   an	   effector	   of	   Rho	   GTPase	   does	   not	   only	   force	   cytoplasmic,	   but	   also	  
nuclear	   actin	   polymerization	   in	   fibroblasts	   after	   serum	   stimulation	   (Baarlink	   C.,	   Wang	   H.,	  
Grosse	   R.,	   2013).	   They	   further	   advanced	   to	   our	   knowledge	   by	   pointing	   out	   that	   nuclear-­‐
targeted	  mutants	  of	  mDia	  proteins	  inhibit	  MKL1	  activation	  without	  affecting	  cytoplasmic	  F-­‐
actin.	   This	   way	   they	   suggested	   that	   MKL1	   activation	   requires	   active	   nuclear	   actin	  
polymerization	   rather	   then	   simple	   equilibration	   of	   cytoplasmic	   and	   nuclear	   actin	   pools.	  
Taken	   together,	   recent	   findings	   support	   actin	   dynamics	   regulating	   SRF	   gene	   activity	   with	  
comparable	  results	  regardless	  of	  whether	  positioned	  to	  the	  cytoplasm	  or	  nucleus.	  
Previously	   it	   has	   been	   shown	   that	   nuclear	   actin	   is	   also	   connected	   to	   virus	   infection,	   e.g.	  
herpes	   simplex	   virus	   (HSV)	   (Roberts	   KL.,	   Baines	   JD.,	   2011).	   Kokai	   E.	   et	   al	   (2013)	   further	  
demonstrated	   that	   overexpression	   of	   nuclear	   wild-­‐type	   actin	   reduced	   the	   percentage	   of	  
HSV-­‐infected	  cells.	  Under	  physiological	  conditions	  instead,	  actin	  levels	  are	  kept	  low	  in	  most	  
cell	  types,	  thereby	  preventing	  nuclear	  F-­‐actin	  generation.	  Cell	  stimulation	  with	  various	  stress	  
factors	  including	  ATP	  depletion	  and	  neurodegenerative	  stimuli	  (Domazetovska	  A.,	  Ilkovski	  B.	  
et	   al,	   2007)	   lead	   to	   F-­‐actin	   polymerization	   favoring	   conditions	   and	   nuclear	   resident	   actin	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2.2.1.3	  SRF	  activating	  pathways	  in	  comparison:	  A	  competition	  for	  cell	  development	  
As	   it	  has	  been	  described	   in	  2.2.1.1	  and	  2.2.1.2,	  both	  the	  Rho-­‐actin-­‐MKL1	  pathway	  and	  the	  
TCF	   cascade	   lead	   to	   SRF	   activation	   and	   contact	   the	   same	   surface	   on	   SRF	   in	   an	   exclusive	  
manner	  (Wang	  Z.,	  Wang	  DZ.	  et	  al,	  2004).	  	  
Growth	   promoting	   factors	   induce	   TCFs,	   which	   are	   able	   to	   dislocate	   MKL1	   from	   SRF	  
suggesting	   that	   TCF	  binding	  might	  block	   activation	  by	   these	   co-­‐activators	   in	   a	   competitive	  
manner	   (Wang	   Z.,	   Wang	   DZ.	   et	   al,	   2004).	   Consistent	   with	   that,	   mutation	   of	   the	   TCF	   site	  
results	  in	  an	  increased	  activation	  rate	  by	  MKL1	  (Wang	  Y.,	  Falasca	  M.	  et	  al,	  1998).	  Since	  TCF	  is	  
activated	  by	  MAP	  kinase,	  this	  would	  allow	  growth	  signals	  to	  prefer	  TCF	  while	  differentiation	  
signals	  could	  favor	  MKL1.	   Interestingly,	   in	  case	  of	  smooth	  muscle	  cells,	   the	  replacement	  of	  
Myocardin	   (founding	  member	   of	   the	  MRTF/MKL1	   family,	   also	   see	   2.3)	   with	   the	   TCF	   Elk1	  
results	   in	   an	   overall	   repression	   of	   transcription,	   since	  Myocardin	   is	   a	   much	   more	   potent	  
transcription	   factor	   than	  Elk1	   (Wang	  Z.,	  Wang	  DZ.	  et	  al,	  2004).	  Further	   investigations	  have	  
shown	   that	   competition	   between	   Elk1	   and	   Myocardin	   in	   smooth	   muscle	   cells	   can	   be	  
characterized	   as	   switch	   among	  proliferation	   and	   differentiation	   upon	   extra	   cellular	   signals	  
(Wang	  Z.,	  Wang	  DZ.	  et	  al,	  2004).	  In	  case	  of	  muscle	  cell	  proliferation	  the	  TCF	  cascade	  is	  active	  
while	  the	  differentiation	  program	  controlled	  by	  Myocardin	  is	  off.	  
2.2.1.4	  Rho	  in	  cancer	  development	  and	  the	  tumor	  suppressor	  DLC1	  	  
There	   is	   a	   rising	   evidence	   that	   deregulated	   Rho	   GTPase	   signaling	   contributes	   to	   cancer	  
initiation,	   tumor	   progression	   and	   survival	   (Ahronian	   LG.,	   Zhu	   LJ.	   et	   al,	   2016;	   Kümper	   S.,	  
Mardakheh	   FK.	   et	   al,	   2016).	   This	   can	   often	   be	   determined	   in	   overexpressed	   Rho	   protein	  
levels	  (Sahai	  E.,	  Marshall	  CJ.,	  2002).	  Besides	  pro	  migratory	  properties,	  increased	  Rho	  GTPase	  
expression	   promoted	   the	   expression	   of	   pro-­‐angiogenetic	   factors	   facilitating	   tumor	  
vascularization	  (Turcotte	  S.,	  Desrosiers	  RR.	  et	  al,	  2003).	  This	  is	  key	  since	  tumor	  cells	  are	  not	  
able	   to	   grow	   without	   the	   appropriate	   blood	   vessel	   support.	   In	   addition	   to	   constitutive	  
activation	   of	   GEF,	   deletion	   of	   GAP	   is	   another	   mechanistic	   way	   to	   achieve	   Rho	   GTPase	  
overexpression.	   One	   important	   group	   of	   Rho	   GAP	   proteins	   in	   tumorigenesis	   is	   the	  
tumorsuppressor	   deleted	   in	   liver	   cancer	   (DLC1)	   protein	   family.	   Similar	   to	   other	   classical	  
tumorsuppressors	  like	  p53,	  which	  prevent	  tumor	  progression,	  downregulation	  or	  deletion	  of	  
DLC1	  has	  been	  discovered	   in	  many	  human	  cancers	   including	  breast,	   lung	  and	  colon	   (Guan	  
M.,	  Zhou	  X.	  et	  al,	  2006;	  Kim	  TY.,	  Jong	  HS.	  et	  al,	  2003;	  Seng	  TJ.,	  Low	  JS.	  et	  al,	  2007).	  Previously	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to	   this	   thesis	   our	   group	   provided	   evidence	   that	   loss	   of	   DLC1	   in	   hepatocellular	   carcinoma	  
(HCC)	   leads	   to	   activation	   of	   RhoA	   combined	   with	   an	   increased	   amount	   of	   actin	  
polymerization	  and	  MKL1	  activation	  (Muehlich	  S.,	  Hampl	  V.	  et	  al,	  2011).	  	  
	  
2.3	  Myocardin-­‐related	  transcription	  factors:	  A	  closer	  insight	  
Before	  identifying	  MKL1	  (2.1),	  Wang	  et	  al	  marked	  a	  novel	  group	  of	  transcriptional	  co-­‐
activators	  called	  the	  family	  of	  myocardin-­‐related	  transcription	  factors	  (MRTFs).	  The	  fact	  that	  
the	  ubiquitously	  expressed	  SRF	  is	  required	  for	  the	  expression	  of	  muscle	  genes	  suggests	  that	  
muscle-­‐specific	  SRF	  cofactors	  contribute	  to	  the	  muscle	  specificity	  of	  SRF	  target	  genes.	  
Myocardin,	  the	  founding	  member	  of	  this	  family	  was	  discovered	  in	  a	  bioinformatics	  screen	  for	  
murine	  cardiac	  specific	  genes	  and	  is	  particularly	  expressed	  in	  cardiac	  and	  smooth	  muscle	  
cells	  (Wang	  D.,	  Chang	  PS.	  et	  al,	  2001).	  In	  contrast,	  MKL1	  and	  the	  third	  member	  of	  the	  family,	  
MKL2	  (MAL16,	  MRTF-­‐B;	  Selvaraj	  A.,	  Prywes	  R.,	  2003)	  are	  spread	  out	  more	  widely	  in	  the	  
organism	  (Wang	  DZ.,	  Li	  S.	  et	  al,	  2002).	  
2.3.1	  Myocardin-­‐related	  transcription	  factors:	  Structure	  
The	   myocardin	   family	   proteins	   share	   a	   high	   degree	   of	   similarity	   in	   multiple	   regions.	   The	  
conserved	  N-­‐terminus	  contains	  three	  RPEL	  motifs	  (Arg-­‐Pro-­‐X-­‐X-­‐X-­‐Glu-­‐Leu),	  which	  represent	  a	  
novel	  binding	   structure	   for	  monomeric	  G-­‐actin	   thus	  maintaining	  MKL1	   in	   the	  cytoplasm	   in	  
un-­‐stimulated	  cells	  (Miralles	  F.,	  Posern	  G.	  et	  al,	  2003;	  Posern	  G.,	  Miralles	  F.,	  et	  al,	  2004).	   It	  
has	   been	   predicted	   that	   binding	   of	   the	   RPEL	   motif	   to	   G-­‐actin	   occurs	   competitively	   with	  
binding	   to	   the	   major	   G-­‐actin-­‐binding-­‐proteins	   profilin	   and	   thymosin	   ß4,	   as	   well	   as	   with	  
assembly	  of	  F-­‐actin	  (Dominguez	  R.,	  2004;	  Posern	  G.,	  Miralles	  F.,	  et	  al,	  2004).	  Profilin-­‐G-­‐actin	  
complexes	  are	  introduced	  into	  growing	  actin	  polymers	  by	  formins,	  this	  way	  profilin	  performs	  
a	  role	  of	  monomeric	  actin	  recruiting	  in	  the	  act	  of	  polymerization	  (Carlsson	  L.,	  Nyström	  LE.	  et	  
al,	  1977).	  Binding	  of	  G-­‐actin	  to	  thymosin	  ß4	  opposes	  this	  procedure	  by	  sequestering	  G-­‐actin.	  
Mouilleron	  S.	  et	  al.	  unveiled	  two	  crystal	  forms	  of	  the	  RPEL-­‐actin	  domain	  complex	  (2011).	  In	  a	  
pentavalent	   actin-­‐RPEL	   domain	   assembly,	   each	   of	   the	   three	   RPEL	  motif	   engages	   an	   actin	  
(RPEL-­‐actins,	  R1,	  R2,	  R3)	  and	  additionally	  two	  more	  actins	  are	  bound	  via	  RPEL2	  and	  RPEL3	  at	  
their	   N-­‐terminal	   extensions	   (spacer-­‐actins,	   S1,	   S2)	   while	   the	   trivalent	   complex	   in	   contrast	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only	  contains	  two	  RPEL-­‐	  and	  one	  spacer-­‐actin	  (R1-­‐S1-­‐R2).	  Moreover	  it	  has	  been	  shown	  that	  
RPEL3	  (R3)	  has	  the	  lowest	  actin-­‐binding	  affinity	  of	  the	  three	  RPEL	  motifs,	  which	  leads	  to	  the	  
conclusion	   of	   a	   more	   stable	   trimeric	   complex	   compared	   with	   the	   pentavalent	   one	  
(Mouilleron	   S.,	   Langer	   C.	   et	   al,	   2011).	   To	   highlight	   the	   important	   role	   of	   spacer-­‐actins	   for	  
MKL1	  localization,	  disruptions	  of	  both	  actin	  S1	  and	  S2	  contacts	  by	  introducing	  mutations	  in	  
spacer1	  and	  spacer2,	  resulted	  in	  effectively	  complete	  nuclear	  accumulation	  of	  MKL1	  in	  un-­‐
stimulated	  cells	   (Mouilleron	  S.,	   Langer	  C.	  et	  al,	  2011).	   In	  contrast,	  myocardin	   is	  exclusively	  
localized	  to	  the	  nucleus,	  which	  is	  likely	  due	  to	  sequence	  divergence	  of	  its	  RPEL	  domains	  and	  




Figure	  3:	  Model	  of	  the	  RPEL	  domain	  and	  binding	  to	  actin	  as	  a	  tri-­‐	  or	  pentavalent	  complex	  (Actin	  R1,R2,R3	  =	  
RPEL-­‐actins,	  Actin	  S1,S2	  =	  Spacer-­‐actins).	  Taken	  from	  Mouilleron	  S.,	  Langer	  C.	  et	  al,	  2011	  	  
Association	  of	  MKL1	  and	  its	  family	  members	  with	  SRF	  takes	  place	  through	  a	  basic	  region	  and	  
a	   glutamin-­‐rich	   domain	   (Wang	   D.,	   Chang	   PS.	   et	   al,	   2001;	   Cen	   B.,	   Selvaraj	   A.	   et	   al,	   2003).	  
Another	  important	  domain	  of	  the	  myocardin	  family	  is	  illustrated	  by	  a	  35-­‐amioacid	  long	  SAP	  
domain,	   named	   after	   SAF-­‐A,	   Acinus	   and	   Pias.	   Its	   main	   functions	   lies	   in	   DNA-­‐binding	   and	  
apoptosis	  (Aravind	  L.,	  Koonin	  EV.	  et	  al,	  2000).	  SAP	  deletion	  mutants	  showed	  to	  be	  defective	  
in	   simulating	   SRF	   activity	   on	   some	   promoters,	   which	   suggests	   a	   certain	   role	   of	   the	   SAP	  
domain	   regarding	   promoter	   specificity	   (Wang	   D.,	   Chang	   PS.	   et	   al,	   2001).	   Homo-­‐	   and	  
heterodimerization	  of	  MKL1	  is	  mediated	  by	  a	  leucine	  zipper	  (Wang	  D.,	  Chang	  PS.	  et	  al,	  2001)	  
and	  the	  C-­‐terminal	  TAD	  domain	  is	  responsable	  for	  activiation	  of	  transcriptional	  activity	  (Cen	  
B.,	  Selvaraj	  A.	  et	  al,	  2003).	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Figure	  4:	  Model	  of	  MKL1	  and	  its	  consisting	  domains	  
	  
2.3.2	  Myocardin-­‐related	  transcription	  factors:	  Subcellular	  localization	  	  
Following	  the	  findings	  of	  Sotiropoulos	  A.	  et	  al.	  that	  cytoskeleton	  actin	  dynamics	  are	  linked	  to	  
Rho	   signaling	   (1999),	   Miralles	   F.	   et	   al	   indicated	   a	   complex	   of	   MKL1	   and	   actin	   (2003).	  
Simultaneously,	  serum	  has	  been	  assigned	  to	  be	  the	  cause	  for	  translocation	  of	  MKL1	  from	  the	  
cytoplasm	  to	  the	  nucleus	  in	  NIH3T3	  fibroblasts	  (Miralles	  F.,	  Posern	  G.	  et	  al,	  2003).	  As	  already	  
mentioned	   in	   2.2.1.2,	   these	   results	   are	   further	   supporting	   thoughts	   that	   G-­‐actin	   binding	  
maintains	   MKL1	   in	   the	   cytoplasm.	   Consistent	   with	   that,	   depletion	   of	   G-­‐actin	   and	  
polymerization	   into	   F-­‐actin	   leads	   to	   a	   release	   of	   MKL1	   from	   the	   inhibitory	   complex	   and	  
translocation	  in	  the	  nucleus	  followed	  by	  SRF	  activation.	  	  
	  
Figure	  5:	  Model	  of	  the	  multiple	  roles	  for	  actin	  in	  MKL1	  regulation.	  (Right)	  Upon	  stimulation	  through	  RhoA	  
and	  serum,	  decreased	  export	  includes	  nuclear	  MKL1	  accumulation	  and	  abolished	  interaction	  with	  
monomeric	  G-­‐actin,	  which	  allows	  SRF	  activation.	  (Left)	  Serum	  starved	  conditions	  lead	  to	  increased	  nuclear	  
MKL1	  export	  and	  elevated	  levels	  of	  MKL1-­‐G-­‐actin	  association.	  Taken	  from	  Vartiainen	  M.,	  Guettler	  S.	  et	  al,	  
2007.	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In	   biochemistry	   the	   reversible	   process	   of	   phosphorylation,	   governed	   by	   kinases,	   and	   the	  
resulting	   phospho-­‐proteins	   are	   one	   of	   cells	  most	   important	   regulatory	   actions.	   Due	   to	   its	  
charge	  and	  polarity,	  phosphorylation	  leads	  to	  a	  change	  in	  protein	  conformation,	  resulting	  in	  
two	   different	   possible	   catalytic-­‐reactive	   protein	   forms.	   Thus,	   a	   protein	   can	   be	   either	  
activated	  or	  inactivated	  by	  phosphorylation.	  Phosphorylation	  only	  occurs	  at	  the	  side	  chains	  
of	  three	  amino	  acids,	  named	  serine,	  threonine	  and	  tyrosine.	  In	  a	  mechanistic	  way	  the	  amino	  
acids	  nucleophilic	  –OH	  group	  attacks	   the	  terminal	  phosphate	  group	  of	   the	  universal	  donor	  
ATP,	   resulting	   in	   a	   transfer	   of	   the	   phosphate	   group	   to	   the	   amino	   acid	   side	   chain.	   Many	  
transcription	  factors	  like	  SRF	  or	  G-­‐protein	  coupled	  receptors	  are	  activated	  this	  way	  (2.2.1.1).	  
Today,	   it	   is	   estimated	   that	  1/10	   to	  ½	  of	   all	   available	  proteins	   are	  phosphorylated	   in	   some	  
cellular	   state	   (Cohen	   AW.,	   Park	   DS.	   et	   al,	   2002).	   Therefore,	   understanding	   the	   state	   of	  
phosphorylation	   is	   essential	   for	   judging	   on	   cell	   status,	   especially	   regarding	   abnormal	  
phosphorylation	  and	  connected	  diseases.	  	  
Besides	   nuclear	   MKL1	   translocation,	   serum	   stimulation	   also	   leads	   to	   extracellular	   signal-­‐
regulated	  kinase	  1/2	  (ERK1/2)	  dependent	  phosphorylation	  of	  MKL1	  at	  serine	  454	  (Muehlich	  
S.,	  Wang	   R.	   et	   al,	   2008),	   also	   visible	   in	   a	  MKL1	  mobility	   shift	   in	   SDS-­‐Page.	   Nuclear	  MKL1	  
export	   is	   facilitated	   by	   MKL1	   phosphorylation	   through	   provoking	   MKL1-­‐G-­‐actin	   binding,	  
thereby	  working	   as	   a	   switch-­‐off	   for	  MKL1/SRF	   signaling,	   correlating	  well	  with	   target	   gene	  
repression.	   Furthermore	   a	   non-­‐phosphoryable	   MKL1	   mutant	   showed	   a	   constant	   nuclear	  
localization	  (Muehlich	  S.,	  Wang	  R.	  et	  al,	  2008).	  One	  expects	  that	  the	  nuclear	  export	  rate	   is	  
the	  determining	  factor	  for	  the	  subcellular	  localization	  of	  MKL1	  (Vartiainen	  MK.,	  Guettler	  S.	  et	  
al,	  2007)	  and	  that	  the	  phosphorylation	  this	  way	  is	  likely	  terminating	  induction	  of	  MKL1	  target	  
genes.	   This	   portrayed	   mechanism	   of	   nuclear-­‐cytoplasmic	   shuttling	   of	   MKL1	   is	   well	  
established	  for	  fibroblasts	  and	  muscle	  cells.	  
	  
Figure	  6:	  Model	  of	  nuclear	  MKL1	  export,	   initiated	  by	  a	   combination	  of	  MKL1	  phosphorylation	  and	  G-­‐actin	  
binding.	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2.4	  Filamin	  A:	  Rising	  of	  a	  new	  MKL1	  interaction	  partner	  
2.4.1	  The	  cytoskeleton:	  A	  cell	  stabilizer	  and	  more	  
A	   complex	   network	   of	   protein	   fibers	   in	   eukaryotic	   cells,	   the	   cytoskeleton	   provides	   rigid	  
structural	  support	  that	  is	  responsible	  for	  maintaining	  cell	  shape	  and	  stability.	  Paradoxically,	  
this	   rigid	  network	   is	   also	  highly	   active	   and	  dynamic,	   providing	   cells	  with	  plasticity	   and	   the	  
ability	   to	   respond	   to	   stimuli	   from	   the	   surrounding	  environment.	  Besides	   its	   effects	  on	   cell	  
firmness	   the	   cytoskeleton	   is	   crucial	   for	   maintaining	   regular	   cell	   activity,	   including	   cellular	  
motion	  and	  intracellular	  transport	  (Yue	  J.,	  Huhn	  S.	  et	  al,	  2013).	  Eukaryotic	  cells	  contain	  three	  
major	   components:	   microfilaments,	   intermediate	   filaments	   and	   microtubules.	  
Microfilaments	   (actin	   filaments	   or	   F-­‐actin)	   are	   composed	   of	   linear	   polymers	   of	   actin	   that	  
form	  the	   thinnest	   filaments	  of	   the	  cytoskeleton.	  A	  unique	   feature	  of	  microfilaments	   is	   the	  
dynamic	  interaction	  with	  each	  other	  (elongation	  and	  shrinkage),	  which	  generates	  force	  and	  
causes	  movement	  (Galkin	  VE.,	  Orlova	  A.	  et	  al,	  2012).	  They	  also	  act	  as	  tracks	  for	  the	  motion	  of	  
myosin	   molecules	   that	   attach	   to	   the	   microfilaments	   and	   head	   along,	   thereby	   once	   more	  
generating	   force	   and	   contributing	   to	   cell	   locomotion	   via	   forming	   of	   actin	   rich	   focal	   cell	  
adhesions	  (Dominguez	  R.,	  Holmes	  KC,	  2011).	  In	  addition	  to	  linear	  formation,	  microfilaments	  
are	  also	  able	  to	  cross-­‐link	  into	  3D	  bundles	  (Cunningham	  CC.,	  Vegners	  R.	  et	  al,	  2001),	  which	  is	  
essential	   for	   dynamic	   remodeling	   of	   the	   cytoskeleton.	   This	   cross-­‐linking	   process	   is	  
orchestrated	   by	   actin-­‐binding-­‐proteins	   (ABP)	   which	   typically	   share	   a	   conserved	   F-­‐actin	  
binding	   domain	   (ABD)	   (Van	   Troys	   M.,	   Vandekerckhove	   J.,	   1999).	   In	   summary	   mechanical	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2.4.2	  The	  family	  of	  the	  filamins:	  Structure	  	  
One	   important	   group	   of	   the	   actin	   binding	   proteins	   is	   the	   filamin	   family,	   which	   has	   been	  
discovered	   in	   1975	   as	   the	   first	   non-­‐muscle	   actin	   filament	   crosslinking	   protein.	   The	   family	  
consists	  of	  three	  homologous	  proteins	  (FLNA,	  FLNB,	  FLNC)	  of	  which	  Filamin	  A	  (FLNA,	  human	  
actin-­‐binding	   protein	   280,	   filamin	   1)	   is	   the	  most	   abundant	   one	   and	   its	   structure	   today	   is	  
discovered	   in	   great	   detail.	   The	   protein	   is	   a	   homodimer	   with	   two	   large	   subunits	   of	   high	  
molecular	  weight	  (280	  kDa),	  which	  form	  a	  V-­‐shaped	  structure	  (van	  der	  Flier	  A.,	  Sonnenberg	  
A.,	  2001).	   It	  consists	  of	  2467	  amino	  acids,	   including	  an	  actin	  binding	  domain	  located	  at	  the	  
amino	  terminus	  of	  each	  monomer,	  followed	  by	  24	  tandem	  repeats	  of	  96	  amino	  acids.	  A	  first	  
hinge	   region	   (H1)	   is	   located	  between	   repeat	   15	   and	  16	   and	  a	   second	  one	   (H2)	   is	   situated	  
between	  repeat	  	  23	  and	  24.	  Both	  add	  much	  needed	  flexibility	  to	  the	  framework.	  	  Repeats	  1	  
to	  15	  are	  named	  Rod1,	  while	   repeats	  16	   to	  23	  are	   called	  Rod2.	  Dimerization	  and	  V-­‐shape	  
structure	   is	   mediated	   by	   the	   C	   terminus	   of	   repeat	   24	   (Gorlin	   JB.,	   Yamin	   R.	   et	   al,	   1990).	  
Interestingly	  besides	  the	  280	  kDa	  full-­‐length	  Filamin	  A,	  the	  relative	  hinge	  regions	  represent	  
cleavage	   sites	   for	   the	   calcium	   dependent	   protease	   calpain	   that	   leads	   to	   two	   shortened	  
variations:	   A	   170	   kDa	   fragment	   composed	   of	   the	   actin	   binding	   domain	   plus	   the	   first	   15	  
repeats	  and	  a	  second	  110	  kDa	  fragment	  consistent	  of	  the	  repeats	  16	  to	  24	  (O'Connell	  MP.,	  
Fiori	  JL.	  et	  al,	  2009).	  
	  
Figure	  7:	  Model	  of	  FLNA	  (blue)	  association	  with	  F-­‐actin	  (red).	  Taken	  from	  Zhou	  A.,	  Hartwig	  J.	  et	  al,	  2010.	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2.4.3	  The	  family	  of	  the	  filamins:	  Broad	  variety	  of	  functions	  
One	   look	  at	  bushes	  and	  trees	   is	  enough	  to	  state	  how	  branched	  scaffoldings	  can	  produce	  a	  
tremendous	   variety	   of	   shapes.	   A	   fundamental	   role	   of	   FLNA,	   attributed	   to	   its	   unique	  
structure,	   is	   binding	   and	   cross-­‐linking	   actin	   filaments	   into	   a	   dynamic	   three-­‐dimensional	  
structure	   through	   its	   actin-­‐binding	   domain,	   adding	   flexibility	   or	   stiffness	   if	   needed,	   for	  
example	   in	   case	   of	   shear	   stress	   or	   hydrostatic	   pressure	   (Gardel	   MK.,	   Nakamura	   F.	   et	   al,	  
2006).	   Zhou	   A.	   et	   al	   (2010)	   indicated	   that	   actin	   stabilization	   takes	   place	   in	   an	   orthogonal	  
structure	  (Fig.	  7),	  which	  makes	  it	  possible	  to	  combine	  a	  maximum	  number	  of	  actin	  filaments	  
with	  a	  modest	  investment	  of	  energy.	  
Cell	   adhesion	   and	   migration	   heavily	   rely	   on	   active	   and	   even	   more	   important	   reversible	  
changes	  in	  the	  mechanical	  properties	  of	  the	  cell.	  Besides	  providing	  cell	  stability,	  FLNA	  adds	  
to	   the	   ability	   of	   the	   cell	   to	   become	   mobile,	   which	   features	   formation	   of	   filopodia	   and	  
lamellipodia.	  These	  slender	  cytoplasmic	  projections,	  composed	  of	  cross-­‐linked	  actin	  bundles	  
by	  FLNA,	  extend	  beyond	  the	  leading	  edge	  in	  migrating	  cells.	  Elements	  which	  spread	  beyond	  
the	  lamellipodium	  frontier	  are	  called	  filopodia	  (Small	  JV.,	  Stradal	  T.	  et	  al,	  2002).	  Many	  types	  
of	  migrating	  cells	  display	   filopodia,	  which	  are	  thought	  to	  be	   involved	   in	  sensing,	  conveying	  
changes	   in	  direct	   locomotion	  and	  cell-­‐cell	   interaction	   (Nakamura	  F.,	  Stossel	  T.	  et	  al,	  2011).	  
FLNA	  knockdown	   results	   in	   inhibition	  of	   these	   formations	   and	  depletes	   cell	  migration	   in	   a	  
drastic	  manner	   (Kim	  H.,	  Nakamura	  F.	  et	  al,	  2010).	  Furthermore	   for	  wound	  closure,	  growth	  
factors	  stimulate	  the	  formation	  of	  filopodia	  in	  fibroblasts	  and	  they	  also	  have	  been	  linked	  to	  
dendrite	   creation	   when	   new	   synapses	   are	   formed	   in	   the	   brain	   and	   phagocytosis	   where	  
filopodia	  act	  as	  phagocytic	  tentacles,	  pulling	  bound	  objects	  towards	  the	  cell	  for	  phagocytosis	  
(Kress	  H.,	  Stelzer	  EH.	  et	  al,	  2007).	  On	  the	  other	  hand,	  filopodia	  are	  also	  used	  for	  movement	  
of	   bacteria	   and	   viruses	   between	   cells	   to	   evade	   the	   host	   immune	   system	   (Lehmann	   MJ.,	  
Sherer	  NM.	  et	  al,	  2005).	  
The	  human	  interactome	  embraces	  a	  network	  of	  an	  estimated	  number	  of	  650000	  molecular	  
interactions	  of	  which	  just	  about	  0.3%	  are	  yet	  discovered	  (Stumpf	  MP.,	  Kelly	  WP.	  et	  al,	  2007,	  
Amaral	  LA,	  2008)	  and	  what	  today	  stands	  more	  and	  more	  as	  a	  benchmark	  for	  complexity	  of	  
the	  human	  organism.	  FLNA	  interacts	  and	  serves	  as	  a	  scaffold	  for	  a	  large	  variety	  of	  more	  than	  
90	  functionally	  diverse	  cellular	  proteins	  like	  ion	  channels,	  receptors	  and	  signaling	  molecules	  
which	   implies	   that	   FLNA	   is	   a	   key	   component	   of	   a	   versatile	   signaling	   complex	   (Stossel	   T.,	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Condeelis	   J.	   et	   al,	   2001;	   Feng	   Y.,	   Walsh	   C.,	   2004).	   FLNA	   also	   has	   a	   direct	   influence	   on	  
transfection	  via	  interaction	  with	  an	  androgen	  receptor	  (Loy	  CJ.,	  Sim	  K.	  et	  al,	  2003;	  Ozanne	  D.,	  
Brady	   M.	   et	   al,	   2000),	   the	   tumor	   suppressor	   BRCA1/2	   (Yuan	   Y.,	   Shen	   Z.,	   2001),	   the	  
transcription	   factor	   FOXC1	   (Berry	   F.,	   O’Neill	  M.	   et	   al,	   2005)	   and	   SMAD-­‐protein	   (Sasaki	   A.,	  
Masuda	   Y.	   et	   al,	   2001).	   This	   way,	   gene	   expression	   is	   not	   only	   regulated	   by	   keeping	  
transcription	  factors	  in	  a	  certain	  area,	  but	  also	  via	  direct	  interaction	  with	  FLNA.	  This	  is	  highly	  
important	  regarding	  the	  background	  of	  this	  thesis	  and	  the	  examined	  MKL1-­‐FLNA	  interaction.	  
In	  contrast	   to	  FLNB	  and	  FLNC,	  Filamin	  A	   is	  widely	  expressed	  and	   its	  drastic	   importance	   for	  
cell	   function	  can	  easily	  be	  seen	  in	  a	   loss	  of	  cell	   locomotion	  and	  the	  occurrence	  of	  blebbing	  
(loss	  of	  mechanic	  cell	   stabilization	  due	  to	   the	  absence	  of	  FLNA	  and	  cell	  damage	  caused	  by	  
hydrostatic	  cell	  pressure)	  in	  FLNA	  deficient	  M2	  melanoma	  cells	  (Cunningham	  CC.,	  Gorlin	  JB.	  
et	  al,	  1992;	  Nakamura	  F.,	  Stossel	  T.	  et	  al,	  2001).	  In	  summary,	  FLNA	  is	  positioned	  at	  both	  the	  
leading	  edge	  and	  the	  rear	  part	  of	  the	  cell,	  orchestrating	  the	  engineering	  of	  the	  cytoskeleton,	  
migration	  and	  interacting	  with	  partner	  proteins,	  thus	  representing	  an	  extraordinary	  example	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2.4.4	  The	  family	  of	  the	  filamins:	  Pathogenesis	  and	  tumorigenesis	  
Genetic	  evidence	  links	  FLNA	  as	  an	  essential	  protein	  for	  human	  development.	  According	  to	  its	  
versatile	   functions,	   mutations	   and	   deletions	   in	   the	   human	   FLNA	   genes	   result	   in	   a	   wide	  
spectrum	  of	  cell	  anomalies	  and	  development	  malformations	  with	  often	  lethal	  consequences.	  
Most	   of	   FLNA	   deficient,	   genetic	   diseases	   are	   based	   on	   disruption	   of	   cell	   motility	   and	  
signaling,	   this	   way	   affecting	   organogenesis.	   Since	   directed	   cell	   movement	   is	   essential	   for	  
embryonic	   development,	   aberrant	   unregulated	   migration	   leads	   to	   pathological	   processes	  
(Feng	  Y.,	  Chen	  MH.	  et	  al,	  2006).	  	  
The	   first	   disease	   linked	   to	   FLNA	   mutations	   is	   the	   brain	   malformation	   known	   as	  
periventricular	  heterotopia.	  A	  typical	  periventricular	  heterotopia	  brain	  is	  characterized	  by	  an	  
abnormal	   appearance	   of	   collections	   of	   neurons	   along	  walls	   of	   the	   lateral	   ventricle,	  where	  
neurons	  are	  originally	  generated	  during	  corticogenesis,	   instead	  of	  migrating	   to	   the	  correct	  
cortical	   site	   (Fox	   JW.,	   Lamperti	   ED.	   et	   al,	   1998).	   The	   major	   clinical	   syndrome	   of	  
periventricular	  heterotopia	   is	   late-­‐onset	  epilepsy	   that	  often	  starts	   in	   the	  second	  decade	  of	  
life.	  
	  
Figure	  8:	  Periventicular	  heterotopia.	  Deregulated	  neuron	  migration	   leads	  to	  mal-­‐localization	  as	  seen	   in	  red	  
circle.	  Taken	  from	  Gonzalez	  G.,	  Vedolin	  L.	  et	  al,	  2012	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Loss	   of	   FLNA	   expression	   in	   mice	   causes	   embryonic	   lethality	   with	   severe	   defects	   in	  
cardiovascular	  formation	  and	  bone	  development.	  FLNA	  deficient	  M2	  melanoma	  cells	  fail	  to	  
move	   because	   they	   have	   highly	   unstable	   surfaces,	   while	   restoring	   regular	   levels	   of	   FLNA	  
rescues	  motility.	  Furthermore,	  FLNA	  restored	  A7	  melanoma	  cells	  showcased	  a	  need	  of	  more	  
than	   twice	   the	   amount	   of	   shear	   stress	   to	   achieve	   a	   given	   deformation	   then	   the	   FLNA	  
depleted	  M2	  cells	  	  (Cunningham	  CC.,	  Gorlin	  JB.	  et	  al,	  1992).	  
Cancer	  has	  been	  described	  as	  the	  product	  of	  development	  error	  leading	  to	  the	  acquisition	  of	  
a	   unique	   cell	   character	   (da	   Costa	   LF.,	   2001).	   It	   is	   a	   multistep	   process	   that	   transforms	   a	  
normal	   cell	   into	  one	   that	   evades	   apoptosis,	   grows	   irrepressibly,	   promotes	   angiogenesis	   to	  
support	   the	   tumor	   and	   finally	   invades	   surrounding	   tissue	   and	   metastasizes	   (Hanahan	   D.,	  
Weinberg	  RA.,	  2000).	  Tracing	  has	  shown	  that	  stem	  cells	  are	  mobilized	  to	  repair	  skin	  wounds	  
and	  that	  this	  process	  may	  contribute	  to	  skin	  tumor	  development	  (Arwert	  EN.,	  Hoste	  E.	  et	  al,	  
2012).	  In	  many	  cases	  cancer	  can	  be	  thought	  of	  as	  continued	  and	  unwanted	  regeneration	  that	  
does	   not	   know	   how	   to	   stop	   resulting	   in	   overexpression	   of	   certain	   key	   proteins.	   FLNA’s	  
function	  as	  a	  scaffolding	  protein	  and	   its	  vital	   importance	   in	  cell	  migration	  can	   transform	   it	  
into	   an	   extremely	   potent	   cancer	   promoting	   protein.	   FLNA	   has	   been	   observed	   being	  
overexpressed	   in	  multiple	   types	   of	   cancer,	   including	   prostate	   (Bedolla	   RG.,	  Wang	   Y.	   et	   al,	  
2009),	  breast	   (Tian	  HM.,	   Liu	  XH.	  et	   al,	   2013),	   lung	   cancer	   (Uramoto	  H.,	  Akyürek	   LM.	  et	   al,	  
2010),	  colon	  cancer	  (Larriba	  MJ.,	  Martin-­‐Villar	  E.	  et	  al,	  2009),	  melanoma	  (Flanagan	  LA.,	  Chou	  
J.	   et	   al,	   2001)	   and	   neuroblastoma	   (Bachmann	   AS.,	   Howard	   JP.	   et	   al,	   2006).	   Although	   this	  
large	  volume	  of	  studies	  linking	  FLNA	  with	  cancer	  metastasis,	  the	  specific	  roles	  of	  FLNA	  during	  
metastatic	   invasion	   remains	   elusive.	   This	   enigma	   is	   a	   reflection	   of	   metastasis	   complex	  
nature.	   Metastasis,	   or	   leaving	   the	   primary	   tumor	   for	   invasion	   into	   other	   tissue	   parts,	  
requires	   a	   strict	   cascade	   of	   locomotion	   events,	   including	   tumor	   cell	   detachment	   from	   the	  
primary	   site,	   followed	  by	   tumor	  cell	   invasion,	  migration	  and	  colonization	  at	   the	   secondary	  
sites	   (Arwert	   EN.,	  Hoste	   E.	   et	   al,	   2012).	  Metastasis	   requires	   the	   cancer	   cells	   to	   be	   able	   to	  
adept	   to	   different	   cell	   shapes,	   resist	   to	  mechanical	   stress	   and	   to	   be	   highly	  motile	   (Yue	   J.,	  
Huhn	  S.	  et	  al,	  2013).	  A	  great	  amount	  of	  these	  key	  processes	  are	  driven	  by	  FLNA	  as	  described	  
in	   2.4.3.	   Thus,	   it	   is	   conceivable	   that	   lack	   of	   FLNA	   would	   decrease	   the	   tumor	   cells	   ability	  
regarding	  mobility	   and	   invasiveness	   and	   furthermore	   cause	   them	   to	   be	  more	   sensitive	   to	  
mechanical	   stress	   (Yue	   J.,	   Huhn	   S.	   et	   al,	   2013).	   This	   demonstrates	   the	   irreparable	   role	   of	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FLNA	   in	   tumorigenesis	   and	   its	   medical	   relevance	   during	   the	   process	   of	   developing	  
malfunctions.	  	  
Aim	  of	  thesis	   	  
	  
	   28	  
	  
3	  Aim	  of	  thesis	  
	  
Previously	  to	  this	  thesis,	  Filamin	  A	  has	  been	  identified	  as	  a	  novel	  interaction	  partner	  of	  MKL1	  
via	  yeast	  two-­‐hybrid	  assay	  by	  Dr.	  S.	  Muehlich	  (Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  
This	  thesis	  covers	  the	  interaction	  of	  MKL1	  and	  FLNA	  and	  takes	  a	  detailed	  look	  at	  functionality	  
behind	  the	  complex	  formation.	  
In	  particular	  the	  thesis	  addresses	  the	  following	  issues:	  
1. Confirming	   the	   interaction	   between	   MKL1	   and	   FLNA	   in	   physiological	   and	  
pathophysiological	   cell	   systems	   and	   furthermore	   map	   the	   necessary	   interacting	  
domains	  on	  the	  respective	  protein.	  
2. Stating	  the	  cell	  compartment	  in	  which	  the	  MKL1-­‐FLNA	  interaction	  takes	  place.	  
3. Correlating	   the	  MKL1-­‐FLNA	   interaction	  with	   induction	   and	   repression	   of	  MKL1-­‐SRF	  
target	  genes.	  
4. Introducing	  FLNA	  as	  a	  transducer	  of	  actin	  polymerization	  into	  SRF	  activity.	  
5. Presenting	   the	   MKL1-­‐FLNA	   interaction	   as	   a	   requirement	   for	   MKL1-­‐dependant	   cell	  
migration,	  invasion	  and	  expression	  of	  MKL1	  target	  genes.	  
Since	   MKL1	   and	   FLNA	   are	   both	   involved	   in	   diseases	   and	   cancer	   development,	   mainly	  
regarding	  migratory	  processes	  like	  tumor	  motility,	  proliferation	  and	  metastasis,	  gaining	  new	  
insights	   into	   functional	   effects	   of	   the	   interaction	   are	   of	   great	   value	   for	   future	   drug	  
development	  including	  MKL1	  and	  FLNA	  as	  possible	  pharmacological	  targets.	  
Materials	   	  
	  




4.1	  Cell	  culture	  
4.1.1	  Cell	  lines	  
Cell	  line	   Organism/	  Cell	  Type	   Culture	  conditions	   Provider/	  Origin	  
	   	   	   	  
A7	   Human	  melanoma	   MEM	   Stossel	  TP.,	  ATCC	  #CRL-­‐
2500,	  Boston	  
M2	   Human	  FLNA-­‐deficient	  
melanoma	  
MEM	   Stossel	  TP.,	  Ohta	  Y.,	  
Boston	  
HuH7	   Human	  hepatocellular	  
carcinoma	  
DMEM	   Singer	  S.,	  Heidelberg	  
MDA-­‐MB-­‐468	   Human	  breast	  
carcinoma	  
DMEM	   Parsons	  R.,	  New	  York	  
NIH-­‐3T3	   Mouse	  embryonic	  
fibroblasts	  
DMEM	   Muehlich	  S.,	  München	  
MEF	   Mouse	  primary	  
embryoic	  fibroblasts	  
DMEM	   Sarikas	  A.,	  München	  
HDFA	   Human	  primary	  
fibroblasts	  
Medium	  106	   Life	  Technologies,	  
Darmstadt	  
MACS	   Mouse	  neuronal	  cells	   DMEM	   Breit	  A.,	  München	  
HEK-­‐293	   Human	  embryonic	  
kidney	  cells	  
DMEM	   Muehlich	  S.,	  München	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HLF	   Human	  lung	  fibroblasts	   DMEM	   Muehlich	  S.,	  München	  
HepG2	   Human	  hepatoma	   RPMI	   Singer	  S.,	  Heidelberg	  
	  
4.1.2	  Cell	  culture	  media	  and	  solutions	  
Reagent	   Provider	  
	   	  
Modified	  Eagle	  Medium	  (MEM)	   Sigma-­‐Aldrich,	  Taufkirchen,	  Germany	  
Dulbecco`s	  Modified	  Eagle	  Medium	  (DMEM)	   Sigma-­‐Aldrich,	  Taufkirchen,	  Germany	  
RPMI	  1640	  Medium	   Sigma-­‐Aldrich,	  Taufkirchen,	  Germany	  
Medium	  106	   Life	  Technologies,	  Darmstadt,	  Germany	  
Opi-­‐MEM®	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
Fetal	  Bovine	  Serum	  (FBS)	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
Penicillin-­‐Streptomycin	  (5000	  U/mL)	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
	  
4.1.3	  Transfection	  reagents	  
Reagent	   Provider	  
	   	  
Lipofectamine®	  2000	   Invitrogen,	  Karlsruhe	  
Lipofectamine®	  RNAiMAX	   Invitrogen,	  Karlsruhe	  
2	  M	  Calcium-­‐Phosphat	   selfmade	  
GenJet™DNA	  In	  Vitro	  Transfection	  Reagent	   SignaGen	  Laboratories,	  Rochville,	  USA	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4.1.4	  Plasmid	  constructs	  
Plasmid	  construct	   Vector	   Provider	  
	   	   	  
Wildtype	  FLAG-­‐MKL1	   pCMV	   Prywes	  R.,	  Columbia	  University,	  
NY,	  	  USA	  
Wildtype	  MYC-­‐FLNA	   pCDNA3	   Blenis	  J.,	  Harvard	  Medical	  
School,	  MA,	  USA	  
Wildtype	  FLAG-­‐MKL2	   pCMV	   Prywes	  R.,	  Columbia	  University,	  
NY,	  	  USA	  
Wildtype	  MYC-­‐Myocardin	   pCDNA3	   Prywes	  R.,	  Columbia	  University,	  
NY,	  	  USA	  
GFP-­‐Actin	   peGFP	   Sheetz	  M.,	  Columbia	  University,	  
NY,	  USA	  
FLAG-­‐MKL1	  mutant	  N100	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  N300	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  C500	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  C630	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  C830	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  Δ301-­‐380	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	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FLAG-­‐MKL1	  mutant	  Δ381-­‐506	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐MKL1	  mutant	  Δ301-­‐342	   pCMV	   Kircher	  P.,	  LMU,	  München	  
FLAG-­‐MKL1	  mutant	  Δ321-­‐342	   pCMV	   Kircher	  P.,	  LMU,	  München	  
FLAG-­‐MKL1	  mutant	  Δ301-­‐310	   pCMV	   Kircher	  P.,	  LMU,	  München	  
FLAG-­‐MKL1	  mutant	  Δ305	   pCMV	   Kircher	  P.,	  LMU,	  München	  
FLAG-­‐MKL1	  mutant	  Δ312	   pCMV	   Kircher	  P.,	  LMU,	  München	  
FLAG-­‐MKL1	  mutant	  ΔSAP	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
FLAG-­‐STS/A	  mutant	  MKL1	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
MYC-­‐FLNA	  mutant	  1-­‐275	   pCI-­‐HA	   Berry	  F.,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
MYC-­‐FLNA	  mutant	  276-­‐570	   pCI-­‐HA	   Berry	  F.,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
MYC-­‐FLNA	  mutant	  571-­‐866	   pCI-­‐HA	   Berry	  F.,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
MYC-­‐FLNA	  mutant	  1155-­‐1442	   pCI-­‐HA	   Berry	  F.	  ,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
MYC-­‐FLNA	  mutant	  1779-­‐2284	   pCI-­‐HA	   Berry	  F.,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
MYC-­‐FLNA	  mutant	  2285-­‐2729	   pCI-­‐HA	   Berry	  F.,	  University	  of	  Alberta,	  
Edmonton,	  CA	  
R62D-­‐FLAG-­‐Actin	   pEF	   Posern	  G.,	  Martin	  Luther	  
University,	  Halle,	  Germany	  
NLS-­‐R62D-­‐FLAG-­‐Actin	   pEF	   Posern	  G.,	  Martin	  Luther	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University,	  Halle,	  Germany	  
S14C-­‐FLAG-­‐Actin	   pEF	   Posern	  G.,	  Martin	  Luther	  
University,	  Halle,	  Germany	  
GFP-­‐MKL1	   peGFP	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
mDiaNES	   pEF	   Posern	  G.,	  Martin	  Luther	  
University,	  Halle,	  Germany	  
mDiact	   pEF	   Posern	  G.,	  Martin	  Luther	  
University,	  Halle,	  Germany	  
Empty	  Vector	   peGFP	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
5	  x	  SRE	   pCMV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
Renilla	  Luciferase	  SV40	   pSV	   Prywes	  R.,	  Columbia	  	  
University,	  NY,	  USA	  
	  
4.1.5	  siRNA	  sequences	  
All	   siRNA	   oligonucleotides	   were	   custom	   synthesized	   by	   Sigma-­‐Aldrich,	   Taufkirchen,	  
Germany.	  
Lyophilized	   siRNA	   oligonucletodides	  were	   dissolved	   in	  water	   to	   a	   concentration	   of	   50	   µM	  
and	  stored	  in	  aliquotes	  at	  -­‐20˚C.	  
Target	   Sequence	  [5`-­‐3`]	  
	   	  
siRNA	  Neg.	  ctrl	   CGU	  ACG	  CGG	  AAU	  ACU	  UCG	  A	  [dT]	  [dT]	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siFLNA	  	   AAA	  AUG	  CAC	  CGC	  AAG	  CAC	  	  AAC	  [dT]	  [dT]	  
siMKL1	   GAA	  UGU	  GCU	  ACA	  GUU	  GAAA	  [dT]	  [dT]	  
siSRF	   GAU	  GGA	  GUU	  CAU	  CGA	  CAA	  CAA	  [dT]	  [dT]	  
	  
4.1.6	  Selection	  antibiotic	  for	  cell	  culture	  
Antibiotic	  	   Stock	  solution	  	   Final	  concentration	   Provider	  
	   	   	   	  
Geneticin	  (G418	  
Sulfate)	  
50	  mg/mL	   200	  µg/mL	   Carl	  Roth,	  Karlsruhe,	  
Germany	  
	  
4.1.7	  Inhibitors	  and	  stimulants	  
Inhibitor/Stimulant	   Final	  concentration	   Provider	  
	   	   	  
Lysophosphatidic	  acid(LPA)	   10	  µM	   Sigma-­‐Aldrich,	  Taufkirchen,	  
Germany	  
Latrunculin	  B	  (LatB)	   0.3	  µM	   Merck,	  Darmstadt,	  Germany	  
Jasplakinolide	   0.5	  µM	   CalBiochem,	  Darmstadt,	  
Germany	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4.2	  Antibodies	  
4.2.1	  Primary	  antibodies	  
All	  antibodies	  were	  diluted	  in	  TBS-­‐T	  and	  conserved	  with	  BSA	  and	  10	  %	  NaN₃	  
Primary	  antibody	   Dilution	   Provider	  
	   	   	  
Alexa	  Fluor®	  Phalloidin	   1:500	   Invitrogen,	  Karlsruhe,	  Germany	  
FLAG	  M2	  (mouse	  monoclonal)	   1:500	   Sigma-­‐Aldrich,	  Taufkirchen,	  
Germany	  
FLNA	  (human)	   1:1000	   Abcam,	  Cambridge,	  UK	  
FLNA	  MAB	  1678	  (human)	   1:1000	  
1:100	  in	  PBS	  (IF)	  
Chemicon	  Millipore,	  
Schwalbach,	  Germany	  
FLNA	  (rabbit)	   1:1000	   Cell	  Signaling	  Technology,	  USA	  
GFP	  (FL)	  (human)	   1:200	   Santa	  Cruz	  Biotechnology,	  CA,	  
USA	  
HA	  (3F10)	  (goat	  monoclonal)	   1:500	   Roche	  Applied	  Science,	  
Germany	  
HSP90	  (mouse	  monoclonal)	   1:500	   Santa	  Cruz	  Biotechnology,	  CA,	  
USA	  
MKL1	  (rabbit)	   1:500	   Muehlich	  S.,	  Munich,	  Germany	  
MRTF-­‐A	  (C19)	  (goat	  polyclonal)	   1:100	  in	  PBS	  (IF)	   Santa	  Cruz	  Biotechnology,	  CA,	  
USA	  
P-­‐MKL1	   1:250	   Muehlich	  S.,	  Munich,	  Germany	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4.2.2	  Secondary	  antibodies	  
Secondary	  antibody	   Target	   Dilution	   Provider	  
	   	   	   	  
Alexa	  Fluor®488	   Mouse	   1:1000	   Invitrogen,	  Karlsruhe	  
Alexa	  Fluor®488	   Rabbit	  	   1:1000	   Invitrogen,	  Karlsruhe	  
Alexa	  Fluor®555	   Goat	   1:1000	   Invitrogen,	  Karlsruhe	  
Anti-­‐rabbit	  IgG	  HRP-­‐
conj	  




Mouse	   1:10000	   Cell	  Signaling	  
Technology,	  USA	  






4.3.1	  Random	  Hexamers	  
Nucleotide	   Sequence	  [5`-­‐3`]	   Provider	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4.3.2	  Real-­‐time	  PCR	  primers	  
Target	  gene	  specific	  primers	  were	  designed	  with	  the	  software	  Universal	  Probe	  Library	  from	  
Roche.	   Custom-­‐synthesized	   primers	   were	   purchased	   by	   Metabion	   International	   AG,	  
Martinsried,	  Germany.	  The	  real-­‐time	  PCR	  primers	  were	  diluted	  to	  a	  concentration	  of	  100	  µM	  
and	  stored	  at	  -­‐20˚C.	  
h=human;	  F=forward;	  R=reverse	  
Name	   Sequence	  [5`-­‐3`]	  
	   	  
h18s	  rRNA	  F	  	   TCG	  AGG	  CCC	  TGT	  AAT	  	  TGG	  AAT	  
h18s	  rRNA	  R	   CCC	  TCC	  AAT	  GGA	  TCC	  TCG	  TTA	  
hCNN1	  F	   GCT	  GTC	  AGC	  CGA	  GGT	  TAA	  GA	  
hCNN1	  R	   CCC	  TCG	  ATC	  CAC	  TCT	  CTC	  AG	  
hCTGF	  F	   TTG	  GCA	  GGC	  TGA	  TTT	  CTA	  GG	  
hCTGF	  R	   GGT	  GCA	  AAC	  ATG	  TAA	  CTT	  TTG	  G	  
hFLNA	  F	   TCG	  CTC	  TCA	  GGA	  ACA	  GCA	  
hFLNA	  R	   TTA	  ATT	  AAA	  GTC	  GCA	  GGC	  ACC	  TA	  
hGLIPR1	  F	   TCT	  TTC	  CAA	  TGG	  AGC	  ACA	  TTT	  
hGLIPR1	  R	   TCT	  TAT	  ATG	  GCC	  AAG	  TTG	  GGT	  AA	  
hITGA5	  F	   TGC	  AGT	  GTG	  AGG	  CTG	  TGT	  ACA	  
hITGA5	  R	   GTG	  GCC	  ACC	  TGA	  CGC	  TCT	  
hMKL1	  F	   CCC	  AAT	  TTG	  CCT	  CCA	  CTT	  AG	  
hMKL1	  R	   CCT	  TGG	  CTC	  ACC	  AGT	  TCT	  TC	  
hSM22	  F	   GGC	  CAA	  GGC	  TCT	  ACT	  GTC	  TG	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hSM22	  R	   CCC	  TTG	  TTG	  GCC	  ATG	  TCT	  
hTGF-­‐beta	  F	   TCT	  TTC	  CAA	  TGG	  AGC	  ACA	  TTT	  
hTGF-­‐beta	  R	   TCT	  TAT	  ATG	  GCC	  AAG	  TTG	  GGT	  AA	  
hFHL2	  F	   GCT	  GTC	  AGC	  CGA	  GGT	  TAA	  GA	  
hFHL2	  R	   CCC	  TCG	  ATC	  CAC	  TCT	  CTC	  AG	  
hSRF	  F	   AGC	  ACA	  GAC	  CTC	  ACG	  CAG	  A	  
hSRF	  R	   GTT	  GTG	  GGC	  ACG	  GAT	  GAC	  
	  
	  
4.4	  Bacterial	  strains	  and	  media	  
Bacterial	  strain	   Provider	  
	   	  




1%	  sodium	  chloride	  
1%	  bacto	  tryptone	  
0.5%	  yeast	  extract	  
1.5%	  bacto	  agar	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LB	  liquid	  medium	  
	  
1%	  sodium	  chloride	  
0.5%	  yeast	  extract	  
1%	  bacto	  tryptone	  




Reagent	   Provider	  
	   	  
Q5®	  Site-­‐Directed	  Mutagenesis	  Kit	   New	  England	  Biolabs,	  MA,	  USA	  
GenElute™	  HP	  Plasmid	  Midiprep	  Kit	   Sigma-­‐Aldrich,	  Taufkirchen,	  Germany	  
Dual	  Luciferase®	  Reporter	  Assay	  System	  	  
	  





Reagent	   Provider	  
	   	  
Protease	  Inhibitor,	  Cocktail	  Set	  III,	  Animal	  Free	   Calbiochem,	  Darmstadt,	  Germany	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Spectra™	  Multicolor	  Broad	  Range	  Protein	  Ladder	   Fermentas,	  St.	  Leon-­‐Rot,	  Germany	  
Rec-­‐Protein	  G-­‐Sepharose®	  4B	  conjugate	   Invitrogen,	  Karlsruhe,	  Germany	  
Roti	  ®-­‐Quant	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Roti	  ®-­‐Lumin	  1;	  Roti	  ®-­‐Lumin2	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Super	  Signal	  West	  Femto	  Trialkit	  (Enhancer	  
peroxide	  solution)	  
Thermo	  Scientific,	  Schwerte,	  Germany	  




Reagent	   Provider	  
	   	  
SuperScript	  II	  Reverse	  Transcriptase	   Invitrogen,	  Karlsruhe,	  Germany	  
RNaseA	   Fermentas,	  St.	  Leon-­‐Rot,	  Germany	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4.8	  Buffers	  and	  solutions	  
4.8.1	  cDNA	  synthesis/	  RT-­‐PCR	  
Reagent	   Provider	  
	   	  
5	  x	  First-­‐Strand	  Buffer	   Invitrogen,	  Karlsruhe,	  Germany	  
dNTPs	  (10	  mM)	   Invitrogen,	  Karlsruhe,	  Germany	  
LightCycler®	  	  480	  SYBR	  Green	  I	  Master	   Roche,	  Penzberg,	  Germany	  
	  
4.8.2	  Protein	  analysis	  
2.5	  M	  CaCl₂	  solution	  
	  




8.0	  g	  NaCl	  
0.2	  g	  Na₂HPO₄*7	  H₂O	  
6.5	  g	  HEPES	  
Adjustment	  of	  pH	  to	  7.0	  
Ad	  500	  mL	  destilled	  water	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Kralewski	  cell	  lysis	  buffer	  
	  
50	  mM	  HEPES	  (pH	  7.4)	  
150	  mM	  NaCl	  
1	  %	  Triton	  X-­‐100	  
1	  mM	  EDTA	  
10	  %	  Glycerol	  
	  
4x	  SDS	  loading/Laemmli	  Sample	  Buffer	  (4xLSB)	  
	  
1	  M	  TRIS/HCL	  (pH	  8.8)	  
0.01	  %	  (w/v)	  Bromphenolblau	  
20	  %	  (w/v)	  SDS	  
2	  %	  (v/v)	  Glycerol	  
0.5	  M	  EDTA	  
5	  %	  (v/v)	  ß-­‐Mercaptoethanol	  
	  
10	  x	  PBS	  pH	  7.4	  
	  
140	  mM	  NaCl	  
2.7	  mM	  KCl	  
10	  mM	  Na₂HPO₄	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1.8	  mM	  KH₂PO₄	  
	  
10	  x	  Gel	  running	  buffer	  (pH	  8.3)	  
	  
0.25	  M	  TRIS	  
2	  M	  Glycin	  
1	  %	  (w/v)	  SDS	  
H₂O	  ad	  1000	  mL	  
	  
10	  x	  TBS	  
	  
0.2	  M	  TRIS	  
1.4	  M	  NaCl	  
H₂O	  ad	  5000	  mL	  
	  
10	  x	  TBST	  
	  
0.2	  M	  TRIS	  
1.4	  M	  NaCl	  
1	  %	  Tween	  20	  
H₂O	  ad	  5000	  mL	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10	  x	  Blotting	  buffer	  
	  
7.25	  g	  	  TRIS	  
3.65	  g	  	  Glycine	  
0.47	  g	  SDS	  
200	  mL	  Methanol	  
H₂O	  ad	  1000	  mL	  
	  
1.5	  M	  TRIS	  (pH	  6.8)	  
	  
121.1	  g	  TRIS	  
Adjustment	  of	  pH	  with	  1	  N	  HCL	  to	  6.8	  
H₂O	  ad	  1000	  mL	  
	  
1.5	  M	  TRIS	  (pH	  8.8)	  
	  
121.1	  g	  TRIS	  
Adjustment	  of	  pH	  with	  1	  N	  HCL	  to	  8.8	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1	  %	  Triton	  IP	  Lysisbuffer	  
	  
50	  mM	  Tris	  
150	  mM	  NaCl	  
1	  %	  Triton	  X-­‐100	  
10	  %	  Glycerol	  	  
Add	  before	  usage:	  0.2	  %	  PMSF,	  protease	  inhibitor	  cocktail	  
	  
Enhanced	  Chemiluminescence	  solution	  (ECL)	  S1	  and	  S2	  
S1	  solution	  
	  
80	  mL	  H₂O	  
10	  mL	  1	  M	  TRIS/HCL	  pH	  8.5	  
1	  mL	  250	  mM	  3-­‐Aminophtalhydrazide	  
0.44	  mL	  90	  mM	  p-­‐Coumaric	  acid	  




80	  mL	  H₂O	  
10	  mL	  1	  M	  TRIS/	  HCl	  pH	  8.5	  
60	  µL	  30%	  H₂O₂	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H₂O	  ad	  100	  mL	  
	  
Both	  solutions	  were	  stored	  at	  -­‐20˚C	  an	  thawed	  prior	  to	  use.	  Both	  solutions	  were	  mixed	  at	  a	  
ratio	  of	  1:1	  to	  yield	  the	  ready-­‐to-­‐use	  assay	  solution.	  
	  
1	  %	  Toluidine	  staining	  solution	  	  
	  
0.1	  g	  toluidine	  blue	  dye	  
0.1	  g	  Sodium	  tetraborate	  decahydrate	  
Dissolved	  in	  100	  mL	  destilled	  water	  
	  
	  
4.9	  Chemicals	   	   	  
Chemicals	   Provider	  
	   	  
2-­‐Propanol	   Carl	  Roth,	  Karlsruhe,	  Germany	  
4,6	  Diamidin-­‐2-­‐phenylindol	  (DAPI)	   Sigma	  Aldrich,	  Taufkirchen,	  Germany	  
30	  %	  Acrylamid,	  Rotiphorese	  ®	  Gel	  30	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Agarose	   PEQLAB,	  Erlangen,	  Germany	  
Ammonium	  peroxodisulfat	  (APS)	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Ampicillin	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
ß-­‐	  Mercaptoethanol	   Serva,	  Heidelberg,	  Germany	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Bovine	  serum	  albumin	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Bromphenol	  blue	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Calcium	  chloride	  (CaCl₂)	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Chloroform	   VWR,	  Ismaning,	  Germany	  
Citric	  acid	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Desoxynucleosid	  triphosphates	  (dATP,	  dCTP,	  
dGTP,	  dTTP)	  
Invitrogen,	  Karlsruhe,	  Germany	  
Dimethyl	  sulfoxide	  (DMSO)	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Dithiothreitol	  (DTT)	   Carl	  Roth,	  Karlstuhe,	  Germany	  
DMF	  (N,N-­‐Dimethylformamide)	   Sigma	  Aldrich,	  Taufkirchen,	  Germany	  
ECM	  gel	  from	  Engelbert-­‐Holm-­‐Swarm	  mouse	  
sarcoma	  
Sigma	  Aldrich,	  Taufkirchen,	  Germany	  
Ethylenediaminetetraacetic	  acid	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Ethanol	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Fetal	  bovine	  serum	  FBS	   Sigma	  Aldrich,	  Taufkirchen,	  Germany	  
FBS	  "South	  American"	   Life	  Technologies,	  Darmstadt,	  Germany	  
Fluoromount	   Sigma	  Aldrich,	  Taufkirchen,	  Germany	  
Glycine	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Glycerol	   Carl	  Roth,	  Karlsruhe,	  Germany	  
HEPES	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Immersion	  Oil	  518F	   Zeiss,	  Oberkochen,	  Germany	  
Low	  fat	  milk	  powder	   Vitalia,	  Bruckmühl,	  Germany	  
Methanol	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Mounting	  Fluoromount	   Sigma	  Aldrich,	  Taufkirchen,	  Germany	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Paraformaldehyd	  (PFA)	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Penicillin	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
Phenylmethylsulfonylfluorid	  (PMSF)	  	   Callbiochem,	  Darmstadt,	  Germany	  
Protease	  Inhibitor,	  Cocktail	  Set	  III	  Animal	  Free	   Callbiochem,	  Darmstadt,	  Germany	  
Roti-­‐Lumin,	  1+2	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Roti-­‐Quant®	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Saccharose	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Sodium	  chloride	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Sodium	  dodecyl	  sulfate	  (SDS)	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Sodium	  hydrogen	  phosphate	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Sodium	  tetraborate	  decahydrate	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Streptomycin	   Gibco®	  Invitrogen,	  Karlsruhe,	  Germany	  
TEMED	   Carl	  Roth,	  Karlsruhe,	  Germany	  
TRIS	  tris(hydroxymethyl)aminomethane	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Trisoidum	  citrate	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Triton	  X-­‐100	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Toluidine	  blue	  dye	   Carl	  Roth,	  Karlsruhe,	  Germany	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4.10	  Technical	  devices	  and	  other	  equipment	   	  
Device	   Provider	  
	   	  
24-­‐well	  Transwell®	  inserts	  8	  µM	   Millipore,	  Germany	  
BD	  BioCoat	  Matrigel	  Invasion	  Chamber	   Thermo	  Scientific,	  Germany	  
BioPhotometer	  plus	   Eppendorf,	  Hamburg,	  Germany	  
Blotting	  equipment	  Mini	  PROTEAN®	  TetraCell	   Bio-­‐Rad,	  Munich,	  Germany	  
Cell	  culture	  dishes	   Sarstedt,	  Nümbrecht,	  Germany	  
Centrifuge	  5424R	   Eppendorf,	  Hamburg	  
Centrifuge	  5804R	   Eppendorf,	  Hamburg	  
Centrifuge	  Heraeus	  Biofuge	  Stratos	   Thermo	  Scientific,	  Freiburg,	  Germany	  
Centrifuge	  Vials	  15	  mL,	  50	  mL	   Sarstedt,	  Nürmbrecht,	  Germany	  
Chemiluminescent	  imager	  Chemismart	  5100	   PEQLAB,	  Erlangen,	  Germany	  
Confocal	  microscope	  LSM	  510	   Zeiss,	  Jena,	  Germany	  
Cryo	  vials	  CryoPure	  1.6	  mL	   Sarstedt,	  Nümbrecht,	  Germany	  
Eppendorf	  tubes	   Eppendorf,	  Hamburg	  
Falcon	  tubes	   Sarstedt,	  Nümbrecht,	  Germany	  
Freezer	   Liebherr,	  Biberach	  an	  der	  Riss,	  Germany	  
Fridge	   Liebherr,	  Biberach	  an	  der	  Riss,	  Germany	  
Gelelectrophorese	  Device	   Bio-­‐Rad,	  Munich,	  Germany	  
Glas	  pearls	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Incubator	  for	  Bacteria	  MaxQ	  6000	   Thermo	  Scientific,	  Germany	  
Laminar	  Flow	  HERACell	  150i	   Thermo	  Scientific,	  Germany	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Light	  Cycler®480	   Roche,	  Penzberg,	  Germany	  
Light	  Cycler®480	  Multiwell	  Plate	  96	   Roche,	  Penzberg,	  Germany	  
Light	  Cycler®480	  Sealing	  Foil	   Roche,	  Penzberg,	  Germany	  
Microscope	  Axiovert	  135M	   Zeiss,	  Göttingen	  
Neubauer	  cell	  counting	  chamber	   Marienfeld,	  Lauda-­‐Königshofen,	  Germany	  
PCR	  machine	   Biometra	  GmbH,	  Göttingen	  
pH	  meter	  Lab850	   Schott	  Instruments,	  SI	  Analytics,	  Mainz,	  
Germany	  
Pipetus	   Hirschmann,	  Eberstadt,	  Germany	  
Power	  supply	  PeqPower	  300	   PEQLAB,	  Erlangen,	  Germany	  
PVDF-­‐membrane	   Millipore,	  Billerica,	  MA	  
Rotation	  Incubator	   Heidolph,	  Schwabach,	  Germany	  
SDS-­‐PAGE	  equipment	   BIORAD,	  München	  
Shaker	  Polymax	  1040	   Heidolph,	  Schwabach,	  Germany	  
Sterile	  cotton	  swabs	   Carl	  Roth,	  Karlsruhe,	  Germany	  
Thermoblock	  	   Eppendorf,	  Hamburg,	  Germany	  
UV-­‐transparent	  cuvettes	   Sarstedt,	  Nümbrecht,	  Germany	  
Vortex	  device	   IKA,	  Staufen,	  Germany	  
Water	  bath	   Memmert,	  Schwabach,	  Germany	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5.1	  Cell	  culture	  methods	  
5.1.1	  Culturing	  and	  maintenance	  of	  eukaryotic	  cell	  lines	  
All	   cell	   work	   was	   carried	   out	   in	   a	   biosafety	   level	   S1	   laboratory	   using	   sterile	   laminar	   flow	  
cabinets.	  	  
Thawing	  was	  achieved	  by	  centrifugation	  of	  5	  mL	  appropriate	  cell	  medium	  including	  the	  pre-­‐
heated	  cell	  suspension	  taken	  out	  of	  the	  cyro	  vial.	  Next,	  peletted	  cells	  were	  re-­‐suspended	  in	  
fresh	  medium	  and	  cultured	  in	  cell	  culture	  dishes.	  	  
For	   freezing,	   centrifuged	   cells	   were	   re-­‐suspended	   in	   FBS	   supplemented	   with	   Dimethyl-­‐
sulfoxide	  	  (DMSO),	  aliquoted	  into	  cryo	  vials	  and	  deposited	  at	  -­‐80°C	  in	  2-­‐propanol	  chambers.	  
48	  hours	  later,	  vials	  were	  transferred	  to	  liquid	  nitrogen	  for	  long-­‐term	  storage.	  	  
All	   mammalian	   cells	   were	  maintained	   as	  monolayers	   at	   37˚C	   in	   a	   humidified	   atmosphere	  
containing	  5	  %	  CO₂	  and	  cultured	  in	  the	  stated	  media,	  containing	  10	  %	  (v/v)	  heat	  inactivated	  
fetal	  bovine	  serum	  and	  5	  %	  (v/v)	  penicillin/streptomycin.	  Passaging	  of	  cells	  was	  performed	  
twice	  per	  week,	  using	  sterile	  buffered	  saline	  (PBS)	  for	  washing	  and	  trypsin	  to	  detach	  cells	  of	  
cell	  culture	  dishes.	  Cell	  dilution	  was	  typically	  1:10.	  Geneticin	  was	  added	  the	  following	  day	  to	  
sustain	  FLNA	  expression	  in	  A7	  cells.	  
5.1.2	  Liposomal	  transient	  transfection	  
A	  Neubauer	   chamber	  was	  used	   for	   cell	   counting.	   24	  h	  after	  plating,	   cells	   at	  60	  %	  confluency	  were	  
transfected	   with	   the	   DNA	   plasmid	   constructs	   using	   Lipofectamine	   2000	   reagent	   according	   to	   the	  
manufacturer's	   instructions	   (Table	   1).	   After	   6	   h	   of	   incubation	   in	   OptiMEM,	  medium	  was	   replaced	  
with	   fresh	   medium.	   	   RNA	   and	   protein	   were	   harvested	   24	   to	   48	   h	   post-­‐transfection	   for	   further	  
analysis.	  Control	  cells	  were	  transfected	  in	  parallel.	  All	  transfections	  were	  performed	  in	  triplicate.	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   DNA	  plasmid	  [µg]	   Lipofectamine®	  
2000	  [µL]	  
OptiMEM	  [µL]	   Total	  medium	  
volume	  post	  
transfection	  [mL]	  
6-­‐well	  dish	   4	   5	   250	   2	  
6	  cm	  dish	   8	   10	   500	   4	  
Table	  1:	  Required	  volumes	  for	  liposomal	  transfection	  
5.1.3	  Calcium-­‐phosphate	  transient	  transfection	  
Second	   to	   the	   liposomal	   transfection	  method,	   transient	   transfection	  was	   accomplished	  by	  
calcium	   DNA-­‐precipitation.	   Shortly	   prior	   to	   transfection,	   medium	   was	   replaced	   by	   fresh	  
medium	  without	  antibiotics.	  For	  the	  actual	  transfection	  two	  solutions	  were	  prepared	  (Table	  
2)	  and	  Solution	  1	  was	  added	  drop	  by	  drop	  to	  Solution	  2	  while	  vortexing.	  Subsequently	  the	  
mix	  was	   incubated	   for	   5	  minutes	   at	   room	   temperature	   and	   added	   to	   the	   cells.	   24	  h	   after	  
transfection,	   cells	   were	   washed	   twice	   with	   PBS	   and	   medium	   was	   replaced	   with	   fresh	  
medium	  including	  antibiotics.	  
	   DNA	  plasmid	  
[µg]	  	  
(Solution	  1)	  
2	  M	  CaCl₂	  [µL]	  
(Solution	  1)	  












6-­‐well	  dish	   4	   3.5	   62.5	   62.5	   2	  
6	  cm	  dish	   8	   7	   125	   125	   4	  
Table	  2:	  Required	  volumes	  for	  calcium-­‐phosphate	  transfection	  
5.1.4	  siRNA	  transient	  transfection	  
Knockdown	  of	   target	  genes	  by	  RNA	   interference	   (RNAi)	   results	   in	  a	   transient	  gene-­‐specific	  
reduction	  in	  gene	  expression.	  For	  RNA	  interference,	  cells	  were	  transfected	  with	  either	  50	  nM	  
gene-­‐specific	   small	   interfering	   RNA	   (siRNA)	   or	   50	   nM	   of	   negative	   control	   siRNA	   using	  
Lipofectamine	  RNAiMAX	  according	  to	  the	  manufacturer's	  instructions.	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All	   knockdown	   experiments	   were	   carried	   out	   in	   6-­‐well	   dishes	   and	   a	   reverse	   transfection	  
method	  was	  used.	  2	  µl	   FLNA,	  MKL1	  or	  negative	   control	   siRNA,	  500	  µL	  OptiMEM	  and	  5	  µL	  
Lipofectamine	   RNAiMAX	   	   were	   furnished	   per	   dish	   and	   incubated	   for	   20	  minutes	   at	   room	  
temperature.	   In	  the	  meantime	  2	  x	  10⁵	  A7	  or	  HuH7	  were	  re-­‐suspended	  in	  1.5	  mL	  OptiMEM	  
and	   added	   to	   the	   prepared	   dishes.	   The	   next	   day,	   Medium	   was	   replaced	   by	   2	   mL	   fresh	  
medium	  containing	  serum	  and	  antibiotics.	  Depending	  on	  type	  of	  analysis	  either	  24,	  48	  or	  72	  
h	  post	  transfection,	  knockdown	  efficiencies	  were	  assessed.	  
5.1.5	  Serum	  starvation	  
Serum	  starvation	  was	  achieved	  by	  two	  time	  PBS	  washing,	  followed	  by	  incubation	  in	  culture	  
medium	  supplemented	  wit	  0.2	  %	  fetal	  bovine	  serum	  without	  antibiotics	  for	  16	  h	  overnight.	  
5.1.6	  Serum	  stimulation	  
After	  serum	  starvation,	  cells	  were	  stimulated	  with	  20	  %	  fetal	  bovine	  serum	  USA	  for	  2	  h	  or	  
the	  indicated	  time	  intervals.	  The	  serum	  was	  directly	  added	  to	  the	  growth	  medium	  used	  for	  
starvation.	  
5.1.7	  Drug	  treatment	  
Lysophosphatidic	  acid	  (LPA),	  Latrunculin	  B	  (LatB),	  Jasplakinolide	  and	  Calpain	  Inhibitor	  III	  were	  
diluted	  to	  the	  required	  working	  concentration	  with	  medium	  and	  exposed	  to	  the	  seeded	  cells	  
for	  the	  precise	  amount	  of	  time.	  
5.1.8	  Cell	  harvest	  and	  lysis	  
For	  harvesting,	  cells	  were	  washed	  twice	  with	   ice	  cold	  PBS	  to	  avoid	  degradation	  of	  proteins	  
and	   lysed	   with	   200	   µL	   Kralewski	   buffer	   containing	   protease	   inhibitor	   cocktail	   1:100,	  
phenylmethanesulfonylfluoride	   (PMSF)	   1:500	   and	   dithiothreitol	   (DTT)	   1:250	   or	   in	   case	   of	  
immunoprecipitation	  with	  500	  µL	  1%	  Triton	   IP	   lysis	  buffer.	  Samples	  were	   incubated	   for	  15	  
minutes	   (45	   minutes	   for	   immunoprecipitation)	   on	   ice	   and	   pelleted	   by	   centrifugation	   at	  
13000	   rpm	   for	   15	  minutes	   at	   4˚C.	   The	   supernatant	   containing	   the	   extracted	   proteins	  was	  
transferred	   into	  a	  new	  Eppendorf	  tube,	  supplemented	  with	  4x	  SDS	   loading/Laemmli	  buffer	  
and	  boiled	  at	  95˚C	  for	  10	  minutes.	  The	  protein	  lysates	  were	  stored	  at	  -­‐20˚C	  or	  directly	  used	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for	   immunoblot	   analysis.	   If	   applicable,	   total	   protein	   concentration	  was	  measured	   prior	   to	  
addition	  of	  Laemmli	  buffer	  using	  the	  Bradford	  method.	  
	  
5.2	  Protein	  biochemistry	  
5.2.1	  Determination	  of	  total	  protein	  concentration	  
For	  measuring	  total	  protein	  concentration	  in	  cell	  lysates	  prior	  to	  immunoblot	  analysis,	  Roti-­‐
Quant®	  Bradford	  reagent	  was	  used	  according	  to	  the	  manufacturer's	   instructions.	  2	  µL	   lysis	  
buffer	   served	   as	   blank	   and	   2	   µL	   of	   each	   sample	   were	   diluted	   with	   1000	   µL	   Roti-­‐Quant®	  
Bradford	  Reagent	  (Coomassie	  Brilliant	  Blue	  G-­‐250	  was	  diluted	  1:5	  with	  H₂O	  and	  filtrated)	  and	  
incubated	  at	   room	  temperature	   for	  5	  minutes.	  The	  protein	  concentration	  was	  analyzed	  by	  
measuring	  the	  absorbance	  at	  595	  nm	  with	  the	  BioPhotometer.	  Typically,	  10	  to	  50	  µg	  of	  total	  
protein	  were	  subjected	  to	  immunoblot	  analysis.	  
5.2.2	  Sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  
The	  SDS-­‐PAGE	  method	  was	  used	   to	   separate	  proteins	  according	   to	   their	  molecular	  weight	  
(Laemmli,	   1970).	   Table	   3	   below	   illustrates	   the	   required	   volumes	   for	   a	   single	   1.5	   mm	  
polyacrylamide	  gel.	  
	  
Separating	  gel	   5	  %	   10	  %	   12	  %	  
	   	   	   	  
H₂O	  [mL]	   4.25	   1.99	   2.4	  
30	  %	  polyacrylamide	  
[mL]	  
1.25	   1.67	   3	  
1.5	  M	  TRIS	  (pH	  8.8)	  
[mL]	  
1.875	   1.25	   1.95	  
10	  %	  SDS	  [µL]	   75	   50	   75	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10	  %	  APS	  [µL]	   100	   50	   75	  
TEMED	  [µL]	   6	   2	   3	  
	  
Stacking	  gel	   	  
	   	  
H₂O	  [mL]	   2.7	  
30	  %	  polyacrylamide	  [mL]	   0.67	  
1.5	  M	  TRIS	  (pH	  6.8)	  [mL]	   1	  
10	  %	  SDS	  [µL]	   40	  
10	  %	  APS	  [µL]	   40	  
TEMED	  [µL]	   4	  
Table	  3:	  Composition	  of	  a	  1.5	  mm	  polyacrylamide	  gel.	  
Water,	   acrylamide	   and	   the	   corresponding	   TRIS	   buffer	   were	   pre-­‐mixed.	   Polymerization	  
reaction	  was	  started	  by	  adding	  APS	  and	  TEMED.	  The	  polymerized	  gel	  was	  clamped	  in	  the	  gel	  
electrophoresis	  device	  (BioRad)	  and	  then	  filled	  with	  gel	  running	  buffer.	  The	  gel	  was	  loaded	  
with	   the	   protein	   lysate	   probes	   denatured	   and	   heated	   in	   95˚C	   in	   4	   x	   Laemmli	   buffer	   for	   5	  
minutes.	   Spectra	  Multicolor	  Brad	  Range	  protein	   standard	  was	  used	   as	   a	  molecular	  weight	  
marker	  in	  parallel.	  The	  gel	  electrophoresis	  ran	  at	  a	  constant	  current	  of	  80	  V.	  
5.2.3	  Immunoblotting	  
After	  gel	  electrophoresis,	  proteins	  separated	  according	  to	  their	  mass	  were	  transferred	  from	  
the	  SDS-­‐gel	  onto	  a	  pre-­‐activated	  polyvinylidene	  fluoride	  (PVDF)	  membrane	  using	  the	  minigel	  
system	  (BIORAD)	  (Towbin	  et	  al,	  1979).	  Using	  the	  wet	  blotting	  method	  and	  a	  transfer	  buffer,	  
the	   proteins	  were	   blotted	   at	   a	   constant	   current	   of	   350	  mA	   for	   105	  minutes.	  Membranes	  
were	  blocked	  directly	  in	  5	  %	  nonfat	  dry	  milk	  in	  TBS-­‐T	  for	  1	  h	  at	  room	  temperature	  to	  prevent	  
unspecific	   bindings	   and	   probed	   with	   the	   primary	   antibody	   overnight	   at	   4	   ˚C	   with	   gentle	  
agitation.	   Next	   day,	   membrane	   was	   washed	   three	   times	   with	   TBS-­‐T	   for	   15	   minutes	   and	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thereafter	  probed	  with	  the	  horseradish	  peroxidase-­‐conjugated	  secondary	  antibody	  in	  TBS-­‐T	  
for	  1	  h	  at	  room	  temperature.	  Final	  washing	  was	  done	  three	  times	  for	  5	  minutes	  with	  TBS-­‐T.	  
Protein	  bands	  were	  visualized	  via	  the	  enhanced	  chemiluminescence	  detection	  method	  at	  a	  
luminescent	  imager	  by	  probing	  the	  membrane	  with	  enhanced	  chemiluminescece	  solution	  S1	  
and	  S2	  for	  1	  minute.	  Detection	  with	  HSP90	  antibody	  was	  used	  as	  a	  loading	  control.	  
5.2.4	  Immunoprecipitation	  
For	   immunoprecipitation	  assays,	   cells	  were	  harvested	  24	  h	  after	   transfection	  or	  24	  h	  after	  
seeding	  if	  endogenous	  interactions	  were	  determined.	  Lysis	  was	  accomplished	  by	  adding	  500	  
µL	   1%	   Triton	   IP	   lysisbuffer	   and	   by	   incubation	   on	   ice	   for	   45	   minutes	   followed	   by	  
centrifugation	   (10	  minutes,	   13000	   rpm,	   4	   ˚C).	   20	  µL	   lysate	  was	   taken	   and	   frozen	   for	   later	  
examinations.	  The	   remaining	  480	  µL	  were	   immunoprecipitated	  with	   the	  help	  of	   the	   fitting	  
antibody	   according	   to	   the	   plasmids	   tag.	   This	   pull-­‐down	  was	   accomplished	   with	   3	   µL	   of	   a	  
specific	   antibody	   against	   HA-­‐FLNA,	   FLAG-­‐MKL1	   or	   endogenous	  MKL1,	   FLNA	   and	   overnight	  
rotation	  at	  4	  ˚C.	  Next	  day,	  100	  µL	  of	  four	  times	  1%	  Triton	  IP	  lysisbuffer	  washed,	  recombinant	  
protein	  G-­‐Sepharose	  beads	   in	  a	  50	  %	  slurry	   in	   immunoprecipitation	  buffer	  was	  added,	  and	  
the	   lysates	   were	   rotated	   for	   3	   h	   at	   4	   ˚C.	   Next,	   beads-­‐antibody	   immunoprecipitates	   were	  
collected	  by	   centrifugation	   at	   13000,	  washed	   four	   times	  with	   immunoprecipitation	  buffer,	  
and	   then	   resolved	   with	   SDS-­‐polyacrylamide	   gel	   electrophoresis.	   The	   proteins	   were	   then	  
transferred	  to	  PVDF	  membranes	  and	  immunoblotted	  with	  the	  respective	  antibody.	  
5.2.5	  Indirect	  Immunofluorescence	  
Cells	  grown	  on	  coverslips	  were	  washed	  with	  1	  mL	  PBS,	  fixed	  in	  4	  %	  paraformaldehyde	  for	  10	  
minutes	  at	  room	  temperature	  and	  extracted	  with	  0.2	  %	  Triton	  X-­‐100	   in	  PBS	  for	  7	  minutes.	  
Blocking	   of	   unspecific	   binding	   sites	   was	   performed	   by	   incubation	   in	   1	   %	   bovine	   serum	  
albumin	  in	  PBS	  for	  60	  minutes	  at	  room	  temperature.	  Afterwards	  cells	  were	  incubated	  with	  
the	   primary	   antibody	   (1:1000	   dilution),	   phalloidin	   for	   F-­‐actin	   staining	   or	   4’6-­‐diamidion-­‐2-­‐
phenylindole	   (DAPI)	   for	  nuclei	   staining	  at	   room	  temperature	   for	  1	  h.	  Thereafter	  cells	  were	  
washed	   three	   times	   each	   with	   PBS	   and	   incubated	   with	   fluorescently	   labeled	   secondary	  
antibodies	  for	  30	  minutes	  at	  room	  temperature	  in	  the	  dark.	  In	  the	  concluding	  washing	  step,	  
cells	   were	   washed	   two	   times	   with	   PBS.	   Finally,	   cells	   were	   embedded	   in	   the	   mounting	  
medium	   (Fluoromount®).	   Depending	   of	   the	   nature	   of	   the	   experiment	   a	   snapshot	  
Methods	   	  
	  
	   57	  
fluorescence	   microscope,	   or	   a	   confocal	   microscope	   was	   used.	   For	   normal	   fluorescence	  
microscopy,	  images	  were	  obtained	  on	  a	  Zeiss	  LSM	  510	  microscope.	  
	  
5.3	  Scratch-­‐wound	  assay	  
Cells	  were	   transfected	  and	  allowed	   to	  grow	   to	  a	   confluent	  monolayer.	  After	  a	  wound	  was	  
scratched	  with	   the	   tip	   of	   a	   pipette,	   the	  mobilization	   of	   cells	   behind	   the	  wound	   edge	  was	  
determined	   via	   cell	   counting,	   measuring	   the	   remaining	   wound	   gap	   in	   comparison	   to	   a	  
control	  sample	  and	  immunoblotting.	  Images	  were	  acquired	  on	  a	  Zeiss	  microscope.	  
	  
5.4	  Invasion	  assay	  
The	   invasive	   capacity	   of	   tumor	   cells	   was	   tested	   using	   a	   BD	   BioCoat	   Matrigel	   Invasion	  
Chamber.	  5	  x	  10⁴	  cells	  in	  200	  µL	  medium	  supplemented	  with	  1	  %	  serum	  were	  placed	  in	  the	  
upper	  chamber	  of	  the	  Transwell®	  insert	  whereas	  the	  lower	  chamber	  was	  filled	  with	  600	  µL	  
medium	  containing	  10	  %	  serum	  as	  a	  chemoattractant.	  The	  cells	  were	  allowed	  to	  invade	  for	  
24	   h	   at	   37˚C.	   Invaded	   cells	   were	   visualized	   by	   toluidine	   staining.	   Non-­‐invading	   cells	   were	  
removed	   from	   the	   top	  of	   the	   gel	  with	   a	   sterile	   cotton	   swap.	   For	   fixation	  of	   invaded	   cells,	  
inserts	  were	   incubated	   in	  100	  %	  methanol	   for	  2	  minutes	  and	   subsequently	   stained	   in	  1	  %	  
toluidine	   blue	   solution	   for	   2	  minutes.	   Excess	   dye	  was	   removed	   by	   washing	   the	   inserts	   in	  
distilled	  water.	  The	  inserts	  were	  allowed	  to	  air	  dry.	  Cells	  were	  quantified	  by	  counting	  the	  cell	  
number	  of	  invaded,	  purple-­‐colored	  cells	  using	  a	  Zeiss	  microscope.	  
	  
5.5	  Nucleic	  acid	  biochemistry	  
5.5.1	  RNA	  isolation	  
For	  RNA	  preparation,	  cells	  were	  washed	  twice	  with	  PBS	  and	  0.5	  mL	  TRIzol®	  reagent	  per	  6-­‐
well	   dish	   was	   added	   for	   harvesting.	   Cells	   were	   scrapped	   off,	   transferred	   into	   a	   tube	   and	  
incubated	  for	  5	  minutes	  at	  room	  temperature.	  Next,	  0.2	  mL	  chloroform	  was	  added	  and	  the	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tube	  was	  shaken	  for	  15	  seconds,	  followed	  by	  incubation	  for	  3	  minutes	  at	  room	  temperature.	  
For	  phase	  separation	  the	  sample	  was	  centrifuged	  at	  12700	  rpm	  for	  15	  minutes	  at	  4˚C.	  The	  
aqueous	  phase,	  containing	  the	  RNA	  was	  removed	  and	  placed	  in	  a	  new	  tube.	  For	  precipitation	  
of	  the	  RNA,	  0.25	  mL	  2-­‐propanol	  was	  added,	  followed	  by	  incubation	  at	  room	  temperature	  for	  
10	  minutes.	  Collection	  of	  the	  RNA	  precipitate	  was	  achieved	  by	  centrifugation	  at	  12000	  rpm	  
for	  10	  minutes	  at	  4˚C	  followed	  by	  a	  careful	  removal	  of	  the	  supernatant.	  The	  RNA	  pellet	  was	  
washed	  with	  1	  mL	  75	  %	  ethanol	  and	  then	  centrifuged	  again	  at	  12000	  rpm	  for	  10	  minutes	  at	  
4˚C.	  The	  supernatant	  was	  discarded	  and	  the	  RNA	  was	  allowed	  to	  air	  dry.	  The	  remaining	  RNA	  
was	  re-­‐suspended	  in	  nuclease-­‐free	  water	  and	  dissolved	  by	  incubation	  at	  55˚C	  for	  10	  minutes.	  
RNA	   concentration	   and	   purity	   were	   determined	   by	   photometric	   measurement	   of	   the	  
absorbance.	  	  
5.5.2	  cDNA	  synthesis	  
cDNA	  synthesis	  was	  accomplished	  with	  help	  of	  reverse	  transcriptase.	  Therefore	  two	  cocktails	  
were	  prepared	  (Table	  4).	  For	  cocktail	  A,	  1	  µg	  of	  total	  RNA	  was	  primed	  with	  1	  µL	  of	  Random	  
Hexamers	   (50	   µM)	   and	   nuclease	   free	   water	   was	   added	   to	   reach	   a	   total	   volume	   of	   5	   µL.	  
Denaturation	  was	  obtained	  by	  heating	  at	  70˚C	  for	  5	  minutes,	  followed	  by	  incubation	  at	  4˚C	  
for	  5	  minutes.	  Meanwhile	  cocktail	  B	  (cDNA	  mix)	  mixed.	  
cDNA	  mix/cocktail	  B	   	  
	   	  
5x	  First	  Strand	  Buffer	  [µL]	   4	  
0.1m	  DTT	  [µL]	   2	  
10	  µM	  dNTPs	  [µL]	   1	  
Superscript	  Reverse	  Transcriptase	  II	  	  [µL]	   1	  
Nuclease	  free	  water	  [µL]	   7	  
Table	  4:	  cDNA	  mix	  for	  RT-­‐PCR	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Following	  the	  preparation	  of	  cocktail	  A	  and	  B	  both	  mixtures	  were	  put	  together	  and	  heated	  at	  
25˚C	   for	   5	   minutes	   and	   then	   at	   42˚C	   for	   60	   minutes.	   Next,	   reverse	   transcriptase	   was	  
inactivated	  by	  heating	  to	  70˚C	  for	  15	  minutes.	  The	  prepared	  cDNA	  was	  stored	  at	  -­‐20˚C.	  
5.5.3	  Real-­‐time	  PCR	  
Quantification	  of	  gen	  expression	  was	  done	  with	  the	  SYBR	  green	  method	  (Table	  5).	  	  
Primer	  mix	   	  
	   	  
SYBR	  green	  Master	  I	  mix	  [µL]	   10	  
1	  µM	  Primer	  forward	  [µL]	   1	  
1	  µM	  Primer	  reverse	  [µL]	   1	  
Nuclease	  free	  water	  [µL]	   2	  
Table	  5:	  Primer	  mix	  for	  RT-­‐PCR	  
Each	  quantitative	  PCR	   (final	   reaction	  volume	  20	  µL)	   included	  6	  µL	  cDNA	  (1:10	  diluted	  with	  
H₂O,	  for	  18S	  rRNA	  diluted	  1:100)	  and	  14	  µL	  Primer	  mix.	  Quantification	  was	  performed	  with	  
the	  LightCylcer	  480	  Real-­‐Time	  PCR	  system	  using	  the	  program	  listed	  below	  (Table	  6).	  
Step	   Temperature	  
profile	  
Time	   Function	   	  
1	  	   95˚C	   5	  min	   pre-­‐incubation	   	  
2	   95˚C	   10	  sec	   amplification	   	  
	   55˚C	   10	  sec	   amplification	   	  
	   72˚C	   10	  sec	   elongation	   50	  cycles	  
3	   95˚C	   10	  sec	   melting	  curve	   	  
	   60˚C	   1	  min	   melting	  curve	   	  
	   95˚C	   10	  sec	   melting	  curve	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4	   40˚C	   30	  sec	   cooling	   	  
Table	  6:	  Times	  and	  temperatures	  for	  a	  quantitative	  real-­‐time	  PCR	  reaction.	  
Gene	   expression	  was	   normalized	  with	   respect	   to	   the	   endogenous	   housekeeping	   gene	   18S	  
rRNA,	  which	  was	  determined	  not	  to	  significantly	  change	  under	  different	  conditions.	  	  
5.5.4	  Generation	  of	  ΔMKL1	  mutants	  
The	  Q5	  Site-­‐Directed	  Mutagenesis	  Kit	   (New	  England	  Biolabs)	  was	  used	  for	  deletion	  mutant	  
generation	  in	  a	  three-­‐step	  manner.	  Step	  1:	  Exponential	  amplification.	  Step	  2:	  Kinase,	  Ligase	  
and	  DpnI	  (KLD)	  treatment.	  Step	  3:	  High	  efficiency	  transformation	  
Exponential	  Amplification	  Mix	   Volume	  
Q5	  Hot	  Start	  High	  Fidelity	  2x	  Master	  Mix	  [µL]	   12.5	  
Forward	  Primer	  10	  µM	  [µL]	   1.25	  
Reverse	  Primer	  10	  µM	  [µL]	   1.25	  
Template	  DNA	  25	  ng/µL	  [µL]	   1	  
Nuclease-­‐free	  water	  [µL]	   9	  
Table	  7:	  Step	  1,	  Exponential	  amplification-­‐Mix	  	  
Exponential	  Amplification	  Cycling	  
Conditions	  
Temperature	   Time	  	  








Final	  extension	   72˚C	   120	  s	  
Hold	   4˚C	   	  
Table	  8:	  Step	  1,	  Exponential	  amplification	  Cycling	  conditions	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In	  step	  2	  Kinase,	  ligase	  and	  DpnI	  are	  added	  to	  the	  mix	  and	  incubated	  for	  5	  minutes	  at	  room	  
temperature	  
KLD	  reaction	   Volume	  
PCR	  product	  of	  step	  1	  	  [µL]	   1	  
2	  x	  KLD	  reaction	  buffer	  [µL]	   5	  
10	  x	  KLD	  enzyme	  mix	  [µL]	   1	  
Nuclease-­‐free	  water	  [µL]	   3	  
Table	  9:	  Step	  2,	  KLD	  reaction	  
Finally,	  transformation	  is	  performed	  in	  step	  3.	  Therefore,	  5	  µL	  of	  step	  2-­‐product	  are	  added	  to	  
50	   	   µL	   of	   chemically-­‐competent	   cells	   and	   incubated	  on	   ice	   for	   30	  minutes.	  Next,	   cells	   are	  
heat-­‐shocked	   at	   42˚C	   for	   30	   seconds	   and	   incubated	   on	   ice	   for	   5	   minutes.	   950	   µL	   SOC	  
medium	   is	   added	  and	   the	  mix	   is	   shaken	  at	  37˚C	   for	  1	  h.	  70	  µL	   is	   spread	  onto	  appropriate	  
selection	   plates	   and	   incubated	   over	   night	   at	   37˚C	   followed	   by	   midi	   scale	   plasmid	  
preparation.	  
5.5.5	  Transformation	  into	  chemically	  competent	  E.coli	  DH5alpha	  bacteria	  cells	  
Aliquots	   of	   competent	   E.coli	   DH5alpha	   bacterial	   cells	   were	   stored	   at	   -­‐80˚C.	   For	   each	  
transformation,	  one	  aliquot	  including	  15	  µL	  bacteria	  suspension	  was	  thawed	  for	  15	  minutes.	  
Afterwards	  1	  µL	  plasmid	  DNA	  was	  added	  and	  incubated	  on	  ice	  for	  30	  minutes.	  Next,	  the	  mix	  
was	   heated	   at	   42˚C	   for	   exactly	   90	   seconds	   and	   stored	   on	   ice	   for	   2	  minutes.	   900	   µL	   pre-­‐
warmed	  LB	  medium	  (without	  antibiotics)	  were	  added	  and	  the	  suspension	  was	  shaken	  at	  150	  
rpm	  at	  37˚C	  for	  one	  hour.	  150	  µL	  of	  the	  bacterial	  suspension	  was	  plated	  on	  pre-­‐warmed	  agar	  
plates	   containing	   the	   selection	   antibiotic	   and	   incubated	   overnight	   at	   37˚C.	   Until	   further	  
processing,	  the	  agar	  plate	  was	  sealed	  with	  Parafilm	  and	  stored	  at	  4˚C.	  
5.5.6	  Midi	  scale	  plasmid	  preparation	  
With	  the	  help	  of	  a	  sterile	  pipette	  tip,	  a	  single	  bacterial	  clone	  was	  picked	  and	  transferred	  in	  50	  
mL	   LB	   medium	   containing	   the	   selection	   antibiotic	   and	   thereafter	   incubated	   for	   16	   h	  
overnight	  while	   shaking	   at	   300	   rpm	   at	   37˚C.	   Next	   day,	   bacterial	   cells	  were	   centrifuged	   at	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3500	   rpm	   for	   10	   minutes	   at	   4˚C	   and	   the	   supernatant	   was	   discarded.	   Plasmid-­‐DNA	   was	  
extracted	  using	   the	  GenElute	  HP	  Plasmid	  Midiprep	  Kit.	   Thereafter	  DNA	   concentration	   and	  
purity	  were	  determined	  by	  photometric	  measurement.	  
	  
5.6	  Luciferase	  reporter	  assay	  
Activation	  of	  a	  5	  x	  SRE	   reporter	  gen	  was	  measured	  with	  help	  of	  a	  dual	   luciferase	   reporter	  
assay	  system.	  Cells	  of	  	  60	  %	  confluence	  were	  transfected	  in	  6	  well	  plates.	  Each	  transfection	  
contained	  500	  ng	  of	  the	  5	  x	  SRE	  reporter	  plasmid	  and	  250	  ng	  of	  Renilla	  luciferase	  simian	  virus	  
40	  reporter	  (SV40)	  reference	  reporter	  plasmid,	  which	  was	  used	  to	  normalize	  for	  transfection	  
efficiency.	  24	  h	  post	  transfection	  the	  cells	  were	  lysed	  with	  the	  help	  of	  1x	  passive	  lysis	  buffer	  
and	  centrifuged	  at	  13000	  rpm	  after	  stored	  on	  ice	  for	  15	  minutes.	  Photoemisson	  and	  firefly	  
luciferase	  activity	  was	  determined	  as	  the	  amount	  of	  converted	  luciferin	  into	  oxyluciferin.	  
	  
5.7	  Statistical	  analysis	  
Unless	   otherwise	   indicated,	   data	   were	   expressed	   as	   mean	   +/-­‐	   standard	   deviation	   (SD).	  
Statistical	  analysis	  among	  two	  groups	  was	  carried	  out	  using	  the	  Student's	  unpaired	  t-­‐test.	  P-­‐
values	  are	  *p≤0.05,	  **p≤0.01,	  ***p≤0.001.	  
	  
5.8	  Software	  and	  databases	  
GraphPad	   Prism®	   (GraphPad	   Software,	   LaJolla,	   CA,	   USA)	   was	   used	   for	   calculations	   and	  
statistical	   analysis.	   Research	   publications	   were	   obtained	   from	   the	   online	   database	   NCBI	  
PubMed.	   Blots	   and	   microscopic	   images	   were	   procedded	   with	   ImageJ	   (Wayne	   Rasband,	  
National	  Institute	  of	  Health,	  Bethesda,	  MD,	  USA).	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6.1	  Identification	  of	  FLNA	  as	  a	  novel	  MKL1	  interacting	  protein	  	  
Previously	   to	   this	   work,	   first	   evidence	   of	   an	   existing	   MKL1-­‐FLNA	   interaction	   has	   been	  
presented	   with	   the	   help	   of	   a	   yeast	   two-­‐hybrid	   screening	   performed	   by	   Dr.	   S.	   Muehlich	  
(Kircher	   P.,	   Hermanns	   C.	   et	   al,	   2015).	   Therefore,	   the	   initial	   part	   of	   this	   thesis	   aimed	   for	   a	  
better	  understanding	  of	  the	  interaction’s	  binding	  properties,	  or	  in	  other	  words,	  a	  revelation	  
of	  the	  association	  and	  its	  surroundings	  in	  greater	  detail.	  	  
To	   open	   research	   on	   the	   MKL1-­‐FLNA	   relationship,	   we	   selected	   well-­‐established	   human	  
melanoma	  cell	  lines	  (Cunningham	  CC.,	  Gorlin	  JB.	  et	  al,	  1992),	  consisting	  of	  the	  FLNA-­‐deficient	  
M2	   and	   the	   matching	   stable	   FLNA-­‐expressing	   A7	   cell	   line	   (Fig.	   1A).	   Both	   cell	   lines	   are	  
predestined	   for	   researching	  FLNA	  and	   its	  environment,	   since	   they	  only	  differ	   in	   their	  FLNA	  
expression	   status,	   while	   MKL1	   levels	   and	   other	   biological	   properties	   remain	   untouched	  
(Cunningham	   CC.,	   1995).	   To	   further	   expand	   our	   knowledge	   about	   the	   MKL1-­‐FLNA	  
association,	  especially	  under	  physiological	  conditions,	  we	  included	  alternative	  cell	   lines	   like	  
primary	  human,	  mouse	  and	  3T3	   fibroblasts,	  HuH7	  hepatocellular	   carcinoma,	  MDA-­‐MB-­‐468	  
mammary	  carcinoma,	  HLF	  hepatocellular	  carcinoma,	  and	  HEK-­‐293	  human	  embryonic	  kidney	  
cells	  in	  the	  later	  stages	  of	  the	  work	  (Fig.	  1B).	  	  
As	   described	   in	   2.4.2,	   the	   FLNA	   protein	   is	   susceptible	   to	   cleavage	   caused	   by	   calpain,	   a	  
calcium	   dependent	   protease	   expressed	   ubiquitously,	   which	   the	   Human	   Genome	   Project	  
recently	   revealed	   (Huang	  Y.,	  Mather	  EL.	  et	  al.,	  2001).	  As	  shown	   in	  Fig.	  1C,	  FLNA	  came	   into	  
sight	  as	  a	  strong	  280-­‐kD	  band,	  representing	  unprocessed	  full-­‐length	  FLNA.	  Furthermore,	  we	  
observed	  two	  weaker	  190-­‐kD	  and	  90-­‐kD	  cleavage	  fragments.	  In	  addition,	  we	  were	  also	  able	  
to	  restrain	  FLNA	  cleavage	  by	  incubating	  cells	  with	  a	  calpain	  inhibitor	  III	  (Fig.	  1C).	  All	  following	  
experiments	   in	   this	   work	   were	   performed	   with	   the	   full-­‐length	   FLNA	   version,	   as	   indicated	  
with	   the	   280-­‐kD	   mark	   in	   every	   relevant	   figure.	   Nevertheless,	   curiousness	   about	   FLNA	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cleavage	  fragment	  presence	  remains,	  especially	  in	  context	  with	  a	  physical	  presence	  of	  MKL1,	  
this	  way	  representing	  a	  topic	  of	  high	  value	  for	  future	  studies.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1A:	  Immunoblotting	  for	  FLNA,	  MKL1	  and	  heat	  shock	  protein	  90	  (HSP90)	  as	  a	  loading	  control	  in	  lysates	  
of	  A7	  cells	  endogenously	  expressing	  FLNA	  and	  FLNA-­‐deficient	  M2	  cells.	  
	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   1B:	   endogenic	   MKL1	   and	   FLNA	   levels	   in	   cells	   lysates,	   determined	   by	   immunoblotting.	   HSP90	   as	   a	  
loading	  control.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1C:	   Immunoblot	  analysis	  of	  FLNA,	   its	  calpain	  cleavage	   forms	  and	  HSP90	   in	  A7	  cells	   treated	  with	  the	  
indicated	  amounts	  of	  Calpain	  inhibitor	  III.	   	   	   	  
Every	   performed	   experiment	   necessarily	   relied	   on	   a	   well-­‐approved	   and	   established	  
interaction	  of	  MKL1	  and	  FLNA.	  Therefore,	  we	  were	  heavily	   interested	   in	  strengthening	   the	  
original	  yeast	  two-­‐hybrid	  findings	  by	  performing	  immunoprecipitations.	  This	  setup	  not	  only	  
allowed	  us	  to	  support	  the	  primary	  findings	  by	  a	  second	  well	  respected	  biochemical	  method	  
but	  also	  guaranteed	  insights	  under	  in	  vivo	  like	  environmental	  conditions.	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We	   carried	   out	   immunoprecipitation	   experiments	   of	   A7	  melanoma	   cells	   expressing	   FLAG-­‐
tagged	  MKL1.	  MKL1	   was	   immediately	   detectable	   after	   immunoprecipitation	   of	   FLNA	   (Fig.	  
1D).	   This	   observation	   proves	   a	   direct	   interaction	   between	  MKL1	   and	   FLNA,	   because	   only	  
FLNA	  bound	  MKL1	  is	  detectable	  after	  the	  process	  of	  precipitation.	  
This	   precipitation	   method	   includes	   A7	   melanoma	   cell	   plating,	   MKL1	   transfection,	   cell	  
harvesting	   and	   lyse,	   addition	   of	   FLNA	   antibody	   for	   association	   with	   available	   MKL1,	  
overnight	   rotation,	   beads	   incubation,	   which	   exclusively	   bind	   the	   before	   incubated	   (FLNA)	  
antibody,	  washing	  and	  finally	  blotting	  with	  a	  second,	  this	  time	  FLAG-­‐MKL1	  antibody	  which	  is	  
only	  able	   to	  detect	  MKL1	   if	  a	  previous	   interaction	  with	  the	  FLNA	  antibody	  has	   taken	  place	  
after	   cell	   lyse.	   To	   furthermore	   exclude	   a	   clonal	   difference	   in	   A7	   cell	   nature,	   control	  
experiments	  were	  carried	  out,	  using	  the	  same	  experimental	  setup	  in	  the	  FLNA-­‐negative	  M2	  
cell	  line.	  As	  anticipated,	  FLNA	  and	  MKL1	  were	  only	  recovered	  from	  FLNA	  immunoprecipitates	  
when	  FLNA	  was	   re-­‐expressed	   in	  M2	  cells	   (Fig.	  1E).	  Moreover,	  neither	  FLNA	  nor	  MKL1	  was	  
observed	  in	  immunoprecipitates	  with	  an	  unspecific	  primary	  antibody,	  further	  confirming	  the	  
specificity	  of	  the	  MKL1-­‐FLNA	  interaction	  (Fig.	  1F).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1D:	   Immunoprecipitation	   (IP)	   for	  FLNA	  and	  Western	  blot	   (IB)	   for	  MKL1	  and	  FLNA	   in	   lysates	   from	  A7	  
cells	  transfected	  with	  FLAG-­‐tagged	  MKL1.	  BO,	  Sepharose	  beads-­‐only	  control,	  without	  antibody.	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Figure	   1E:	   Recovery	   of	   FLNA	  and	  MKL1	   in	   immunoprecipitates	  with	   FLNA	  antibody	  upon	   reconstitution	  of	  
FLNA	   in	   the	   FLNA-­‐negative	   cell	   line	   M2,	   transfected	   with	   FLAG-­‐MKL1	   or	   EV.	   BO,	   Sepharose	   beads-­‐only	  
control,	  without	  antibody.	  EV,	  empty	  vector.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1F:	  Immunoprecipitation	  with	  HSP90	  antibody	  as	  an	  unspecific	  primary	  antibody	  in	  A7	  cells	  expressing	  
FLAG-­‐tagged	  MKL1	  yielding	  no	  binding	  of	  FLNA	  and	  MKL1.	  	  
Next,	  we	  were	  wondering	   if	   it	   likewise	  would	  be	  possible	   to	  detect	  an	  endogenous	  MKL1-­‐
FLNA	  interaction	  besides	  the	  so	  far,	  in	  a	  certain	  way	  forced	  interaction	  based	  on	  transfection	  
into	  the	  cell.	  Consequently,	  we	  expanded	  our	  cell	   library	  with	  mouse	  embryonic	  fibroblasts	  
(MEFs)	   (Fig.	   1G),	   HuH7	   hepatocellular	   carcinoma	   cells	   (Fig.	   1H),	   MDA-­‐MB-­‐468	   mammary	  
carcinoma	   cells	   (Fig.	   1H),	   HLF	   hepatocellular	   cancer	   cells	   (Fig.	   1I)	   and	   HEK-­‐293	   human	  
embryonic	   kidney	   cells	   (Fig.	   1I).	   MEF,	   HuH7	   and	   MDA-­‐MB-­‐468	   cell	   lines	   successfully	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confirmed	  the	  data	  obtained	  in	  A7	  cells	  (Fig	  1G,H),	  while	  HLF	  and	  HEK-­‐293	  cells	  displayed	  no	  
measurable	   interaction	  (Fig.	  1I).	  Thus,	  we	  were	  able	  to	  majorly	  add	  to	  our	  knowledge	  that	  
the	  MKL1-­‐FLNA	  interaction	  takes	  place	  in	  a	  broad	  variety	  of	  non-­‐cancer	  and	  cancer	  cell	  lines	  
instead	  of	  just	  melanoma	  cells.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1G:	  IP	  for	  FLNA	  and	  IB	  for	  MKL1	  and	  FLNA	  in	  lysates	  from	  MEFs.	  BO,	  without	  antibody.	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Figure	  1I:	  IP	  for	  FLAG	  and	  IB	  for	  FLAG	  and	  FLNA	  in	  lysates	  from	  HLF,	  HEK293	  and	  MDA	  MB-­‐468.	  MDA	  MB-­‐468	  
as	  a	  positive	  control.	  BO,	  without	  antibody.	  
After	  successfully	  stating	  the	  presence	  of	  a	  new	  interaction	  in	  a	  variety	  of	  cancer	  and	  non-­‐
cancer	  cell	   lines,	  questions	  were	  raised	  in	  which	  cell-­‐compartment	  the	  interaction	  is	  taking	  
place.	  Consistent	  with	   literature	  knowledge	   that	  MKL1	   is	   regularly	   found	   in	   the	  nucleus	  of	  
DLC1-­‐defficient	  tumor	  cells	  (Muehlich	  S.,	  Hampl	  V.	  et	  al,	  2011),	  double	  immunofluorescence	  
with	   differentially	   labeled	   antibodies	   specific	   for	  MKL1	   and	   FLNA	   revealed	   that	  MKL1	   and	  
FLNA	  co-­‐localized	  predominantly	  in	  the	  nucleus	  in	  A7	  melanoma	  cells	  (Fig.	  1J).	  Adding	  to	  our	  
data	  that	  MKL1	  accumulated	  in	  the	  nucleus	  of	  A7	  melanoma	  cells,	  we	  demonstrated	  MKL1	  
relocation	  to	  the	  cytoplasm	  in	  FLNA-­‐deficient	  M2	  cells	  or	  A7	  cells	  treated	  with	  FLNA	  siRNA	  
(Fig.	  1K).	  Untreated	  A7	  cells	  displayed	  70	  %	  nuclear	  MKL1	  localization,	  while	  FLNA	  depletion	  
or	   experiments	   performed	   in	   M2	   cells	   lead	   to	   a	   strong	   reduction	   of	   nuclear	   MKL1	  
appearance	  to	  around	  20	  %	  (Fig.	  1K).	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Figure	   1J:	   Immunofluorescence	   analysis	   of	   MKL1	   and	   FLNA	   in	   A7	   cells.	   Scale	   bar,	   20	   μm.	   Representative	  
images	  are	  shown.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   1K:	   Immunofluorescence	   analysis	   with	   anti-­‐FLAG	   antibody	   of	   MKL1	   in	   M2	   and	   A7	   cells	   (top	   and	  
bottom	   left)	  and	  A7	  cells	   treated	  with	  50	  nM	  siFLNA	  or	  50nM	  negative	  control	   siRNA	  (ctrl)	   (bottom	  right).	  
Data	   are	  means	   +/-­‐	   SD	   (n=3	   experiments).	   100	   cells	   counted	   each	   experiment.	   Representative	   images	   are	  
shown.	  	  Scale	  bar,	  20	  μm	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6.2	  Mapping	  of	  MKL1-­‐FLNA	  binding	  sites	  
After	  validating	  the	  interactions	  existence	  and	  further	  proving	  its	   location	  of	  appearance	  in	  
the	   cell,	  we	  devoted	   to	   the	   upcoming	   question	  which	  MKL1	   regions	   are	   indispensable	   for	  
binding	   FLNA.	   To	   catch	   answers,	   we	   staked	   genetically	   engineered	   FLAG-­‐tagged	   MKL1	  
mutants.	  More	  precisely,	  we	  used	  different	  MKL1	  deletion	  variants,	  covering	  a	  certain	  span	  
of	  amino	  acids	  to	  identify	  protein	  segments	  essential	  for	  FLNA	  interaction	  (Fig.	  2A).	  Based	  on	  
this	  model	  of	  step-­‐by-­‐step	   isolation	  of	  unnecessary	  MKL1	  regions,	  we	  were	  able	  to	  narrow	  
down	  the	  localization	  of	  the	  interaction	  to	  a	  region	  of	  10	  amino	  acids	  on	  the	  MKL1	  protein	  
(MKL1	  301-­‐310)	  (Fig.	  2A	  and	  B).	  
	  
Figure	  2A:	  Schematics	  oft	  the	  MKL1	  derivatives	  used	  for	  mapping	  MKL1-­‐FLNA	  binding	  sites.	  RPEL,	  conserved	  
N-­‐terminal	   domain;	   B,	   basic	   domain;	   Q,	   glutamine-­‐rich	   domain;	   SAP,	   SAF-­‐A/B-­‐Acinus-­‐PIAS	   domain;	   LZ,	  
leucine	  zipper-­‐like	  domain;	  TAD,	  transactivation	  domain.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  2B:	  Table	  of	  MKL1	  derivatives	  indicating	  binding	  (+)	  or	  no	  binding	  (-­‐)	  to	  FLNA.	  	  
Since	  one	  of	  MKL1s	  most	   important	   regulator	  and	  binding	  partner	  G-­‐actin	   is	   facilitated	  via	  
MKL1s	  N-­‐terminal	  RPEL	  domain	  we	  thought	  about	  starting	  the	  investigation	  right	  here	  at	  the	  
N-­‐terminal	  site.	  Immunoprecipitation	  of	  cell	  extracts	  with	  an	  antibody	  against	  the	  FLAG-­‐Tag	  
and	  detection	  with	  FLNA	  antibodies	  showed	  that	  an	  N-­‐terminal	  deletion	  construct	  of	  MKL1	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lacking	  the	  first	  300	  amino	  acid	  residues	  (N300),	   this	  way	  also	   lacking	  the	  considered	  RPEL	  
domain,	  was	  still	  able	  to	  bind	  FLNA	  (Fig.	  2C).	  After	  eliminating	  the	  N-­‐terminal	  domain	  as	  a	  
possible	   interacting	   area,	   we	   shifted	   focus	   on	   the	   C-­‐terminal	   protein	   end.	   However,	   C-­‐
terminal	   deletion	   constructs	   of	  MKL1	   (C500,	   C630	   and	   C830)	   likewise	   still	   interacted	  with	  
FLNA,	  narrowing	  the	  possible	  field	  of	  interaction	  with	  FLNA	  down	  to	  amino	  acid	  MKL1	  300-­‐
500	  (Fig.	  2D).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
Figure	  2C:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	   or	   the	   indicated	  MKL1	  mutants.	   BO,	   Sepharose	   beads-­‐only	   control.	   A	   portion	   of	   the	   cell	  
lysate	  was	  also	  directly	  immunoblotted.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2D:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	   or	   the	   indicated	  MKL1	  mutants.	   BO,	   Sepharose	   beads-­‐only	   control.	   A	   portion	   of	   the	   cell	  
lysate	  was	  also	  directly	  immunoblotted.	  
To	  further	  progress	  in	  cutting	  down	  the	  potential	  region	  of	  interaction,	  we	  next	  constructed	  
internal	  deletions	  of	  amino	  acids	  301	  to	  380	  (Δ301-­‐380)	  and	  amino	  acids	  381	  to	  506	  (Δ381-­‐
506),	   spanning	   the	   remaining	   200	   unexplored	   amino	   acids.	  Whereas	  MKL1	   Δ381-­‐506	   still	  
associated	   with	   FLNA,	   an	   interaction	   between	   MKL1	   Δ301-­‐380	   and	   FLNA	   was	   hardly	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detectable,	  no	  matter	  which	  antibody	  was	  used	   for	  pull-­‐down	  efforts	   (FLNA	  or	  FLAG)	   (Fig.	  
2E).	  
	  
	  	   	  	  
	  
	   	  
	  
Figure	  2E:	   Immunoprecipitation	  and	  Western	  blot	  as	   indicated	   in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  
wild-­‐type	  (WT)	  MKL1	  or	  the	  indicated	  MKL1	  mutants.	  FLNA	  pulldown	  (top),	  FLAG	  pulldown	  (bottom).	  BO,	  
Sepharose	  beads-­‐only	  control.	  A	  portion	  of	  the	  cell	  lysate	  was	  also	  directly	  immunoblotted.	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As	   described	   in	   2.3.1	   the	   SAP	   domain	   of	   MKL1	   is	   supposed	   to	   be	   of	   certain	   importance	  
regarding	  promoter	  activity.	  Moreover	  the	  domain	  lies	  between	  amino	  acids	  343	  and	  378	  in	  
MKL1,	   which	   made	   us	   wondering	   about	   its	   contribution	   to	   the	   MKL1-­‐FLNA	   interaction.	  
However,	  FLNA	  still	  interacted	  with	  an	  MKL1	  mutant	  lacking	  the	  SAP	  domain	  (Fig.	  2F).	  
	  	  	  	  	  	  	   	  
Figure	  2F:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	   or	   the	   indicated	  MKL1	  mutants.	   BO,	   Sepharose	   beads-­‐only	   control.	   A	   portion	   of	   the	   cell	  
lysate	  was	  also	  directly	  immunoblotted.	  
Following	  the	  result	  of	  this	  experiment	  we	  predicted	  that	  the	  FLNA	  binding	  site	  was	  located	  
in	   a	   region	   spanning	   residues	   301	   to	   342	   in	   MKL1.	   Indeed,	   a	   Δ301-­‐342	   MKL1	   construct	  
displayed	   diminished	   FLNA	   binding	   in	   immunoprecipitation	   assays	   and	   binding	   further	  
decreased	  with	   a	  mutant	   lacking	   amino	   acids	   301	   to	   310,	   supporting	   our	   conclusion	   that	  
these	   amino	   acids	   are	   required	   for	   FLNA	  binding	   (Fig.	   2G	   and	  H).	   Concluding	   experiments	  
were	  performed	  by	  addressing	  MKL1	  amino	  acids	  305	  and	  312.	  We	  chose	  these	  amino	  acids	  
in	   particular	   because	   both	   of	   them	   provide	   targets	   for	   a	   possible	   phosphorylation,	   which	  
plays	  a	  major	  role	  in	  MKL1	  regulation	  and	  both	  are	  located	  in/next	  to	  the	  newly	  discovered	  
interaction	   area.	   However,	   imunoprecipitation	   analysis	   including	   point	   mutants	   of	   MKL1	  
T305A	  and	  S312A	  showed	  no	  abolished	  FLNA	  interaction	  (Fig.	  2I).	  In	  addition	  we	  took	  a	  look	  
at	   the	   interaction	  of	  MKL2	  with	   FLNA.	  MKL2	  displayed	  a	  weaker	   association	   to	   FLNA	   than	  
MKL1	  did	  (Fig.	  2J).	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Figure	  2G:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	   or	   the	   indicated	  MKL1	  mutants.	   BO,	   Sepharose	   beads-­‐only	   control.	   A	   portion	   of	   the	   cell	  




Figure	  2H:	  Model	  of	  the	  MKL1-­‐FLNA	  interaction	  happening	  at	  aa	  301-­‐310	  on	  the	  MKL1	  protein.	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Figure	  2I:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	   or	   the	   indicated	  MKL1	  mutants.	   BO,	   Sepharose	   beads-­‐only	   control.	   A	   portion	   of	   the	   cell	  
lysate	  was	  also	  directly	  immunoblotted.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  2J:	  Immunoprecipitation	  and	  Western	  blot	  as	  indicated	  in	  A7	  cells	  transfected	  with	  FLAG-­‐tagged	  wild-­‐
type	   (WT)	  MKL1	  or	  MKL2.	  BO,	  Sepharose	  beads-­‐only	   control.	  A	  portion	  of	   the	   cell	   lysate	  was	  also	  directly	  
immunoblotted.	  
To	   onward	   expand	   our	   knowledge	   about	   MKL1-­‐FLNA	   interaction,	   we	   set	   out	   to	   define	  
protein	  segments	  of	  FLNA	  essential	  for	  the	  interaction	  with	  MKL1.	  FLNA	  offers	  a	  large	  variety	  
of	  possible	  interaction	  sites	  for	  binding	  partners	  as	  already	  mentioned	  in	  2.4.3.	  It	  contains	  a	  
filamentous	  F-­‐actin	  binding	  domain	  at	   the	  N	   terminus	  and	  a	   rod	   segment	   consisting	  of	  24	  
homologous	  repeats,	  separated	  into	  Rod1	  (repeats	  1	  to	  15)	  and	  Rod2	  (repeats	  16	  to	  23)	  by	  
two	  hinge	  domains	  (Stossel	  TP.,	  Condeelis	  J.	  et	  al,	  2001).	  Therefore	  we	  transfected	  a	  series	  
T305A  BO    S312A 
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of	  vectors	  expressing	  hemagglutinin	  (HA)-­‐tagged	  FLNA	  fragments	  spanning	  the	  FLNA	  protein	  
into	  A7	  melanoma	  cells	  together	  with	  FLAG-­‐MKL1	  cDNA.	  Immunoprecipitation	  experiments	  
revealed	  that	  FLNA	  amino	  acids	  571	  to	  866	  and	  amino	  acids	  1779	  to	  2284	  (corresponding	  to	  
repeats	  4	  to	  7	  in	  the	  Rod1	  domain	  and	  repeats	  16	  to	  18	  in	  the	  Rod2	  domain)	  were	  essential	  
for	   the	   interaction	   with	   MKL1,	   whereas	   other	   FLNA	   regions	   did	   not	   contribute	   to	   the	  
interaction	  (Fig.	  2K	  and	  L).	  Therefore	  we	  could	  show	  two	  possible	  interaction	  sites	  on	  FLNA,	  
located	  on	  both,	  Rod1	  and	  2,	  suggesting	  a	  complex	  interaction	  occurring	  between	  multiple	  
regions	  of	  FLNA	  and	  MKL1.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2K:	  Immunoprecipitation	  and	  immunoblotting	  as	  indicated	  in	  A7	  cells	  co-­‐transfected	  with	  a	  HA-­‐tagged	  
FLNA	  construct	  (1:	  FLNA	  amio	  acids	  276	  to	  570;	  2:	  FLNA	  amino	  acids	  571	  to	  866;	  3:	  FLNA	  amino	  acids	  1155	  to	  
1442;	  4:	  FLNA	  amino	  acids	  1779	  to	  2284;	  5:	  FLNA	  amino	  acids	  2285	  to	  2729)	  and	  FLAG-­‐MKL1.	  BO,	  Sepharose	  
beads-­‐only	  control.	  A	  portion	  of	  the	  cell	  lysate	  was	  also	  directly	  immunoblotted.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   2L:	   Immunoprecipitation	   assay	   of	   A7	   cells	   cotransfected	   with	   FLAG-­‐MKL1	   and	   HA-­‐tagged	   FLNA	  
fragments	   spanning	  FLNA	  aa	  1-­‐275	  or	  571-­‐866	  using	  antibodies	  against	  HA	  or	  FLAG.	  BO,	  Sepharose	  beads-­‐
only	  control.	  A	  portion	  of	  the	  cell	  lysate	  was	  also	  directly	  immunoblotted.	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6.3	   The	   dynamic	   MKL1-­‐FLNA	   interaction,	   its	   correlation	   with	   the	  
induction	   and	   repression	   of	   MKL1-­‐SRF	   target	   genes	   and	  
phosphorylation	  influence	  
After	  mapping	  the	  interaction	  in	  detail,	  our	  attention	  next	  focused	  on	  its	  condition	  under	  the	  
influence	  of	  extracellular	  signals.	  	  Since	  activation	  of	  the	  Rho-­‐actin	  cascade	  is	  known	  to	  have	  
a	  significant	  effect	  on	  MKL1	  activity	  (2.2.1.2),	  we	  first	  took	  a	  look	  at	  this	  particular	  pathway.	  
In	   detail,	   we	   examined	   whether	   activation	   or	   inhibition	   of	   Rho-­‐actin	   signaling	   alters	   the	  
MKL1-­‐FLNA	   association.	   Activation	   of	   Rho-­‐actin	   signaling	   was	   achieved	   via	   treatment	   of	  
primary	   human,	   3T3	   fibroblasts	   and	   HepG2	   human	   liver	   cells	   with	   lysophosphatidic	   acid	  
(LPA).	  LPA	  is	  a	  potent	  lipid	  mediator	  with	  actions	  on	  many	  cell	  types.	  One	  prominent	  cellular	  
response	   induced	  by	  LPA	   is	   rearrangement	  of	   the	  actin	   cytoskeleton.	   LPA	   therefore	   forces	  
actin	   polymerization	   by	   Rho	   activation,	   resulting	   in	   stress-­‐fiber	   formation	   (Muehlich	   S.,	  
Schneider	  N.	  et	  al,	  2004;	  Fukushima	  N.,	  Ye	  X.	  et	  al,	  2002).	  	  
Regarding	   IP-­‐binding	  experiments,	  we	  found	  that	  LPA	  stimulation	  promotes	  the	  amount	  of	  
endogenous	  MKL1	  that	  co-­‐immuoprecipitated	  with	  endogenous	  FLNA	  in	  both	  fibroblast	  cell	  
lines	  (Fig.	  3A)	  and	  HepG2	  cells	  (Fig.	  3B).	  	  
	  	  	  	  
	  
Figure	  3A:	  Immuoprecipitation	  using	  FLNA	  antibody	  and	  Western	  blot	  for	  the	  indicated	  endogenous	  proteins	  
in	   3T3	   fibroblasts	   (left)	   and	  primary	  human	   fibroblasts	   (right)	   incubated	  with	  or	  without	   10	  μM	  LPA	   for	   2	  
hours.	  A	  portion	  of	  the	  cell	  lysate	  was	  also	  directly	  immunoblotted.	  
Results	  	  	  	  	  	  	  
	  
	   78	  
	  	  	  	  	   	  
Figure	  3B:	  Immuoprecipitation	  using	  FLNA	  antibody	  and	  Western	  blot	  for	  the	  indicated	  endogenous	  proteins	  
in	  HepG2	  cells	  incubated	  with	  or	  without	  10	  μM	  LPA	  for	  2	  hours.	  A	  portion	  of	  the	  cell	  lysate	  was	  also	  directly	  
immunoblotted.	  
To	  further	   investigate	  on	  this	  phenomenon,	  we	  once	  again	  examined	  MKL1	  localization.	  As	  
anticipated,	  MKL1	  relocated	  into	  the	  nucleus	  of	  primary	  and	  3T3	  fibroblasts	  when	  incubated	  
with	  LPA	  in	  comparison	  to	  cytoplasmic	  MKL1	  rest	  without	  LPA	  treatment	  (Fig.	  3C).	  Again,	  this	  
fits	  well	  with	  the	  immunoprecipitation	  data	  obtained	  in	  3T3	  and	  primary	  human	  fibroblasts	  
(Fig.	  3A),	  showing	  no	  or	  only	  little	  signs	  of	  interaction	  prior	  LPA	  treatment.	  Apparently,	  these	  
findings	  also	  differ	  from	  the	  IP-­‐binding	  data	  we	  obtained	  in	  cancer	  cells,	  like	  for	  instance	  A7	  
(Fig.	  1D),	  HuH7	   (Fig.	  1H)	  or	  MDA	  MB-­‐468	   (Fig.	  1H).	   Interestingly	   these	  cancer	  cells	  neither	  
had	   to	  be	  activated	   to	  achieve	  MKL1-­‐FLNA	  association,	  nor	  has	   it	  been	  necessary	   to	   force	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Figure	   3C:	   Immunofluorescence	   analysis	   of	  MKL1	   in	   primary	   fibroblasts	   treated	  with	  or	  without	   LPA.	   4’,6-­‐
Diamidino-­‐2-­‐phenylindole	  (DAPI)	  (blue)	  as	  nuclear	  counterstain.	  Scale	  bar,	  200μm.	  
In	   addition,	  MKL1	  also	   accumulated	   in	   the	  nucleus	  of	   LPA-­‐treated,	   post	   knockdown	  FLNA-­‐
depleted	   fibroblasts,	   suggesting	   that	   the	   actual	  MKL1	   nuclear	   translocation	   process	   upon	  
LPA	  addition	  is	  not	  essentially	  dependent	  on	  a	  FLNA	  binding	  in	  fibroblasts	  (Fig.	  3D).	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Figure	  3D:	  Immunofluorescence	  with	  an	  antibody	  specific	  for	  MKL1	  (and	  counterstained	  with	  DAPI)	  to	  assess	  
the	   translocation	   of	  MKL1	   to	   the	   nucleus	   upon	   LPA	   treatment	   in	   3T3	   fibroblasts	   expressing	   50	   nM	   FLNA	  
siRNA.	  Scale	  bar,	  200μm.	  
Next,	  we	  explored	  the	  functional	  effects	  implicated	  by	  the	  MKL1-­‐FLNA	  interaction.	  Therefore	  
we	   addressed	   qRT-­‐PCR	   analysis.	   Interestingly,	   we	   found	   that	   association	   of	   endogenous	  
MKL1	   and	   FLNA	   upon	   LPA	   treatment	   was	   accompanied	   by	   the	   induction	   of	   the	   well-­‐
established	  MKL1	  target	  genes	  SM22,	  CTGF,	  ITGA5	  and	  CNN1	  in	  primary	  fibroblasts	  (Fig.	  3E).	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Figure	  3E:	  Quantitative	   real-­‐time	  polymerase	  chain	   reaction	   (qRT-­‐PCR)	  analysis	  of	   the	  mRNA	  expression	  of	  
SM22,	  CTGF,	  ITGA5	  and	  CNN1	  in	  primary	  human	  fibroblasts	  after	  2	  hours	  of	  LPA	  stimulation	  compared	  with	  
controls.	  Data	  are	  means	  +/-­‐	  SD	  (n=3	  experiments).	  *P	  <	  0.05,	  **P	  <	  0.01,	  unpaired	  Student’s	  t	  test.	  
After	  picturing	  the	  correlation	  between	  Rho-­‐actin/LPA	  activation	  and	  MKL1-­‐FLNA	  association	  
we	   next	   investigated	   on	   its	   biological	   counterpart:	   Suppression	   of	   the	   interaction	   via	  
utilization	   of	   an	   actin	   polymerization	   inhibitor.	   Treatment	   with	   latrunculin	   B	   (LatB)	  
effectively	  blocked	  complex	   formation	  between	  MKL1	  and	  FLNA	   in	  A7	  melanoma	  cells	  and	  
led	   to	   redistribution	   of	   MKL1	   into	   the	   cytoplasm,	   therefore	   showing	   fibroblast-­‐like	  
characteristics	  (Fig.	  3F).	  Strengthening	  our	  findings	  about	  cytoplasmic	  MKL1	  re-­‐localization,	  
performed	   qRT-­‐PCR	   analysis	   revealed	   an	   inhibitory	   effect	   by	   LatB	   incubation	   on	   the	  
characteristic	  MKL1	   target	   gene	   SRF	   in	   A7	   cells	   (Fig.	   3G).	   As	   expected,	   FLNA-­‐depleted	  M2	  
cells	  showed	  no	  discrepancy	  by	  treatment	  with	  LatB	  compared	  to	  no	  LatB	  incubation.	  Their	  
SRF	   levels	   remained	   low	   in	  either	  approach	   (Fig.	  3G).	  These	  observations	  are	  also	  meshing	  
very	  well	  with	  the	  previously	  achieved	  oppositional	  effect	  on	  target	  gene	  activation	  by	  LPA	  
treatment	  (Fig.	  3E).	  Additionally	  executed	  SRF	  reporter	  gene	  assays	  confirmed	  this	  data	  once	  
again	  by	  delivering	  similar	  results	  as	  obtained	  in	  qRT-­‐PCR	  investigations	  (Fig.	  3H).	  
On	   a	   mechanistic	   viewpoint,	   LatB	   binds	   actin	   monomers	   in	   a	   one	   to	   one	   stoichiometry,	  
thereby	   efficiently	   blocking	   binding	   to	   adenosintriphosphat	   (ATP),	   preventing	   actin	  
polymerization	  (Yarmola	  E.,	  Somasundaram	  T.	  et	  al,	  2000).	  	  Only	  while	  bound	  to	  ATP,	  G-­‐actin	  
is	   able	   to	   polymerize	   into	   filamentous	   F-­‐actin,	   this	  way	   LatB	   disrupts	   F-­‐actin	   cytoskeleton	  
formation	  and	  particularly	  important,	  forces	  MKL1	  localization	  into	  the	  cytoplasm.	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To	  sum	  it	  up,	  the	  MKL1-­‐FLNA	  interaction	  displays	  a	  highly	  dynamic	  form	  of	  interaction	  which	  
consequences	   in	  divergent	   levels	  of	  visible	  association	  and	  MKL1	   localization.	  Moreover,	   it	  
pinpoints	   a	   clear	   correlation	   between	   the	   intensity	   of	   the	  MKL1-­‐FLNA	   interaction	   and	   the	  
amplitude	  of	  MKL1-­‐SRF	  target	  gene	  induction	  (Illustrated	  by	  the	  usage	  of	  actin	  drugs	  LPA	  and	  
LatB).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  3F:	  (Top	  left)	  Immunoprecipitation	  and	  Western	  Blot	  as	  in	  (A)	  in	  A7	  cells	  expressing	  FLAG-­‐tagged	  MKL1	  
treated	  with	  or	  without	  0.3	  μM	  LatB	   for	  45	  min.	   (Top	  right)	   Immunofluorescence	  analysis	  of	  MKL1	   in	  cells	  
treated	  as	  in	  top	  left.	  Scale	  bar	  200	  μm.	  (Bottom)	  Statistical	  analysis	  of	  (Top	  right),	  100	  cells	  counted.	  	  
	  
Figure	  3G:	  A7	  and	  M2	  cells	  were	  subjected	  to	  qRT-­‐PCR	  using	  SRF	  primers.	  Data	  are	  means	  +/-­‐	  SD	  (	  n	  =	  2).	  rel,	  
relative	  to	  18S	  rRNA.	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Figure	  3H:	   	  Luciferase	  assays	   for	  5xSRE	  reporter	  activity	   in	  A7	  cells	   transfected	  with	  a	  5xSRE	  reporter	  gene	  
and	  a	  Renilla	  luciferase	  internal	  control	  vector	  (pRL-­‐SV40P)	  and	  treated	  with	  or	  without	  0.3	  μM	  LatB	  for	  45	  
min.	  	  
Work	   from	   our	   laboratory	   revealed	   that	   MKL1	   phosphorylation	   by	   the	   kinase	   ERK	   1/2	  
enhances	  G-­‐actin	  binding	  to	  MKL1,	  thus	  leading	  to	  a	  significant	  higher	  rate	  of	  nuclear	  export	  
(Muehlich	   S.,	  Wang	   R.	   et	   al,	   2008).	   For	   that	   reason	  we	  wondered	  weather	   there	   is	   a	   link	  
between	  FLNA	  binding	   to	  MKL1	  and	  a	   thereby	   forced	   switch	   from	  the	   repressive	  MKL1-­‐G-­‐
actin	  to	  a	  MKL1-­‐F-­‐actin	  complex	  due	  to	  alteration	  of	  MKL1	  phosphorylation	  status	  by	  FLNA.	  
Phosphorylated	  MKL1	  finds	  itself	  shifted	  to	  a	  slower-­‐migrating	  form	  in	  SDS	  gels,	  plus	  it	  is	  well	  
detectable	   by	   an	   antibody	   that	   specifically	   recognizes	   phosphorylated	   MKL1.	   Under	  
experimental	   conditions	   we	   observed	   the	   change	   in	   mobility	   caused	   by	   MKL1	  
phosphorylation	  and	  could	  detect	  p-­‐MKL1	  in	  FLNA-­‐deficient	  M2.	  In	  FLNA-­‐expressing	  A7	  cells	  
however,	   no	   p-­‐MKL1	   signal	   was	   observable	   (Fig.	   3I).	   To	   provide	   further	   evidence,	   we	  
knocked	   down	   FLNA	   in	   A7	   cells,	   creating	   a	  M2	   cell-­‐like	   environment.	   Consistent	  with	   the	  
previous	   obtained	   results,	   the	   p-­‐MKL1	   signal	   became	   visible	   after	   treatment	   with	   FLNA	  
siRNA	  (Fig.	  3I).	  Taken	  together,	  these	  experiments	  provide	  evidence	  that	  FLNA	  inhibits	  MKL1	  
phosphorylation	   and	   may	   this	   way	   counteract	   the	   repressive	   MKL-­‐G-­‐actin	   complex	   by	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Figure	  3I:	  Immunoblotting	  for	  the	  indicated	  proteins	  in	  A7	  and	  M2	  cells	  (left)	  and	  A7	  cells	  expressing	  50nM	  














Results	  	  	  	  	  	  	  
	  
	   85	  
6.4	  Identification	  of	  FLNA	  as	  a	  transducer	  of	  actin	  polymerization	  to	  
SRF	  activity	  
Since	   the	  MKL1-­‐FLNA	  complex	   formation	  appeared	   to	  be	  highly	  dynamic	  on	   the	  one	  hand	  
and	   also	   relied	   to	   actin	   dynamics	   on	   the	   other,	  we	   thought	   about	   examining	   if	   there	   is	   a	  
mechanistic	   link	   between	   actin	   polymerization,	   FLNA	   and	   MKL1.	   Being	   a	   member	   of	   the	  
actin-­‐binding-­‐protein	   class,	   FLNA	   has	   a	   compelling	   role	   in	   linking	   actin	   in	   the	   process	   of	  
cytoskeleton	   dynamics	   (2.4.3).	  Therefore	   it	   did	   not	   come	   by	   surprise	   that	   FLNA	   bound	   an	  
actin	  mutant,	  which	  does	  favor	  actin	  polymerization	  (S14C-­‐actin).	  In	  contrast	  no	  observable	  
interaction	   between	   FLNA	   and	   a	   non-­‐polymerizing	   actin	   mutant	   (R62D-­‐actin)	   was	  
determined	  in	  melanoma	  and	  hepatocellular	  cancer	  cells	  (Fig.	  4A).	  	  
	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4A:	  	  Immunoprecipitation	  using	  FLNA	  antibody	  and	  Western	  Blot	  for	  the	  indicated	  proteins	  in	  A7	  cells	  
(top)	  and	  HuH7	  cells	  (bottom)	  transfected	  with	  FLAG-­‐tagged	  R62D-­‐actin	  or	  S14C-­‐actin.	  A	  portion	  of	  the	  cell	  
lysate	  (bottom)	  was	  immunoblotted.	  BO,	  beads	  only.	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Next,	  we	  expressed	  MKL1	  and	  the	  indicated	  actin	  mutant.	  Remarkably,	  we	  found	  that	  FLNA	  
was	   required	   for	   an	   association	   between	   the	   actin	   mutant	   favoring	   actin	   polymerization	  
(S14C-­‐actin)	   and	   MKL1.	   We	   were	   able	   to	   co-­‐immunoprecipitate	   S14C-­‐actin	   with	   MKL1	   in	  
FLNA-­‐expressing	  A7	  cells,	  but	  however	  not	  in	  FLNA-­‐deficient	  M2	  cells	  (Fig.	  4B).	  As	  expected,	  
binding	  of	  the	  non-­‐polymerizable	  actin	  mutant	  (R62D-­‐actin)	  to	  MKL1	  was	  detectable	  in	  both	  
FLNA-­‐expressing	   and	   FLNA-­‐deficient	   cells	   (Fig.	   4B).	   To	   strengthen	   the	  achieved	   results,	  we	  
went	   on	   and	   reintroduced	   FLNA	   into	   FLNA-­‐deficient	  M2	   cells.	   As	   a	   result,	   rescuing	   of	   the	  
S14C-­‐actin-­‐MKL1	  binding	  was	  obtained	  (Fig.	  4B),	  which	  further	  marked	  the	  specificity	  of	  the	  
effect.	  Endogenic	  complex	  analysis	  in	  LPA	  stimulated	  3T3	  fibroblasts	  revealed	  similar	  results	  
by	   displaying	   complex	   formation	  of	   FLNA,	  MKL1	   and	   S14C-­‐actin	   in	   contrast	   to	  monomeric	  
R62D-­‐actin	   transfection,	   where	   no	   such	   interaction	   was	   observable	   (Fig.	   4C).	   To	   further	  
address	  MKL1-­‐FLNA-­‐actin	  forming	  complex	  issues	  and	  in	  particular	  FLNAs	  role,	  we	  designed	  
an	   experiment	   comparing	   wt-­‐MKL1	   and	   MKL1	   Δ301-­‐380	   binding	   to	   GFP-­‐actin,	   which	  
comprises	  monomeric	  G-­‐actin	  and	  polymerized	  F-­‐actin.	  Interestingly,	  MKL1	  Δ301-­‐380,	  which	  
is	  not	  able	  to	  bind	  FLNA,	  displayed	  weaker	  GFP-­‐actin	  binding	  patterns	  then	  wt-­‐MKL1	  did	  (Fig.	  
4D).	  	  
	  	  	  	  	  	  	  	  	  	   	  
Figure	  4B:	   Immunoprecipitation	  and	  Western	  Blot	  as	   in	   (A)	   in	  A7	  and	  M2	  cells	   transfected	  with	  GFP-­‐MKL1	  
and	   FLAG-­‐R62D-­‐actin	   or	   FLAG-­‐S14C-­‐actin.	   Separate	   cultures	   of	   M2	   cells	   transfected	   as	   described	   were	  
reconstituted	  with	  myc-­‐tagged	  FLNA	  or	  an	  empty	  vector	  (EV).	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Figure	   4C:	   Immunoprecipitation	   and	   Western	   Blot	   as	   in	   (A)	   in	   LPA	   stimulated	   (2h)	   3T3	   fibroblast	   cells,	  
transfected	  with	  FLAG-­‐R62D-­‐actin	  or	  FLAG-­‐S14C-­‐actin.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4D:	  Immunoprecipitation	  and	  Western	  Blot	  as	  in	  (A)	  in	  A7	  cells	  transfected	  with	  GFP-­‐actin	  and	  FLAG-­‐
MKL1.	  	  
To	  put	  this	  data	  in	  context,	  we	  hypothesized	  FLNA	  as	  a	  transducer,	  which	  efficiently	  converts	  
the	   signal	   of	   polymerized	   actin	   into	   SRF	   activation	   by	   mediating	   an	   association	   between	  
polymerized	   actin	   and	  MKL1.	   To	   further	   investigate	   this	   concept,	   we	   performed	   reporter	  
gene	   assays	   with	   5	   x	   SRE	   reporter	   gene	   and	   the	   F-­‐actin-­‐formation-­‐favoring	   S14C-­‐actin	  
mutant	   and	   secondly	   screened	   the	   effective	   polymerization	   ability	   of	   this	   mutant	   by	  
submitting	  it	  to	  immunocytochemistry.	  We	  chose	  a	  5	  x	  SRE,	  which	  SRF	  is	  connecting	  to,	  this	  
way	  presenting	  an	  excellent	  option	  to	  measure	   its	  activity.	  Flag-­‐tagged	  S14C-­‐actin	  enabled	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the	   identification	  of	   transfected	  cells	  using	  microscopy	  with	  FLAG	  antibody	  and	  phalloidin,	  
which	   specifically	  binds	  F-­‐actin.	  As	  a	   result,	   compared	   to	   surrounding	  un-­‐transfected	  cells,	  
A7	  cells	  transfected	  with	  S14C-­‐actin	  displayed	  enhanced	  actin	  polymerization	  (Fig.	  4E).	  
	  	   	  
Figure	  4E:	  	  Immunofluorescence	  analysis	  of	  phalloidin	  or	  FLAG	  in	  A7	  cells	  transfected	  with	  FLAG-­‐S14C-­‐actin.	  
Scale	  bar,	  200	  μm.	  
Regarding	   reporter	   gene	   assay	   results	   we	   experienced	   a	   13-­‐fold	   induction	   of	   luciferase	  
activity	   in	   S14C-­‐actin	   and	   FLNA	   expressing	   cells	   compared	   to	   the	   only	   slight	   increase	   in	  
luciferase	  expression	  in	  S14C-­‐actin-­‐expressing	  but	  FLNA-­‐deficient	  cells	  (Fig.	  4F).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4F:	  	  Luciferase	  assays	  for	  5xSRE	  reporter	  activity	  in	  A7	  or	  M2	  cells	  transfected	  with	  FLAG-­‐S14C-­‐actin	  or	  
EV	  along	  with	  a	  5xSRE	  reporter	  gene	  and	  a	  Renilla	   luciferase	   internal	  control	  vector	   (pRL-­‐SV40P).	  Data	  are	  
means	  +/-­‐	  SD	  (n=3).	  *P	  <	  0.05,	  unpaired	  Student’s	  t	  test.	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This	  data	  provides	  first	  evidence	  that	  FLNA	  plays	  an	   important	  role	   in	  actin-­‐dependent	  SRF	  
activation.	   To	   reinforce	   these	   results,	   we	   performed	   the	   same	   assay	   setup	   including	  
Jasplakinolide,	   a	   substance	   originally	   isolated	   by	   marine	   sponge,	   to	   force	   actin	  
polymerization.	   Jasplakinolide	   causes	  F-­‐actin	   stabilization	  and	   stimulation	  of	  actin	   filament	  
nucleation,	   this	   way	   decreasing	   cellular	   G-­‐actin	   pool	   quantity.	   It	   furthermore	   differs	   from	  
other	   actin	   stabilizers	   by	   showing	   exceptional	   cell	   permeability	   (Bubb	   R.,	   Spector	   I.	   et	   al,	  
2000).	  As	  a	  result,	  Jasplakinolide	  treatment	  led	  to	  an	  enhanced	  luciferase	  activity	  in	  A7	  cells,	  
but	  not	  in	  FLNA	  depleted	  M2	  cells,	  similar	  to	  the	  data	  obtained	  in	  Fig.	  4F	  (Fig.	  4G).	  Moreover,	  
and	  to	  once	  again	  prove	  the	  dynamic	  nature	  of	  the	  occurring	  process,	  we	  reconstituted	  M2	  
cells	  with	  different	  amounts	  of	  FLNA,	  which	  led	  to	  a	  step-­‐by-­‐step	  restoration	  of	  SRF	  activity	  
(Fig.	   4H).	   In	   general	   and	   consistent	  with	   the	  previous	  obtained	  data,	   reporter	   gene	  assays	  
revealed	  a	  5-­‐fold	  induction	  difference	  in	  untreated	  A7	  versus	  M2	  cells	  (Fig.	  4I).	  After	  proving	  
the	   sensitive	   impact	   available	   FLNA	   quantity	   has	   on	   SRF	   activity,	   we	   addressed	   questions	  
regarding	  similar	  fine	  dosing	  effects	  caused	  by	  MKL1	  involvement.	  In	  context	  with	  the	  results	  
achieved	   by	   FLNA,	   5	   x	   SRE	   activity	   raised	   when	   melanoma	   cells	   where	   treated	   with	  
increasing	  amounts	  of	  MKL1	  in	  a	  step-­‐by-­‐step	  manner	  (Fig.	  4J)	  
	  
Figure	   4G:	   Luciferase	   assay	   performed	   as	   in	   (F)	   in	   A7	   and	   M2	   cells	   treated	   with	   or	   without	   0.5	   μM	  
Jasplakinolide	  (Jasp.)	  for	  7	  hours.	  ***	  P	  <	  0.001,	  unpaired	  Student’s	  t	  test.	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Figure	  4H:	  Luciferase	  assays	  performed	  as	  in	  (F)	  in	  M2	  cells	  expressing	  increasing	  amounts	  of	  FLNA	  expressing	  
vector	  and	  a	  5xSRE	  reporter	  gene.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4I:	  	  Luciferase	  assays	  performed	  as	  in	  (F)	  in	  M2	  and	  A7	  cells	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4J:	  	  Luciferase	  assays	  performed	  as	  in	  (F)	  in	  M2	  and	  A7	  cells	  expressing	  increasing	  amounts	  of	  MKL1.	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Compared	   to	   the	   fine-­‐meshed	   actin	   network	   construct	   in	  A7	   cells,	   achieved	  by	   S14C-­‐Flag-­‐
actin	   transfection,	   no	   network	   formation	   was	   detectable	   in	   FLNA-­‐deficient	   M2	   cells	   post	  
transfection	   (Fig.	   4K).	   Together	   with	   the	   other	   results	   displayed	   in	   chis	   chapter,	   these	  
findings	  support	  the	  theory	  that	  actin	  polymerization	  requires	  FLNA.	  
	  
Figure	   4K:	   	   Immunofluorescence	   analysis	   using	   phalloidin	   or	   FLAG	   antibody	   in	   M2	   cells	   transfected	   with	  
S14C-­‐FLAG-­‐actin.	  Scale	  bar,	  200μm.	  	  	  
On	  a	   further	   note,	   Baarlink	  C.	   et	   al	   (2013)	   showed	   that	  MKL1-­‐SRF	   activation	   is	   in	   need	  of	  
nuclear	   actin	   polymerization,	   driven	   by	   the	   formin	   mDia.	   To	   additional	   increase	   our	  
knowledge	   about	   actin	   network	   formation	   and	   to	   clarify	   weather	   nuclear	   actin	  
polymerization	  requires	  FLNA,	  we	  expressed	  a	  constitutively	  active	  version	  of	  mDia1	  (Dia1ct)	  
that	  displays	  predominant	  nuclear	  localization	  and	  causes	  increased	  nuclear	  actin	  assembly.	  
Interestingly,	  only	  FLNA-­‐expressing	  A7	  cells	  reacted	  with	  a	  8-­‐fold	  increase	  in	  SRF-­‐dependent	  
transcriptional	   activity	  when	   compared	   to	  mock	   transfections	   (Fig.	   4L),	   further	   suggesting	  
that	  nuclear	  actin	  polymerization	  requires	  FLNA	  for	  MKL1	  activation. Together	  these	  results	  
are	   compatible	   with	   the	   concept	   that	   FLNA	   couples	   actin	   polymerization	   to	   MKL1-­‐SRF	  
transcriptional	  activity.	  	  
After	   investigating	   nuclear	   F-­‐actins	   role,	   we	   analyzed	   its	  monomeric	   counterpart,	   G-­‐actin.	  
We	  performed	  SRF	  reporter	  gene	  assays	  including	  NLS-­‐R62D-­‐actin,	  a	  R62D-­‐actin	  mutant	  that	  
constitutively	   localizes	  to	  the	  nucleus	  The	  NLS-­‐R62D-­‐actin	  dose	  was	   increased	  in	  a	  step-­‐by-­‐
step	  manner,	  which	  led	  to	  an	  expected	  reduction	  of	  SRF	  reporter	  activity	  in	  FLNA	  expressing	  
melanoma	  cells	  (Fig.	  4M	  and	  N).	  Next,	  we	  extended	  the	  assay	  setup	  by	  introducing	  mDia-­‐ct,	  
a	   constitutively	   nuclear	   active	   mDia	   mutant	   or	   mDia-­‐NES,	   causing	   increased	   cytoplasmic	  
actin	   assembly	   to	   the	   experiment.	   Nuclear	   formin	   was	   able	   to	   counteract	   the	   repressive	  
nuclear	  G-­‐actin	   effect	   in	   a	   certain	  manner,	   this	  way	   retaining	   luciferase	   activity	   on	   higher	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levels	   (Fig.	   4M)	   in	   contrast	   to	   treatment	   with	   cytoplasmic	   formin	   in	   FLNA	   expressing	  
melanoma	  cells,	  where	  luciferase	  activity	  remained	  on	  a	  lower	  level	  (Fig.	  4N).	  FLNA	  depleted	  
M2	   melanoma	   cells	   remained	   at	   minor-­‐level	   reporter	   gene	   activity	   throughout	   the	  
experiment	  (Fig	  4M	  and	  N).	  
 
Figure	  4L:	  mDiact	  expression	  vector	  (mDiact)	  or	  empty	  vector	  (EV)	  were	  transfected	  into	  A7	  and	  M2	  cells	  and	  
luciferase	  assays	  carried	  out	  as	  described	  before.	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4M:	  mDiact	  expression	  vector	  and	  the	  stated	  amount	  of	  NLS	  R62D	  actin	  were	  transfected	  into	  A7	  and	  
M2	  cells	  and	  luciferase	  assays	  carried	  out	  as	  described	  before.	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Figure	  4N:	  mDia	  NES	  expression	  vector	  and	  the	  stated	  amount	  of	  NLS	  R62D	  actin	  were	  transfected	  into	  A7	  
and	  M2	  cells	  and	  luciferase	  assays	  carried	  out	  as	  described	  before.	  
	  
6.5	  Interaction	  of	  FLNA	  and	  MKL1	  in	  cell	  migration	  and	  invasion	  
Both,	   MKL1	   and	   its	   new	   binding	   partner	   FLNA	   are	   known	   for	   their	   tremendous	   and	  
autonomous	  influence	  in	  the	  broad	  field	  of	  migrating	  procedures	  (2.2,	  2.4.3).	  This	  obviously	  
raises	  the	  question	  if	  FLNA	  plays	  a	  valuable	  role	  in	  MKL1	  mediated	  cellular	  functions,	  such	  as	  
the	  above-­‐mentioned	  migration.	  To	  address	  this	  issue	  in	  an	  experimental	  way,	  we	  first	  chose	  
a	   setup	   devoting	   RNA	   interference	   (RNAi)	   and	   therefore	   the	   effect	   of	   MKL1	   and	   FLNA	  
depletion	  on	  cell	  migration.	  Expression	  of	  MKL1	  and	  FLNA	  at	  the	  protein	  level	  was	  reduced	  
by	  90	  %	  post	  knockdown	  (Fig.	  5A).	  	  
	  	  	  	  	  	   	  
Figure	   5A:	   Knockdown	  efficiencies.	   Cell	  migration	   (assessed	  by	   a	   culture	   scratch-­‐wound	   assay)	   by	  A7	   cells	  
transfected	   with	   50nM	   negative	   control	   siRNA	   (ctrl),	   50	   nM	   FLNA	   siRNA	   (siFLNA),	   or	   50	   nM	  MKL1	   siRNA	  
(siMKL1).	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As	  described	  in	  2.4.3,	  filopodia	  hold	  a	  crucial	  role	  in	  terms	  of	  cell	  mobility.	  This	  tempted	  us	  to	  
take	  a	  closer	  look	  at	  the	  appearance	  of	  these	  slender	  projections	  composed	  of	  cross-­‐linked	  
actin	  bundles	  by	  FLNA.	   Interestingly,	   filopodia	  presence	  in	  A7	  melanoma	  cells	  was	  reduced	  
up	  to	  30	  %	  after	  MKL1	  and	  FLNA	  knockdown	  in	  comparison	  to	  the	  control	  (Fig.	  5B	  and	  C).	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5B:	  Filopodia	  appearance	  in	  A7	  cells.	  Cells	  transfected	  with	  50nM	  negative	  control	  siRNA	  (ctrl),	  50	  nM	  
FLNA	  siRNA	  (siFLNA),	  or	  50	  nM	  MKL1	  siRNA	  (siMKL1).	  	  n=3	  experiments,	  100	  cells	  counted.	  
	  
	  
	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5C:	  Filopodia	  appearance	  in	  A7	  cells.	  Immunofluorescence	  analysis	  using	  phalloidin.	  Cells	  transfected	  
with	   (left)	   50nM	  negative	   control	   siRNA	   (ctrl)	   or	   (right)	   50nM	  FLNA	   siRNA	   (siFLNA),	   n=3	   experiments,	   100	  
cells	  counted.	  Representative	  picture	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To	   investigate	  cell	  migration	   in	  detail,	  we	  took	  advantage	  of	  wound-­‐healing-­‐scratch	  assays.	  
24	   hours	   post	   scratch	   creation,	   control	   cells	   succeeded	   in	   closing	   the	  wound	   gap	   entirely	  
while	  siMKL1	  and	  siFLNA	  treated	  cells	  clearly	  were	  not	  (Fig.	  5D).	  
	  	  
Figure	   5D:	   Cell	  migration	   (assessed	   by	   a	   culture	   scratch-­‐wound	   assay)	   by	   A7	   cells	   transfected	  with	   50nM	  
negative	  control	  siRNA	  (ctrl),	  50	  nM	  FLNA	  siRNA	  (siFLNA),	  or	  50	  nM	  MKL1	  siRNA	  (siMKL1).	  Data	  are	  means	  
+/-­‐	  SD	  (n=3	  experiments).	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001.	  (Right)	  Representative	  images.	  	  
Next,	  we	  shifted	  focus	  on	  a	  possible	  synergetic	  effect	  of	  MKL1	  and	  FLNA	  regarding	  migratory	  
events.	   Interestingly,	   reintroduction	   of	   siRNA-­‐resistant	   wild-­‐type	   MKL1,	   but	   not	   siRNA-­‐
resistant	   mutant	   MKL1	   Δ301-­‐380	   or	   Δ301-­‐342,	   which	   are	   unable	   to	   interact	   with	   FLNA,	  
partly	   restored	   the	  migrating	   ability	   of	   A7	  melanoma	   cells	   depleted	   of	   endogenous	  MKL1	  
(Fig.	  5E).	  Identically	  results	  were	  obtained	  from	  HuH7	  hepatocellular	  carcinoma	  cells	  (Fig.	  5E)	  
and	  are	  displayed	  as	  a	  representative	  example	  for	  A7	  cells	  including	  wild-­‐type-­‐MKL1,	  MKL1	  
Δ301-­‐380	   and	   an	   empty	   vector	   as	   control	   (Fig.	   5F).	   These	   data	   suggests	   that	   MKL1	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Figure	  5E:	  Cell	  migration	  assessed	  as	  in	  (D)	  by	  A7	  cells	  (top)	  and	  HuH7	  cells	  (bottom)	  transfected	  with	  50	  nM	  
negative	  control	  siRNA	  (ctrl)	  or	  50	  nM	  MKL1	  siRNA	  (siMKL1)	  and	  reconstituted	  with	  FLAG-­‐tagged	  WT	  MKL1,	  
MKL1	  Δ301-­‐380	  or	  Δ301-­‐342,	  confirmed	  by	  Western	  Blot.	  Data	  are	  means	  +/-­‐	  SD	   (n=	  3).	  *P	   	  <	  0.05,	  **	  P	  <	  
0.01.	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Figure	  5F:	  Cell	  migration	  assessed	  as	  described	  in	  5E.	  Representative	  images	  from	  A7	  cells	  are	  shown.	  
Together	   with	   the	   fact	   that	   migration	   and	   invasion	   share	   a	   descent	   amount	   of	   specific	  
characteristics	  we	  wanted	  to	  know	  about	  possible	  effects	  of	  the	  FLNA-­‐MKL1	  interaction	  on	  
invasive	   cell	   migration.	   For	   that	   reason	   we	   introduced	   Transwell	   invasion	   assays.	   A7	  
melanoma	  cells	  were	  allowed	  to	  penetrate	  through	  a	  three-­‐dimensional	  Matrigel	  propelled	  
by	  a	  cell	  medium	  gradient.	  As	  a	  result,	  invasive	  migration	  of	  A7	  cells	  was	  strongly	  reduced	  in	  
the	   absence	   of	   MKL1	   (Fig.	   5G).	   Even	   more	   important	   and	   in	   match	   with	   our	   previously	  
obtained	   results	   in	   scratch-­‐wound	   assays,	   reconstitution	   with	   siRNA-­‐resistant	   wild-­‐type	  
MKL1	  enhanced	  the	   invasive	  nature	  of	  MKL1	  siRNA-­‐expressing	  A7	  cells,	  while	  on	  the	  other	  
hand	   invasive	   cell	   migration	   remained	   nearly	   unchanged	   upon	   reconstitution	   with	   siRNA-­‐
resistant	   MKL1	   Δ301-­‐380,	   proving	   once	   again	   that	   FLNA	   promotes	   MKL1-­‐dependent	   cell	  
motility	  (Fig.	  5G).	  	  
	  
Figure	   5G:	   Cell	   invasion,	   assessed	   by	   a	   three-­‐dimensional	  Matrigel	   invasion	   assay,	   by	   A7	   cells	   transfected	  
with	  50	  nM	  negative	  control	  siRNA	  (ctrl)	  or	  50	  nM	  MKL1	  siRNA	  (siMKL1)	  and	  reconstituted	  with	  FLAG-­‐tagged	  
WT	  or	  mutant	  MKL1.	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6.6	  Interaction	  of	  FLNA	  and	  MKL1	  in	  the	  expression	  of	  MKL1	  target	  
genes	  
Besides	   its	   large	   variety	   of	   influences	   on	   biological	   functionality,	   MKL1’s	   core	   task	   is	  
operating	   transcriptional	   activity.	   Therefore	   with	   the	   introduction	   of	   a	   new	   interaction	  
partner,	  it	  was	  key	  to	  us	  to	  tie	  the	  knot	  on	  our	  research	  by	  having	  a	  more	  in	  detail	  look	  on	  
the	   impact	   of	   the	   FLNA-­‐MKL1	   interaction	  on	   the	   transcriptional	   activity	   of	  MKL1.	  We	   first	  
investigated	  the	  effect	  of	  FLNA	  on	  the	  expression	  of	  established	  MKL1	  target	  genes,	  such	  as	  
SRF,	  CTGF,	  SM22,	   ITGA5,	  FHL2	  and	   TGF-­‐beta	   (Schmidt	  L.,	  Duncan	  K.	  et	  al,	  2012;	  Elberg	  G.,	  
Chen	  L.,	  et	  al,	  2008;	  Cheng	  X.,	  Yang	  Y.,	  et	  al	  2015)	  by	  once	  again	  turning	  to	  FLNA	  expressing	  
A7	  cells	  and	  FLNA	  deficient	  M2	  cells.	  Expression	  of	  SRF,	  CTGF,	  SM22,	  ITGA5,	  FHL2	  and	  TGF-­‐
beta	  was	  strongly	  inhibited	  in	  M2	  cells	  lacking	  FLNA	  (Fig.	  6A).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6A:	  A7	  and	  M2	   cells	  were	   subjected	   to	  qRT-­‐PCR	  using	  SRF,	   CTGF,	   SM22,	   ITGA5,	   FHL2	  and	  TGF-­‐beta	  
primers.	  Data	  are	  means	  +/-­‐	  SD	  (	  n	  =	  3	  experiments,	  FHL2	  and	  TGF-­‐beta	  n	  =	  2).	  *	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  
0.001.	  rel,	  relative	  to	  18S	  rRNA.	  
To	   further	   support	   these	   findings	   that	   FLNA	   deficiency	   accounts	   for	   impaired	   MKL1-­‐
dependent	  target	  gene	  expression	  we	  silenced	  FLNA	  in	  MEFs	  (Fig.	  6B)	  and	  A7	  cells	  (Fig.	  6C)	  
using	   RNA	   interference.	   In	   line	  with	   the	   data	   obtained	   from	  A7	   and	  M2	   cells,	   silencing	   of	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FLNA	  expression	   in	  MEFs	  and	  A7	  resulted	   in	  a	  strong	  reduction	  of	  FLNA,	  SRF,	  SM22,	  CTGF,	  
ITGA5,	  TGF-­‐beta	  and	  FHL2	  expression	  (Fig.	  6B	  and	  C).	  To	  underline	  the	  observed	  results	  we	  
continued	  addressing	  MKL1	  target	  gene	  expression	  by	  looking	  at	  protein	  levels.	  Western	  Blot	  
analysis	  revealed	  a	  strong	  abolishment	  of	  SM22	  protein	  levels	  after	  again	  silencing	  FLNA	  (Fig.	  
6D).	   Drexler	   M.	   and	   Nossek	   M	   achieved	   similar	   results	   investigating	   on	   CTGF	   and	   ITGA5	  
(Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  Additionally,	  after	  MKL1	  knockdown,	  SRF	  protein	  levels	  
were	  decreased	  and	  totally	  revoked	  after	  a	  combined	  MKL1	  and	  FLNA	  knockdown	  in	  A7	  cells	  
hinting	  at	  a	  synergetic	  effect	  of	  MKL1	  and	  FLNA	  regarding	  target	  gene	  expression	  (Fig.	  6E).	  
	  
Figure	  6B:	  MEF	  cells	  were	  subjected	  to	  qRT-­‐PCR	  using	  SRF,	  CTGF,	  SM22	  and	  ITGA5	  primers.	  Transfection	  with	  
negative	  control	  siRNA	  (ctrl)	  or	  50	  nM	  FLNA	  siRNA	  (siFLNA).	  	  Data	  are	  means	  +	  /	  -­‐	  SD	  (n=3).	  **	  P	  <	  0.01,	  ***	  P	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Figure	   6C:	   A7	   cells	   were	   subjected	   to	   qRT-­‐PCR	   using	   FLNA,	   SRF,	   CTGF,	   SM22,	   ITGA5,	   TGF-­‐beta	   and	   FHL2	  
primers.	  Transfection	  with	  negative	  control	  siRNA	  (ctrl)	  or	  50	  nM	  FLNA	  siRNA	  (siFLNA).	  	  Data	  are	  means	  +	  /	  -­‐	  
SD	  (n=3,	  TGF-­‐beta	  and	  FHL2	  n	  =	  2).	  **	  P	  <	  0.01.	  rel,	  relative	  to	  18S	  rRNA.	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Figure	  6D:	  A7	  cells	  were	  subjected	  to	  Western	  Blot	  analysis.	  Transfection	  with	  negative	  control	  siRNA	  (ctrl)	  or	  
50	  nM	  FLNA	  siRNA	  (siFLNA)	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6E:	  A7	  cells	  were	  subjected	  to	  Western	  Blot	  analysis.	  Transfection	  with	  negative	  control	  siRNA	  (ctrl)	  or	  
50	  nM	  FLNA	  siRNA	  (siFLNA)	  or	  50	  nM	  MKL1	  siRNA	  (siMKL1).	  	  	  
To	   further	   validate	   that	   FLNA	   deficiency	   directly	   accounts	   for	   the	   impaired	   MKL/SRF	  
expression,	  we	  depleted	  FLNA	  expression	   in	  A7	  melanoma	  cells	   in	   a	   step-­‐by-­‐step	  manner.	  
When	   increasing	   amounts	   of	   FLNA	   siRNA	   were	   transfected,	   SRF	   expression	   decreased	  
simultaneously,	   further	   confirming	   a	   straightforward	   correlation	   between	   FLNA	   and	   SRF	  
expression	  (Fig.	  6F).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6F:	  A7	  cells	  were	  subjected	  to	  Western	  Blot	  analysis.	  Transfection	  with	  50	  nM	  FLNA	  siRNA	  (siFLNA).	  
Hermanns	  C.	   found	   that	  GLIPR1	  and	   CNN1	   represent	   novel	  MKL1-­‐dependent	   target	   genes	  
because	  of	  their	  notably	  reduced	  expression	  upon	  MKL1	  depletion	  (Kircher	  P.,	  Hermanns	  C.	  
et	   al,	   2015).	   Similar	   observations	   as	   in	   Fig.	   6B	   were	   made	   for	   primary	   human	   and	   3T3	  
fibroblasts	   as	  well	   as	   for	   HuH7	   hepatocellular	   carcinoma	   cells	   depleted	   of	   FLNA	   (Fig.	   6G).	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Hermanns	   C.	   added	   data	   for	   HepG2	   hepatocellular	   carcinoma	   cells,	   3T3	   fibroblasts	   and	  
MDA-­‐MB-­‐468	  mammary	  carcinoma	  (Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  
	  
Figure	  6G:	  Primary	  human,	  3T3	  fibroblasts	  and	  HuH7	  cells	  were	  subjected	  to	  qRT-­‐PCR	  using	  SRF,	  CTGF,	  SM22,	  
ITGA5	  and	  GLIPR1	   primers.	   Transfection	  with	  negative	   control	   siRNA	   (ctrl)	   or	   50	  nM	  FLNA	   siRNA	   (siFLNA).	  
Data	  are	  means	  +/-­‐	  SD	  (n=3).	  *	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001.	  rel,	  relative	  to	  18S	  rRNA.	  
Since	   all	   these	   findings	   caused	   by	   FLNA	   silencing	   primary	   aim	   on	   a	   repressive	   effect,	   we	  
wanted	   to	   know	   whether	   FLNA	   introduction	   in	   turn	   induces	  MKL1-­‐SRF	   dependent	   target	  
gene	  expression.	  FLNA	  overexpression	  strongly	  activated	  the	  expression	  of	  MKL1-­‐SRF	  target	  
genes,	   which	   was	   prevented	   by	   knocking	   down	   SRF	   or	   MKL1	   (Fig.	   6H).	   These	   results	  
demonstrate	  the	  SRF	  and	  MKL1	  dependency	  of	  FLNA-­‐induced	  target	  gene	  expression.	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Figure	   6H:	   CTGF	   (left)	   and	   CNN1	   (right)	   mRNA	   expression,	   determined	   by	   qRT-­‐PCR	   as	   in	   (A),	   in	   M2	   cells	  
expressing	   negative	   control	   siRNA	   (ctrl),	   50	   nM	   MKL1	   siRNA	   (siMKL1),	   or	   50	   nM	   SRF	   siRNA	   (siSRF)	   and	  
reconstituted	  with	  myc-­‐FLNA.	  Data	  are	  means	  +/-­‐	  SD	  (n=3).	  ***	  P	  <	  0.001.	  
Investigations	  with	   the	   help	   of	   reporter	   gene	   assays	  with	   5	   x	   SRE	   reporter	   gene	   including	  
constitutively	  active	  MKL1	   (MKL1	  N100)	   led	   to	  similar	   results.	  Luciferase	  activity	  proved	  to	  
be	   FLNA-­‐dependent	   because	   it	   was	   strongly	   reduced	   in	   FLNA-­‐deficient	   cells	   compared	   to	  
FLNA-­‐expressing	   cells	   (Fig.	   6I).	   Hermanns	   C.	   fortified	   the	   data	   by	   qRT-­‐PCR	   experiments	  
(Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6I:	   	  Luciferase	  assays	  for	  5	  x	  SRE	  reporter	  activity	   in	  A7	  or	  M2	  cells	  transfected	  with	  FLAG-­‐wt-­‐MKL1,	  
FLAG-­‐N100-­‐MKL1	  or	  EV	  along	  with	  a	  5	  x	  SRE	   reporter	  gene	  and	  a	  Renilla	   luciferase	   internal	   control	  vector	  
(pRL-­‐SV40P).	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To	  ultimately	  reach	  our	  goal,	  linking	  FLNA-­‐MKL1	  symbiosis	  to	  MKL1	  target	  gene	  expression,	  
we	  last	  but	  not	  least	  tested	  whether	  introduction	  of	  the	  MKL1	  mutants	  unable	  to	  bind	  FLNA	  
would	  also	  affect	   the	   transcription	  of	  MKL1	   target	  genes.	   Indeed,	  expression	  of	  SM22	   and	  
CTGF	  mRNA	  was	  clearly	  reduced	  in	  the	  presence	  of	  the	  MKL1	  mutants	  Δ301-­‐380,	  Δ301-­‐342	  
and	  Δ301-­‐310	  (Fig.	  6J).	  
	  
	  
Figure	  6J:	  	  The	  abundance	  of	  CTGF	  and	  SM22	  mRNA	  in	  A7	  cells	  transfected	  with	  FLAG-­‐MKL1,	  MKL1	  Δ301-­‐380,	  
MKL1	   Δ301-­‐342	   and	  MKL1	   Δ301-­‐310	   or	   EV	   for	   48	   hours,	   as	   analysed	   by	   qRT-­‐PCR.	   Data	   are	  means	   +/-­‐	   SD	  
(n=3).	  **	  P	  <	  0.01.	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7.1	  Identification	  of	  a	  novel	  MKL1	  interacting	  protein:	  Impact	  of	  the	  
new	  MKL1-­‐FLNA	  interaction	  on	  cellular	  functions	  
7.1.1	  Consequences	  and	  biological	  effects	  of	  the	  MKL1-­‐FLNA	  binding	  
The	  goal	  of	  this	  thesis	  was	  to	  shed	   light	  on	  the	   interaction	  between	  the	  co-­‐activator	  MKL1	  
and	  the	  actin-­‐binding	  protein	  FLNA	  and	  furthermore	  to	  examine	  the	  biological	  effects	  of	  this	  
association	   in	   order	   to	   reveal	   its	   linked	   physiological	   and	   pathophysiological	   function.	  We	  
found	  a	  new	  mechanism	  of	  MKL1	  activation	   that	   is	  mediated	   through	   its	  binding	   to	  FLNA.	  
The	   interaction	   is	   required	   for	   the	   expression	  of	  MKL1	   target	   genes	   and	  MKL1-­‐dependent	  
cell	  motility.	   Cells	   expressing	   a	  MKL1	  mutant	   unable	   to	   bind	   FLNA	   exhibited	   impaired	   cell	  
migration	   and	   invasion	   along	   with	   reduced	   MKL1	   target	   gene	   expression.	   Increased	   or	  
decreased	  MKL1-­‐FLNA	  interaction	  correlated	  with	   induction	  and	  repression	  of	  MKL1	  target	  
genes,	  and	  protein	  levels	  respectively.	  Therefore,	  we	  provide	  evidence	  that	  the	  association	  
not	  only	   is	  strictly	  sensitive	  to	  the	  available	  amounts	  of	  MKL1	  and	  FLNA,	  but	  moreover	  we	  
are	  able	  to	  define	  the	  interaction	  as	  highly	  dynamic	  (Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  	  
We	  were	  able	  to	  present	  a	  somewhat	  weaker	  interaction	  between	  MKL2	  and	  FLNA	  as	  well.	  
This	   discrepancy	   between	   MKL1	   and	   2	   regarding	   binding	   properties	   could	   be	   a	   result	   of	  
MKL2	  consisting	  of	  three	  RPEL	  domains	  in	  contrast	  to	  the	  two	  of	  MKL1	  (Cen	  B.,	  Selvaraj	  A.	  et	  
al,	  2003).	  We	  hypothesize	  that	  the	  extra	  RPEL	  domain	  provides	  additional	  affinity	  for	  G-­‐actin	  
to	   successfully	   interact	   with	   MKL2,	   this	   way	   stronger	   inhibiting	   nuclear	   entrance	   and	  
association	  with	  FLNA.	  	  
Furthermore,	   after	   confirming	   the	   interaction	   between	  MKL1	   and	   FLNA,	  we	   identified	   the	  
necessary	  binding	  zones	  on	  both	  proteins,	  picturing	  a	  complex	  pattern	  of	  interaction,	  which	  
involves	   multiple	   regions.	   We	   investigated	   the	   association	   between	   MKL1	   and	   FLNA	   in	  
different	   physiological	   and	   cancer	   cell	   lines.	   In	   total	   we	   used	   melanoma,	   hepatocellular	  
carcinoma,	   mammary	   carcinoma	   as	   well	   as	   primary	   murine,	   primary	   human	   and	   3T3	  
fibroblast	   cell	   lines	   as	   physiological	   cell	   representatives	   to	   highlight	   the	   interactions	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existence	  and	   its	  broad	  significance	  for	  the	  first	  time	  (Kircher	  P.,	  Hermanns	  C.	  et	  al,	  2015).	  
For	  the	  sake	  of	  completeness	  one	  has	  to	  mention	  that	  not	  all	  examined	  cell	  lines	  fortified	  a	  
functioning	   interaction.	   We	   discovered	   that	   hepatocellular	   cancer	   cells	   (HLF)	   and	   human	  
embryonic	  kidney	  cells	  (HEK-­‐293)	  witnessed	  no	  or	  only	  a	  rather	  weak	  detectable	  interaction.	  
It	   is	  possible	   that	   the	   respectively	   low	  amounts	  of	   total	  MKL1	  or	   FLNA	  expressed	   in	   these	  
cells	   affect	   the	   MKL1-­‐FLNA	   interaction	   in	   this	   scenario.	   Still,	   the	   possibility	   of	   an	   actual	  
interaction	   occurring	   in	   these	   cell	   lines	   might	   not	   be	   totally	   ruled	   out	   under	   certain	  
circumstances	  (eg	  cellular	  stress,	  diseases).	  	  
7.1.2	  Localization	  of	  the	  MKL1-­‐FLNA	  binding	  and	  potential	  DLC1	  influence	  
We	  found	  that	  MKL1	  and	  FLNA	  co-­‐localized	  predominantly	   in	  the	  nucleus	   in	  A7	  melanoma	  
cells	  as	  well	  as	  in	  fibroblasts	  after	  LPA	  stimulation,	  while	  FLNA-­‐depleted	  M2	  melanoma	  cells	  
and	  FLNA	  knockdown	  treated	  A7	  cells	  displayed	  cytoplasmic	  MKL1	  localization.	  This	  hints	  at	  
FLNA	  maybe	  holding	  MKL1	   in	   the	  nucleus,	  which	  will	   be	  discussed	   in	   greater	  detail	   in	   the	  
later	  paragraphs	  of	  this	  chapter.	  Nuclear	  MKL1	  localization	  is	  especially	  important,	  since	  co-­‐
activator	  functionality	  and	  cellular	  localization	  are	  tightly	  connected	  (Miralles	  F.,	  Posern	  G.	  et	  
al,	  2003).	  The	  transcriptional	  machinery	  is	  in	  desperate	  need	  of	  a	  nuclear-­‐based	  co-­‐activator	  
before	  getting	  started.	  This	  demand	  for	  a	  catalyser	  is	  perfectly	  fulfilled	  by	  MKL1	  in	  its	  active	  
nuclear	  condition.	  	  
Regarding	  FLNA	  localization	  these	  findings	  likewise	  fit	  well	  with	  literature	  knowledge,	  since	  a	  
large	  amount	  of	  nuclear	  FLNA	  in	  A7	  melanoma	  cells	  has	  been	  described	  previously	  (Berry	  F.,	  
O’Neill	  M.	  et	  al,	  2005).	  In	  an	  additional	  manner,	  prior	  studies	  of	  our	  group	  revealed	  nuclear	  
localization	   of	   MKL1	   in	   tumor	   cells	   lacking	   the	   tumor	   suppressor	   DLC1,	   while	   DLC1	  
expressing	  cells	  display	  MKL1	  in	  the	  cytoplasm	  (Hampl	  V.,	  Martin	  C.	  et	  al,	  2013;	  Muehlich	  S.,	  
Hampl	   V.	   et	   al,	   2012).	   Consistent	   with	   our	   novel	   findings	   of	   no	   observable	   interaction	   of	  
MKL1	   and	   FLNA	   in	   DLC1-­‐expressing	   cells,	   like	   HLF	   cells,	   these	   results	   offer	   room	   for	  
speculation	  about	  an	  exclusive	  nuclear	  MKL1-­‐FLNA	  complex	  formation	   in	  absence	  of	  DLC1.	  
The	   interaction	   of	   the	   transcription	   factor	   FOXC1	  with	   FLNA,	   which	   also	   exclusively	   takes	  
place	  in	  the	  nucleus	  strengthens	  this	  theory	  (Berry	  F.,	  O’Neill	  M.	  et	  al,	  2005).	  Hampl	  V.	  and	  
colleagues	  furthermore	  linked	  DLC1	  depletion	  to	  a	  strong	  formation	  of	  F-­‐actin	  network	  and	  
MKL1	  activity	   (2013).	  This	   leads	   to	  a	   theory	  about	  connectivity	  of	  DLC1	   loss	  and	   increased	  
FLNA	   activity.	   Furthermore,	   restoration	   of	   DLC1	   in	   DLC1-­‐deficient	   cells	   resulted	   in	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suppression	   of	   CTGF	   expression	   (Hampl	   V.,	   Martin	   C.	   et	   al,	   2013),	   similar	   to	   the	   data	  
obtained	   in	   the	   present	   work	   through	   FLNA	   knockdown.	   It	   is	   tempting	   to	   speculate	   that	  
FLNA	  works	  as	  an	  antagonist	  to	  regular	  DLC1	  activity.	  Nevertheless,	  future	  investigations	  will	  
definitely	   be	   necessary	   to	   deliver	   the	   missing	   piece	   of	   a	   possible	   FLNA-­‐DLC1	   connection.	  
Since	  we	  were	  able	  to	  figure	  out	  that	  FLNA	  is	  also	  representing	  a	  direct	  target	  gene	  of	  MKL1,	  
one	   proposal	   for	   further	   analysis	   concerning	   that	   topic	   would	   be	   the	   usage	   of	   DLC1	  
knockdown	   experiments	   followed	   by	   measurements	   on	   FLNA	   expression	   levels.	   If	   our	  
thoughts	  are	  correct,	  DLC1	  knockdown	  should	  lead	  to	  up-­‐regulated	  FLNA	  levels.	  	  
7.1.3	  MKL1	  shuttling	  affected	  by	  FLNA?	  
MKL1-­‐shutteling	   in	   and	  out	  of	   the	  nucleus	   is	   known	   to	  be	   governed	  by	   actin	   treadmilling,	  
phosphorylation	  status,	  RhoA	  activity,	  DLC1	  expression,	  appearance	  of	  external	  stimulation	  
signals,	  cellular	  stress	  or	  diseases	  and	  last	  but	  not	  least	  sources	  in	  two	  totally	  different	  cell	  
environments,	  notably	  the	  nucleus	  and	  the	  cytoplasm	  (Muehlich	  S.,	  Wang	  R.	  et	  al,	  2008;	  Cen	  
B.,	   Selvaraj	   A.	   et	   al,	   2004;	   Vartiainen	  M.,	   Guettler	   S.	   et	   al,	   2007;	   Posern	   G.,	   Treisman	   R.	  
2006).	   As	   one	   can	   obviously	   sense,	   a	   fairly	   high	   number	   of	   parameters	   are	   in	   charge	   for	  
operating	  this	  complex	  program.	  	  
Our	   investigations	  hint	  at	   yet	  another	   factor	   coming	   into	  play.	  We	  suggest	  a	   link	  between	  
FLNA	   appearance	   and	   MKL1-­‐shutteling	   and	   localization,	   since	   both	   proteins	   are	   heavily	  
affected	  by	  actin	  dynamics,	   FLNA	   represents	  a	   F-­‐actin	  binding	  protein	  while	   F-­‐actin-­‐bound	  
MKL1	   is	   kept	   nuclear	   (Baarlink	   C.	   et	   al,	   2013).	   Our	   very	   own	   results	   complement	   these	  
finding	   by	   providing	   a	   necessity	   of	   FLNA	   appearance	   for	   MKL1-­‐F-­‐actin	   association.	  
Furthermore,	  we	   are	  providing	   evidence	   that	   FLNA	   interferes	  with	  MKL1	  phosphorylation.	  
MKL1	  phosphorylation	   leads	   to	  export	  out	  of	   the	  nucleus	   into	   the	  cytoplasm	  (Muehlich	  S.,	  
Wang	   R.	   et	   al,	   2008).	   Thus	   it	   is	   tempting	   to	   speculate	   to	   name	   FLNA	   a	   catalyzer	   of	  MKL1	  
activation,	   in	   this	   case	   by	   conducting	   MKL1s	   cellular	   localization.	   Further	   studies	   will	  
definitely	  be	  necessary	  to	  judge	  clearly	  on	  this	  theory,	  but	  nevertheless	  even	  referring	  to	  our	  
current	  knowledge	  we	  are	  able	  to	  postulate	  that	  FLNA	  seems	  to	  have	  at	  least	  some	  kind	  of	  
supportive	   influence	   on	   MKL1	   shuttle	   mechanism	   by	   its	   impact	   on	   actin	   and	  
phosphorylation.	  
If	  speculating	  about	  a	  collective	  MKL1-­‐FLNA	  entrance	  into	  the	  nucleus,	  one	  has	  to	  remember	  
that	   the	   MKL1-­‐FLNA	   complex	   represents	   a,	   without	   question,	   very	   large	   macromolecule	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(Nakamura	  F.,	  Stossel	  T.	  et	  al,	  2011).	   In	  contrast	  to	  small	  molecules	  that	  enter	  the	  nucleus	  
without	  further	  regulation	  procedures,	  these	  types	  of	  large	  proteins,	  and	  even	  MKL1	  on	  its	  
own,	   require	   association	   with	   transport	   factors	   like	   importins.	   Importins	   bind	   nuclear	  
localization	  signals	  (NLS)	  located	  on	  the	  protein,	  for	  example	  as	  on	  MKL1,	  this	  way	  allowing	  
the	   Importin-­‐NLS-­‐MKL1	   complex	   to	   interact	   with	   the	   nuclear	   pore	   and	   successfully	   pass	  
through	  its	  channel	  (Depping	  R.,	  Jelkmann	  W.	  et	  al,	  2015).	  Based	  on	  the	  stated	  arguments	  of	  
size	   and	   pore	   restrictions,	   a	   collective	  MKL1-­‐full-­‐length-­‐FLNA	   entrance	   into	   the	   nucleus	   is	  
highly	  doubtful,	  however	  a	  translocation	  of	  FLNA	  fragments	  together	  with	  the	  transcription	  
factor	  androgen	  receptor	  has	  been	  demonstrated	  (Loy	  C.,	  Sim	  K.	  et	  al,	  2003).	  Future	  studies	  
laying	  focus	  on	  MKL1s	  condition	  during	  nuclear	  entrance	  or	  exit	  might	  be	  of	  great	  interest,	  
especially	  regarding	  its	  FLNA	  binding	  status	  during	  that	  process.	  
MKL1	   is	   inactive	   and	   rests	   in	   the	   cytoplasm	  when	   bound	   to	  monomeric	   G-­‐actin,	   however	  
signals	   that	   activate	  RhoA	  cause	  actin	  polymerization	  and	  MKL1	  dissociation	   from	  G-­‐actin,	  
followed	  by	  nuclear	  entrance	   (Vartiainen	  M.,	  Guettler	  S.	  et	  al,	  2007).	  We	  hypothesize	   that	  
nuclear	   FLNA	   impairs	   MKL1	   phosphorylation	   and	   facilitates	   actin	   networking,	   thereby	  
probably	  holding	  MKL1	  in	  the	  nucleus.	  Regardless	  the	  matter	  of	  fact	  that	  our	  work	  is	  setting	  
its	  focus	  on	  MKL1s	  meaningful	  nuclear	  actions	  while	  bound	  to	  FLNA,	  this	  shuttle-­‐scenario	  is	  a	  
prime	   example	   for	   MKL1s	   ability	   to	   rapidly	   influence	   its	   surroundings,	   serving	   as	   an	  
immediate	  on-­‐off	   switch	  depending	  on	   its	   current	  position	  with	   valuable	   impact	  on	   genes	  
and	  cell	  mobility	  on	  the	  one	  hand,	  but	  also	  playing	  a	  significant	  role	  in	  disease	  progression	  
on	  the	  other.	  	  
7.1.4	   RhoA-­‐actin	   signaling	   activating	   and	   inhibiting	   drugs	   and	   its	   functional	  
effects	  on	  the	  MKL1-­‐FLNA	  interaction	  
RhoA	  induction	  through	  LPA	  in	  primary	  human	  and	  3T3	  fibroblasts	  promoted	  the	  association	  
of	   endogenous	   MKL1	   with	   FLNA	   and	   increased	   MKL1	   target	   gene	   expression,	   whereas	  
exposure	   to	   an	   actin	   polymerization	   inhibitor	   dissociated	  MKL1	   from	   FLNA	   and	   decreased	  
MKL1	  target	  gene	  expression	   in	  cancer	  cells.	  These	  results	   involve	  a	   relocation	  of	  MKL1	  to	  
the	   nucleus	   with	   LPA	   and	   to	   the	   cytoplasm	   under	   LatB	   treatment	   (Scharenberg	   M.,	  
Pippenger	   B.	   et	   al,	   2014;	   Vartiainen	  M.,	   Guettler	   S.	   et	   al,	   2007).	   These	   observations	   also	  
reveal	   first	  signs	  of	  different	  MKL1-­‐FLNA	  complex	  role,	  regarding	  the	  cell	  model	  one	  keeps	  
track	  on	  examining.	  Expanding	  this	  thought,	  one	  can	  postulate	  that	  MKL1-­‐FLNA	  interaction	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takes	   place	   at	   least	   in	   part	   in	   the	   nucleus	   under	   pathophysiological	   or	   at	   least	   stressful	  
conditions,	   which	   often	   involves	   growth	   factor	   or	   serum	   release,	   comparable	   to	   the	   LPA-­‐
activation	  model	  in	  the	  present	  chapter.	  Consistent	  with	  our	  findings	  about	  impaired	  MKL1	  
phosphorylation	  in	  the	  presence	  of	  FLNA,	  we	  investigated	  that	  administration	  of	  LatB	  leads	  
to	   cytoplasmic	  MKL1	   redistribution	   due	   to	   its	   phosphorylation.	   LatB	   causes	  MKL1-­‐G-­‐actin	  
complex	  formation	  including	  phosphorylated	  MKL1.	  	  
We	  explored	  the	  functional	  effects	  implicated	  by	  the	  MKL1-­‐FLNA	  interaction.	  Therefore	  we	  
addressed	  qRT-­‐PCR	  analysis.	   Interestingly,	  we	   found	   that	  association	  of	  endogenous	  MKL1	  
and	  FLNA	  upon	  LPA	  treatment	   in	  primary	  fibroblasts	  was	  accompanied	  by	  the	   induction	  of	  
the	  well-­‐established	  MKL1	  target	  genes	  SM22,	  CTGF,	  ITGA5	  and	  CNN1	  (Smith	  E.,	  Teixeira	  A.	  
et	  al,	  2013;	  Medjkane	  S.,	  Perez-­‐Sanchez	  C.	  et	  al,	  2008;	  Muehlich	  S.,	  Hampl	  V.	  et	  al,	  2012).	  
This	   is	   particularly	   fascinating	   since	   similar	   results	   were	   obtained	   in	   FLNA	   expressing	   A7	  
cancer	   cell,	   compared	   to	  a	   relatively	   low	   level	  of	   target	  gene	  expression	   in	  FLNA-­‐depleted	  
M2	  cells.	  Furthermore	  we	  were	  able	   to	   reduce	   target	  gene	  expression	   in	  A7	  cells	  by	  FLNA	  
siRNA	   or	   LatB	   treatment.	   Therefore,	   comparison	   of	   the	   A7,	   A7	   siFLNA	   and	  M2	   data	   with	  
results	  obtained	   in	  fibroblasts	  with	  LPA	  or	  no	  LPA	   incubation	  makes	  sense.	  One	  now	  could	  
assume	   that	   LPA	   treated	   fibroblast	   cells	   behave	   in	   a	   certain	   way	   like	   a	   hepatocellular	  
carcinoma	   cell	   with	   nuclear	   active	   MKL1,	   concerning	   their	   biological	   properties	   such	   as	  
target	   gene	  expression	   	   (Muehlich	   S.,	  Hampl	  V.	   et	   al,	   2012).	   This	   is	   suiting	  well,	   as	   stress-­‐
stimulated	  fibroblasts	  cells	  may	  operate	  in	  a	  similar	  way	  as	  cancer	  cells.	  
	   	  
Figure	  9:	  Model	  of	  activating	  LPA	  and	  inhibitory	  LatB	  affecting	  MKL1/SRF	  activation.	  Adapted	  from	  Miralles	  
F.,	  Posern	  G.,	  2003	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7.2	  Rounding	  the	  puzzle:	  Where	  do	  MKL1	  and	  FLNA	  gear?	  
Besides	  its	  task	  as	  a	  gelation	  factor,	  stabilizer	  and	  director	  for	  actin	  networks,	  helping	  the	  cell	  
to	  save	  and	  position	  actin,	  FLNA	  has	  a	  known	  reputation	  for	  being	  a	  binding	  partner	  for	  an	  
extensive	  amount	  of	  other	  proteins	  (Savoy	  M.,	  Ghosh	  M.	  et	  al,	  2013;	  Nakamura	  F.,	  Stossel	  P.	  
et	   al,	   2011).	   To	   date,	   the	   transcription	   factor	   FOXC1,	   the	   androgen	   receptor	   AR,	   Smad	  
proteins	  and	  many	  more	  have	  been	  described	  to	  be	  regulated	  by	  FLNA	  (Berry	  F.,	  O’Neil	  M.	  et	  
al,	  2005;	  Sasaki	  A.,	  Masuda	  Y.	  et	  al,	  2001;	  Loy	  C.,	  Sim	  K.	  et	  al,	  2003).	  We	  introduce	  the	  co-­‐
activator	  MKL1	  as	   the	  newest	  member	  of	   the	  FLNA	  binding	  partner	   family.	  Surprisingly,	   in	  
terms	  of	  binding	  patterns	  (FOXC1,	  AR)	  or	  phosphorylation	  status	  (Smad),	  similarities	  to	  the	  
MKL1-­‐FLNA	   interaction	   are	   detectable.	   It	   has	   been	   discovered	   that	   these	   dynamic	  
interactions	   involving	   FLNA	   have	   positive	   and	   negative	   influences	   on	   transcriptional	  
processes,	  which	  sounds	  reasonable	  in	  reference	  to	  the	  large	  variety	  of	  FLNA	  binding	  partner	  
proteins	   including	  their	  different	  origins	  and	  duties	  (Berry	  F.,	  O’Neill	  M.	  et	  al,	  2004;	  Brandt	  
T.,	  Baarlink	  C.	  et	  al,	  2009;	  Loy	  C.,	  Sim	  K.	  et	  al,	  2003;	  Sasaki	  A.,	  Masuda	  Y.	  et	  al,	  2001).	  We	  are	  
expanding	  the	  FLNA	  paradigm	  by	  announcing	  MKL1	  as	  a	  protein,	  which	  benefits	  in	  a	  strong	  
way	  of	  the	  FLNA	  interaction,	  ultimately	  resulting	  in	  high	  rates	  of	  transcriptional	  activity	  and	  
gene	  expression.	  	  
7.2.1	  MKL1-­‐interacting	  region	  on	  FLNA	  
Since	   FLNA	   is	   a	   rather	   large	   molecule,	   it	   holds	   the	   role	   of	   a	   scaffold,	   simplifying	   MKL1	  
docking	   and	   binding	   processes.	   Besides	   the	   N-­‐terminal	   actin	   association	   domain,	   most	  
protein	  interactions	  take	  place	  at	  one	  of	  the	  two	  Rod	  segments	  of	  FLNA,	  containing	  so-­‐called	  
repeats	   which	   adopt	   an	   immunoglobulin-­‐like	   fold	   (Nakamura	   F.,	   Stossel	   T.	   et	   al,	   2011).	  
Because	  of	   the	  major	   similarity	  between	   these	   repeats,	  proteins	  can	  bind	  at	  multiple	   sites	  
(Nakamura	  F.,	  Stossel	  T.	  et	  al,	  2011).	  In	  our	  case,	  mapping	  of	  the	  FLNA	  protein	  revealed	  that	  
repeats	  4	  to	  7	  on	  Rod1	  and	  repeats	  16	  to	  18	  on	  Rod2	  (amino	  acids	  571	  to	  866	  and	  1779	  to	  
2284,	   respectively)	   are	   essential	   for	   the	   interaction	   with	   MKL1,	   suggesting	   a	   complex	  
interaction	  occurring	  between	  multiple	  regions	  of	  MKL1	  and	  FLNA.	  	  
This	  is	  stunning	  since	  another	  transcription	  factor	  called	  FOXC1	  associates	  with	  FLNA	  in	  the	  
exact	  same	  way	  (Berry	  F.,	  O’Neill	  M,	  et	  al,	  2004).	   Interestingly,	   following	  elevated	   levels	  of	  
nuclear	   FLNA,	   FOXC1	   is	   unable	   to	   activate	   transcription	   by	   being	   transported	   to	  
Discussion	   	  
	  
	   111	  
transcriptionally	   inactive	   regions	   of	   the	   nucleus.	   The	   targeting	   of	   FOXC1	   to	   these	   regions	  
might	   prevent	   it	   from	   accessing	   the	   required	   co-­‐activators	   necessary	   for	   transcriptional	  
activation	   (Berry	   F.,	   O’Neill	   M.	   et	   al,	   2004).	   Consistent	   with	   the	   findings	   of	   Berry	   F.	   and	  
colleagues,	  we	  speculate	  on	  FLNA	  holding	  MKL1	  to	  a	  particular	  cell	   region,	   in	  our	  case	  the	  
nucleus.	  This	  opposed	  role	  of	  activating	  and	  inhibiting,	  depending	  on	  its	  interaction-­‐partners	  
utilized,	  demonstrates	  a	  prime	  example	  for	  FLNAs	  mechanistic	  multi-­‐functionality.	  Its	  origin	  
duty	  of	  crosslinking	  actin	  filaments	  has	  been	  supplemented	  by	  various	  additional	  tasks	  in	  the	  
process	   of	   evolution.	   In	   this	   particular	   case	   FLNA	   is	   working	   as	   transcriptional	   barrier	   or	  
catalyst,	  since	  in	  contrast	  to	  our	  findings	  it	  has	  the	  opposite	  effect	  on	  FOXC1	  then	  on	  MKL1.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  10:	  Model	  of	  the	  FLNA-­‐MKL1	  interaction	  taking	  place	  at	  Rod1	  and	  2	  on	  the	  FLNA	  protein.	  
Another	  nuclear	  transcription	  factor	  linked	  to	  FLNA	  is	  the	  androgen	  receptor	  (AR),	  which	  is	  
not	   only	   mediating	   male	   sexual	   differentiation	   but	   its	   limitless	   activity	   is	   associated	   to	  
prostate	  cancer	  (Loy	  C.,	  Sim	  K.	  et	  al,	  2003).	  Interestingly	  and	  consistent	  with	  our	  findings,	  AR	  
interacted	  with	  FLNA	  in	  the	  same	  area	  MKL1	  does	  (repeat	  16	  to	  18	  on	  Rod2).	  The	  interaction	  
resulted	  in	  a	  repression	  of	  androgen	  signaling,	  measured	  by	  an	  androgen-­‐regulated	  control	  
protein	  widely	  used	  as	  a	  marker	  for	  prostate	  cancer	  progression	  (Loy	  C.,	  Sim	  K.	  et	  al,	  2003).	  
Together	  with	  our	  results	  about	  FLNAs	  nuclear	  activity	   in	  terms	  of	  MKL1,	  regulation	  of	  the	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androgen	   receptor	   is	   an	   additional	   example	   about	   nuclear	   processes	   controlled	   by	   a	  
formerly,	   primarily	   for	   its	   cytoplasmic	   presence	   known	   FLNA.	   In	   contrast	   to	   our	   findings	  
using	  full	  length	  FLNA	  during	  all	  performed	  investigations,	  Loy	  C.	  and	  colleagues	  specifically	  
address	   cleaved	   FLNA.	   They	   postulate	   an	   interaction	   of	   AR	   with	   the	   shorter,	   cleaved	   C-­‐
terminal	   100	   kDa	   fragment	   of	   FLNA.	   This	   is	   particularly	   appealing	   since	   smaller	   FLNA	  
fragments	   probably	   have	   less	   trouble	   to	   enter	   the	   nucleus	   then	   the	   large	   full-­‐length	  
macromolecule.	   It	   is	  more	   likely	   that	   a	   complex	   of	   fragmented	   FLNA	   and	   AR	   handles	   the	  
shuttle	  procedure	  with	  success	  than	  the	  massive	  full-­‐length	  FLNA-­‐MKL1	  complex.	  In	  addition	  
to	   the	   thoughts	   stated	   in	   the	   previous	   chapter,	   this	   strengthens	   the	   theory	   about	   a	   FLNA	  
independent	  MKL1	   shuttling.	   Nevertheless,	   nuclear	   entrance	   of	   FLNA	   is	   still	   controversial	  
and	   very	   little	   is	   known	   about	   the	   exact	   shuttle	   operation.	   Our	   experiments	   confirm	   the	  
existence	  of	  two	  shorter	  FLNA	  fragments	  (190	  kDa	  and	  90	  kDa),	  however	  at	  the	  present	  we	  
do	  not	  know	  how	  both	  of	  them	  differ	   in	  their	  biological	   functions	  and	   localization.	  Further	  
investigations	  respective	   full	   length	  FLNA	  movement	  and	  experiments	   regarding	  a	  possible	  
connectivity	  with	  smaller	  FLNA	  fragments	  and	  MKL1	  will	  be	  necessary	  to	  judge	  clearly	  on	  this	  
topic.	  	  
Smad	  proteins	  are	  involved	  in	  the	  transforming	  growth	  factor	  (TGF-­‐beta)	  signaling	  pathway	  
(Sasaki	   A.,	   Masuda	   Y.	   et	   al,	   2001).	   Before	   they	   enter	   the	   nucleus,	   Smads	   are	   getting	  
phosphorylated	  and	  afterwards	  participate	   in	   target	  gene	  transcription.	  Recently,	  Sasaki	  A.	  
and	  colleagues	   identified	  FLNA	  as	  a	  Smad	  binding	  partner	  along	  with	  stating	  that	  TGF-­‐beta	  
signaling	  was	  defective	   in	  FLNA-­‐deficient	  melanoma	  M2	  cells,	  compared	  to	  strong	  signal	   in	  
the	   FLNA-­‐expressing	   A7	   cells.	   In	   contrast	   to	   our	   investigations	   where	   FLNA	   impairs	  MKL1	  
phosphorylation,	   it	  might	  be	  possible	  that	   in	  this	  case,	  FLNA	  is	  essential	   for	  effective	  Smad	  
phosphorylation	   (Sasaki	   A.,	   Masuda	   Y.	   et	   al,	   2001).	   It	   is	   a	   known	   fact	   that	   MKL1-­‐
phosphorylation	  heavily	   impacts	  MKL1-­‐shutteling	  out	  of	  the	  nucleus	  (Muehlich	  S.,	  Wang	  R.	  
et	   al,	   2008).	   As	   a	   consequence	   of	   ERK	   1/2	   phosphorylation,	   G-­‐actin	   binding	   to	   MKL1	   is	  
simplified.	   We	   were	   able	   to	   demonstrate	   that	   MKL1-­‐phosphorylation	   processes	   were	  
suppressed	  by	  FLNA,	  therefore	  possibly	  restraining	  the	  MKL1-­‐FLNA	  complex	  in	  the	  nucleus.	  
This	   scenario	   might	   offer	   a	   potentially	   interesting	   target	   for	   future	   drug	   treatment	  
investigations,	  namely	  inhibitors	  of	  the	  MKL1-­‐FLNA	  interaction.	  Blocking	  of	  FLNA	  would	  lead	  
to	  enhanced	  MKL1	  phosphorylation,	  decreased	  nuclear	  MKL1	  levels	  and	  therefore	  reduction	  
of	   MKL1	   provoked	   tumorigenic	   events,	   including	   migration,	   invasion	   and	   target	   gene	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overexpression	   which	   is	   supported	   by	   the	   studies	   of	   Hampl	   V.	   and	   colleagues	   and	   their	  
findings	   of	   abolished	   hepatocellular	   carcinoma	   (HCC)	   xenograft	   growth	   after	   MKL1/2	  
depletion	  (2013).	  	  
7.2.2	  FLNAs	  unique	  structure-­‐properties	  simplifying	  MKL1	  association?	  	  
Speculations	  arising	  about	  the	  particular	  interaction	  area	  of	  MKL1	  at	  the	  beginning	  on	  both	  
FLNA	  rods	  (repeat	  4	  and	  16)	  might	  be	  addressed	  if	  one	  takes	  a	  more	  in	  detail	  look	  at	  FLNAs	  
unique	   structure.	   FLNAs	   vast	   variety	   of	   cellular	   tasks	   starts	   and	   ends	   with	   its	   structural	  
flexibility.	   Two	   hinges	   grant	   the	   flexibility	   for	   the	   protein	   itself	   and	   the	   connected	   actin	  
networks	   (Popowicz	   G.,	   Schleicher	  M.	   et	   al,	   2006).	   This	   high	   degree	   of	   elasticity	   not	   only	  
allows	   an	   easier	   formation	   of	   complex	   actin	   structures	   but	   also	   could	   help	   to	   enable	  
interaction	  partners	  an	  association	  with	  FLNA	  by	   simplifying	   the	  docking	  process,	   this	  way	  
making	  it	  more	  accessible	  then	  a	  rigid	  skeleton.	  This	  theory	  is	  strengthened	  by	  the	  fact	  that	  
filamins	  in	  higher	  organisms	  showcase	  a	  weaker,	  less	  rigid	  form	  of	  dimerization	  as	  a	  result	  of	  
evolution	  (Popowicz	  G.,	  Schleicher	  M.	  et	  al,	  2006).	  Furthermore,	  filamins	  in	  higher	  organisms	  
share	  a	  greater	  amount	  of	  interaction	  partners	  then	  the	  ones	  in	  lower	  organisms.	  Popowicz	  
G.	  and	  colleagues	  moreover	  revealed	  that	  single	  repeats	  have	  the	  ability	  to	  unfold	  if	  exposed	  
to	   force.	  The	  occurring	   force	  also	  enhances	   the	  repeats	   length,	   this	  way	  probably	  granting	  
straightforward	   access	   for	   binding	   candidates.	   It	   also	   has	   been	   postulated	   that	   sudden	  
unfolding	  of	  the	  filamin	  rod	  during	  stressful	  cytoskeletal	  situations	  might	  work	  as	  a	  method	  
to	  protect	   the	  structure	   from	  being	  damaged	  or	   leading	   to	  prevention	   from	   fatal	  breaking	  
issues	  (Popowicz	  G.,	  Schleicher	  M.	  et	  al,	  2006).	  	  
Fascinatingly,	   especially	   repeat	   4,	   which	   associates	   with	  MKL1,	   unfolds	   easily	   on	   the	   one	  
hand	  but	  also	  has	  a	  stable	  folding	  intermediate	  on	  the	  other	  (Popowicz	  G.,	  Schleicher	  M.	  et	  
al,	  2006).	  Thus,	  repeat	  4	  seems	  to	  be	  an	  excellent	  choice	  for	  MKL1	  to	  bind	  since	  it	  is	  flexible,	  
able	   to	  absorb	  and	  withstand	   force	  and	  stress.	  These	  circumstances	  allow	  simplification	  of	  
the	  act	  of	  docking	  due	  to	  unfolding	  and	  formation	  of	  a	  stable	  intermediate	  state.	  	  	  
Since	   FLNA	   is	   known	   to	   generate	   and	   connect	   a	   fine	   meshed	   and	   large	   network	   of	  
polymerized	   F-­‐actin	   in	   an	   orthogonal	   manner	   (Nakamura	   F.,	   Stossel	   T.	   et	   al,	   2011)	   and	  
furthermore	   represents	   a	   rather	   huge	   molecule	   by	   itself,	   questions	   arise	   about	   possible	  
spots	  for	  MKL1	  to	  enter	  the	  network	  and	  perform	  the	  docking	  process,	  in	  particular	  viewed	  
from	   a	   steric	   perspective.	   As	   it	   has	   been	   said	   before,	   the	   extraordinary	   qualities	   of	   FLNA	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repeat	  number	  4	  in	  terms	  of	  elasticity	  and	  unfolding	  should	  provide	  help	  for	  MKL1	  to	  find	  its	  
estimated	  binding	   area.	   Since	  both	   interacting	   repeats	   lay	  quiet	   close	   to	  one	  of	   the	  hinge	  
regions,	  it	  might	  be	  tempting	  to	  guess	  about	  these	  hinge	  regions	  generating	  space	  in	  case	  of	  
an	  incoming	  MKL1	  interaction	  by	  using	  their	  unique	  flexibility	  attributes.	  Further	  geometric	  
investigations	  will	  be	  necessary	  to	  solve	  this	  riddle	  in	  particular.	  	  
7.2.3	   Force,	   mechanical	   stress	   and	   a	   potential	   influence	   on	   MKL1	   binding	  
nature	  
Mechanical	  stress	  might	  be	  another	  factor	  coming	  into	  play.	  It	  is	  defined	  as	  the	  distribution	  
of	   forces	   applied	  on	  a	   solid	  or	   fluid	  body,	  which	   is	  deformed	  as	   a	   result	  of	   these	  external	  
loads	  (Noguerira	  M.,	  Moreira	  J.	  et	  al,	  2015).	  These	  forces	  not	  only	  lead	  to	  deformation,	  they	  
furthermore	   are	   changing	   the	   relative	   locations	   of	   molecules	   within	   a	   body.	   An	   intuitive	  
comparison	  would	  be	  pressure.	  This	   is	  correct	   if	  we	  speak	  of	  vertical	  forces.	  Parallel	   forces	  
however	  are	  considered	  shear	  stress	  (Noguerira	  M.,	  Moreira	  J.	  et	  al,	  2015).	  Thus,	  mechanical	  
stress	  holds	  the	  ability	  to	  unfold	  the	  FLNA	  repeat	  together	  with	  dissociation	  and	  association	  
of	  binding	  partners	  like	  MKL1.	  	  
Force	  furthermore	  is	  able	  to	  activate	  MKL1	  through	  RhoA	  stimulation	  (Zhao	  X.,	  Laschinger	  C.,	  
et	   al,	   2007).	   During	   pressure	   situations,	   myocardium	   growth	   is	   linked	   to	   myofibroblast	  
differentiation,	   an	   event	   where	   cardiac	   fibroblasts	   express	   smooth	   muscle	   actin	   (SMA),	  
thereby	  enhancing	  the	  ability	  to	  increase	  cell	  contractility.	  Force	  application	  induced	  nuclear	  
MKL1	  translocation	  as	  a	  follow	  up	  of	  Rho	  activation	  and	  actin	  assembly	  (Zhao	  X.,	  Laschinger	  
C.	  et	  al,	  2007),	  with	  MKL1	  also	  being	  an	   important	  determinant	  of	  SMA	  expression	   (Wang	  
DZ.,	   Li	   S.	   et	   al,	   2002).	   If	  we	   think	  one	   step	   ahead,	   a	   released	  or	   newly	   FLNA-­‐bound	  MKL1	  
protein	  this	  way	  could	  be	  a	  useful	  cellular	  sensor	  for	  mechanical	  forces	  taking	  influence	  on	  
the	  cell.	  In	  addition,	  mechanical	  stress	  is	  a	  critical	  factor	  in	  cancer	  as	  many	  solid	  tumors	  show	  
increased	   fluid	   pressure,	   building	   a	   barrier	   for	   transcapillary	   transport	   (Noguerira	   M.,	  
Moreira	  J.	  et	  al,	  2015).	  These	  barriers	  often	  provide	  problems	  for	  therapeutic	  schemes,	  since	  
agent	   uptake	   is	   inefficient.	   Physicians	   try	   to	   detect	   these	   increased	  pressures	  when	  doing	  
clinical	   exams,	   but	   measuring	   methods	   still	   lag	   satisfying	   reproducibility.	   Interestingly,	  
increased	  pressure	   is	  also	   responsible	   for	   cancer	   invasion.	   Invasive	  cells	  prefer	   soft	   tissues	  
like	  muscle	   rather	   then	  bone	   (Noguerira	  M.,	  Moreira	   J.	   et	   al,	   2015).	   Cells	   are	   also	   able	   to	  
escape	   easier	   and	   reach	   blood	   vessels	   to	   form	  distant	  metastasis	   under	   pressure.	   Protein	  
Discussion	   	  
	  
	   115	  
quantification,	  like	  MKL1	  might	  be	  the	  future	  key	  for	  sensing	  force	  and	  pressure	  parameters	  
and	  moreover	  would	  offer	  a	  much	  saver,	  easier	  and	  accurate	  approach.	  	  
7.2.4	  FLNA-­‐interacting	  region	  on	  MKL1	  
Regarding	  mapping	  from	  MKL1s	  perspective	  view,	  mutational	  analysis	  revealed	  that	  amino	  
acids	  301	  to	  310	  on	  MKL1	  are	  required	  for	   the	   interaction	  with	  FLNA.	  To	  reach	  this	  amino	  
acid	   span,	  we	   used	   deletion	   variants	   of	  MKL1,	   step	   by	   step	   narrowing	   down	   the	   possible	  
region	  responsible	  for	  interaction	  procedures.	  One	  has	  to	  keep	  in	  mind	  that	  the	  actual	  area	  
of	  interaction	  might	  surpass	  the	  ten	  described	  amino	  acids	  by	  a	  certain	  amount,	  potentially	  
looming	   into	   regions	   up-­‐	   or	   downstream	   301	   to	   310,	   since	   it	   is	   not	   possible	   to	   exclude	   a	  
somehow	  more	   compact	  way	   of	   interaction	   by	  mutation	   analysis.	   To	   sum	   it	   up,	  we	   have	  
identified	   a	   previously	   unrecognized	   region	   between	  MKL1	   amino	   acids	   301	   and	   310	   that	  
balances	   the	   interaction	  with	  FLNA.	  Curiously,	  none	  of	  MKL1s	  essential	  domains	   is	   getting	  
affected	  by	  binding	  events	  in	  this	  area.	  The	  SAP	  domain	  lays	  a	  little	  bit	  further	  upstream	  at	  
amino	  acids	  343	  to	  378	  representing	  the	  closest	  one.	  	  
Our	   group	   generated	   data,	   significantly	   showing	   that	   FLNA	   enhances	   MKL1	   activity.	   This	  
being	   said,	   it	   appears	   odd	   to	   question	   these	   strong	   results	   at	   first.	   Still,	   one	   has	   to	   be	  
cautious	   and	   ask	   self-­‐critical	   about	   possible	   divergent	   issues	   happening	   under	   certain	  
circumstances.	   First	  of	  all,	   almost	  all	  of	  our	   results	  hint	   in	   the	  direction	  of	  a	   strong	  MKL1-­‐
FLNA	   complex	   formation	   under	   pathophysiological	   conditions	   (growth	   factors,	   wound	  
healing,	   invasion,	   diseases,	   cancer	   cells	   with	   impaired	   tumor	   suppressor),	   so	   what	   about	  
physiological	   scenarios?	   Searching	   for	   a	   reason	   to	   answer	   that	   question,	   once	   again	   actin	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7.3	  Actin	  in	  control.	  Role	  of	  actin	  in	  the	  FilaminA-­‐MKL1	  machinery	  
We	   hypothesize	   about	   FLNA	   functioning	   as	   a	   positive	   cellular	   transducer,	   linking	   actin	  
polymerization	  to	  MKL1	  activity	  and	  counteracting	  the	  known	  repressive	  complex	  of	  MKL1	  
and	  monomeric	   actin.	   SRF	   reporter	   gene	   assays	   revealed	   a	   13-­‐fold	   induction	   of	   luciferase	  
activity	  in	  F-­‐actin,	  FLNA	  and	  MKL1	  expressing	  cells	  compared	  to	  only	  a	  slight	  induction	  when	  
no	  FLNA	  was	  available.	  Similar	  results	  were	  achieved	  in	  FLNA-­‐expressing	  cells	  versus	  FLNA-­‐
depleted	  cells	  by	  treating	  cells	  with	  or	  without	  actin	  stabilizer	   Jasplakinolide.	  Furthermore,	  
this	  data	  was	  strengthened	  by	  Immunofluoresence	  investigations,	  examining	  actin	  network	  
formation.	  Experiments	  in	  FLNA-­‐depleted	  cells	  revealed	  that	  only	  very	  little	  network	  building	  
was	   achieved	   if	   FLNA	   was	   not	   available,	   compared	   to	   strong	   actin-­‐network	   formation	   in	  
FLNA-­‐expressing	  cells.	  Taken	  together,	  these	  results	  provide	  evidence	  for	  FLNA	  working	  as	  a	  
positive	  cellular	  transducer,	  resulting	  in	  MKL1	  activity	  through	  actin	  polymerization.	  
No	  MKL1-­‐F-­‐actin	  interaction	  was	  observable	  in	  FLNA	  depleted	  melanoma	  cells,	  in	  contrast	  to	  
a	   clear	   measurable	   association	   in	   FLNA	   expressing	   ones.	   This	   data	   hints	   at	   a	   potential	  
complex	  formation	  scenario	  of	  MKL1,	  FLNA	  and	  F-­‐actin	  in	  tumor	  cells.	  	  
7.3.1	  Possible	  formation	  of	  a	  trimeric	  MKL1-­‐FLNA-­‐F-­‐actin	  complex	  
Now,	   speculating	   about	   the	   existence	   of	   a	   trimeric-­‐complex	   of	   MKL1-­‐FLNA-­‐F-­‐actin,	   we	  
carefully	  have	  to	  embrace	  steric	  thoughts.	  First	  of	  all,	  we	  have	  to	  state	  that	  we	  do	  not	  hold	  
any	  information	  in	  which	  fashion	  MKL1-­‐FLNA-­‐F-­‐actin	  possibly	  do	  interact.	  Do	  we	  know	  MKL1	  
interacts	  FLNA?	  That	  is	  the	  key	  part	  of	  this	  work	  and	  presented	  in	  great	  detail.	  Is	  there	  any	  
available	  data	  about	  FLNA-­‐F-­‐actin	  binding?	  This	  is	  verified	  in	  numerous	  publications	  as	  well	  
(Nakamura	  F.,	  Stossel	  T.	  et	  al,	  2011;	  Cunningham	  C.,	  Gorlin	  J.	  et	  al,	  1992).	  What	  about	  MKL1s	  
association	   to	   F-­‐actin?	   We	   provided	   evidence	   of	   this	   association	   taking	   place	   in	   FLNA	  
expressing	  A7	  cells,	  while	  no	  such	  interaction	  was	  visible	  in	  FLNA	  depleted	  M2	  cells,	  hinting	  
at	  a	  crucial	  necessity	  of	  FLNA	  for	  a	  putative	  MKL1-­‐FLNA-­‐F-­‐actin	  complex.	  	  
A	  speculative	  setting	  with	  FLNA	  as	  a	  core	  protein,	  flanked	  by	  MKL1	  at	  repeat	  4	  and	  16	  on	  the	  
one	   side	  and	  F-­‐actin	  bond	   to	   FLNAs	  actin	  binding	  domain	  on	   the	  other	  might	   sound	  most	  
suitable	   (Fig.	   13).	   Viewed	   from	  MKL1s	   perspective,	   FLNA	   is	   binding	  MKL1	   at	   aa	   301-­‐310,	  
however	  we	  do	  not	  know	  where	  the	  MKL1-­‐F-­‐actin	  interaction	  takes	  place	  yet.	  Interestingly,	  
an	   immunoprecipitaion	  setup	  comparing	  MKL1	  Δ301-­‐380	  and	  wt-­‐MKL1	  binding	  patterns	  to	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actin	  displayed	  a	  weaker	  MKL1	  Δ301-­‐380-­‐Actin	  association	  versus	  wt-­‐MKL1-­‐Actin,	  which	  also	  
hints	  at	  trimeric	  complex	  formation	  since	  MKL1	  Δ301-­‐380	  is	  not	  able	  to	  bind	  FLNA	  anymore.	  
Nevertheless	   this	   has	   to	   be	   investigated	   in	   greater	   detail,	   since	   the	   examined	   GFP-­‐Actin	  
displays	  F-­‐actin	  as	  well	  as	  the	  monomeric	  G-­‐actin,	  making	   it	  difficult	  to	  credit	  the	  effect	  to	  
polymerized	  F-­‐actin	  alone.	  	  
Since	   immunoprecipitation	   analysis,	   in	   terms	   of	   searching	   for	   an	   answer	   on	   these	  
complicated	  complex	  formations	  are	  slowly	  reaching	  their	   limits,	  alternative	  binding	  assays	  
will	  be	  necessary	  to	  shade	  light	  on	  this	  “complex”	  topic.	  	  
7.3.2	  G-­‐actin	  terminating	  MKL1-­‐FLNA	  machinery?	  
To	  round	  up	  formation	  theories,	  one	  should	  also	  consider	  G-­‐actin.	  Since	  FLNA	  is	  such	  a	  huge	  
molecule,	   it	   might	   be	   arguable	   that	   its	   long	   and	   voluminous	   rod	   domains	   deliver	   steric	  
trouble	  for	  G-­‐actin	  to	  reach	  MKL1s	  RPEL	  domain.	  This	  would	  bring	  us	  to	  a	  competitive	  model	  
between	  FLNA	  and	  G-­‐actin	  competing	  for	  a	  MKL1	  association.	  Consistent	  with	  this	  idea,	  it	  is	  
known	   that	  actin	   sterically	  occludes	   the	  NLS	   region	  on	  MKL1	  by	  binding	   the	  RPEL	  domain,	  
this	   way	   blocking	   nuclear	   import	   in	   a	   competitive	   manner	   by	   blocking	   importin	   signaling	  
(Mouilleron	  S.,	  Langer	  C.	  et	  al,	  2011;	  Pawlowski	  R.,	  Rajakylä	  EK.	  et	  al,	  2010).	   In	  contrast	  to	  
competing	   theories,	   RNA	   export	   factor	   Ddx19	  which	   is	   facilitating	  MKL1	   nuclear	   entrance	  
does	  not	  compete	  with	  actin	  for	  MKL1	  binding	  (Rajakylä	  EK.,	  Viita	  T.	  et	  al,	  2015).	  To	  shade	  
light	   on	   this	   topic	   we	   designed	   a	   reporter	   gene	   assay	   setup	   using	   NLS-­‐R62D-­‐actin,	   a	  
constitutive	  cytoplasmic	  mutant	  of	  actin.	  We	   increased	  the	  NLS-­‐R62D-­‐actin	  dose	   in	  a	  step-­‐
by-­‐step	  manner,	  which	   led	   to	   a	   reduction	   of	   SRF	   reporter	   activity	   in	   FLNA	   expressing	   and	  
FLNA	  depleted	  melanoma	   cells	   because	  MKL1	   is	   getting	   shuttled	  back	   into	   the	   cytoplasm.	  
We	   moved	   forward	   by	   introducing	   mDia-­‐ct,	   a	   constitutive	   nuclear	   mutant	   of	   the	   formin	  
mDia	  and	  secondly	   fusing	  a	  NES	  signal	   to	  mDia,	  which	  thereby	  enables	  cytoplasmic	   formin	  
localization	   (Baarlink	   C.,	   Wang	   H.	   et	   al,	   2013).	   Fascinatingly,	   nuclear	   formin	   was	   able	   to	  
counteract	   the	   repressive	   nuclear	   G-­‐actin	   effect,	   this	   way	   retaining	   luciferase	   activity	   on	  
higher	   levels	   in	   contrast	   to	   treatment	   with	   cytoplasmic	   formin,	   where	   luciferase	   levels	  
dropped	  heavily.	  FLNA	  depleted	  melanoma	  cells	  remained	  at	  low-­‐level	  reporter	  gene	  activity	  
throughout	  the	  entire	  experiment,	  no	  matter	  how	  much	  G-­‐actin	  or	  formin	  was	  introduced.	  	  
We	   suggest	   a	   model	   in	   which	   nuclear	   G-­‐actin	   terminates	   the	   highly	   active	   MKL1-­‐FLNA	  
machinery	  by	  dismissing	  MKL1	  from	  FLNA,	  binding	  MKL1	  by	  itself	  and	  exporting	  it	  out	  of	  the	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nucleus	  in	  a	  concentration	  dependent	  manner.	  The	  hypothesis	  is	  furthermore	  strengthened	  
by	   our	   results	   that	   FLNA	   displays	   no	   interaction	   with	   the	  monomeric	   R62D-­‐actin	  mutant.	  
However,	   one	   has	   to	   put	   in	   perspective	   that	   this	   model	   may	   only	   hold	   a	   secondary	   role	  
under	   biological	   circumstances.	   The	   available	   G-­‐actin	   pool	   is	   rather	   small	   under	  
predominant,	  high	  F-­‐actin	  levels	  and	  active	  MKL1	  conditions	  in	  the	  nucleus	  (Vartiainen	  MK.,	  
Guettler	   S.	   et	   al,	   2007),	  which	  we	  consider	   the	   case	   in	  our	  experiments.	  Nevertheless	   this	  
competing	  scenario	  could	  still	  exist	  and	  might	  be	  used	  to	  terminate	  transcriptional	  activity.	  
7.3.3	  Linking	  actin	  dynamics	  to	  state	  of	  the	  art	  drug	  development	  
Individual	  cells	  steadily	  undergo	  physical	  changes	  in	  appearance,	  shape	  and	  position	  during	  
embryonic	   development	   as	   well	   as	   in	   the	   state	   of	   functional	   components	   of	   mature	  
multicellular	   organisms	   (Olson	   E.,	   Nordheim	   A.,	   2010).	   These	   physical	   changes	   demand	  
cellular	   motile	   functionality,	   which	   is	   regulated	   by	   physiological	   and	   pathophysiological	  
stimuli.	   The	  physical	   properties	   for	   cellular	  motility	   rest	   upon	  macromolecular	   assemblies,	  
like	  actin	  filaments	  (Olson	  E.,	  Nordheim	  A.,	  2010).	  Actin	  filaments	  heavily	  rely	  on	  FLNA	  as	  a	  
gelation	  factor	  and	  networking	  scaffold	  on	  the	  one	  hand	  but	  are	  also	  the	  key	  activator	   for	  
MKL1.	  We	  are	   linking	  actin	  polymerization	  to	  MKL1-­‐FLNA	  activity	   for	   the	  first	   time.	  Recent	  
publications	   provide	   evidence	   that	   nuclear	   and	   cytoplasmic	   actin	   pools	   communicate	   in	   a	  
dynamic	   way	   (Vartiainen	   M.,	   Guettler	   S.	   et	   al,	   2007;	   Grosse	   R.,	   Vartiainen	   MK.,	   2013).	  
Therefore	   it	   is	   key	   to	   take	  a	  more	  precise	   look	  at	   cytoskeletal	   reorganization.	  Cytoskeletal	  
actin	   dynamics	   are	   controlled	   by	   different	   membrane	   receptors	   like	   Receptor	   Tyr	   kinase,	  
Integrins	   and	  TGF-­‐beta,	  which	  modulate	   the	  activity	  of	  Rho	  GTPases	   through	  Rho	  guanine	  
nucleotide	   exchange	   factors	   (GEFs)	   (Olson	   E.,	   Nordheim	   A.,	   2010).	   Receptor	   Tyr	   kinases	  
include	   insulin	  and	  epidermal	  growth	   factor	   (EGF)	   receptors.	   Interestingly,	   insufficient	  EGF	  
receptor	   signaling	   is	   associated	   to	   similar	   neurodegenerative	   diseases	   as	   caused	   by	   FLNA	  
mutations	  (Bublil	  E.,	  Yarden	  Y.,	  2007).	  On	  the	  other	  hand,	  excessive	  EGF	  signaling	  is	  linked	  to	  
a	  wide	  variety	  of	   tumor	   formation	   (Lee	  MY.,	  Chou	  CY.	  et	   al,	   2008;	   	   Lo	  HW.,	  Hsu	  SC.	  et	   al,	  
2007).	   This	   led	   to	   development	   of	   EGFR	   inhibitors	   including	   Gefitinib®	   for	   lung-­‐	   and	  
Cetuximab® for	   colon	   cancer.	   Downstream	   effects	   of	   EGF	   activation	   result	   in	   high-­‐level	  
amounts	  of	  cytoplasmic	  F-­‐actin	  (Mouneimne	  G.,	  Soon	  L.	  et	  al,	  2004;	  Olson	  E.,	  Nordheim	  A.	  
2010)	  leading	  to	  MKL1	  target	  gene	  activity	  in	  the	  nucleus.	  Thus,	  current	  state-­‐of-­‐the	  art	  EGF	  
inhibitor	   agents	   represent	   a	   valuable	   example	   how	   there	   are	   already	   indirect	   MKL1	  
influencing	  drugs	  successfully	  used	  in	  cancer	  treatment.	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7.3.4	   The	   formin	   mDia	   as	   the	   missing	   key	   in	   launching	   MKL1-­‐FLNA-­‐F-­‐actin	  
complex	  activity?	  
Still,	   several	   actin	   related	   questions	   remain.	   Is	   nuclear	   actin	   actively	   responding	   to	  
cytoplasmic	  alterations?	  Do	  the	  two	  pools	  freely	  exchange?	  Does	  nuclear	  actin	  assemble	  into	  
F-­‐actin	  the	  same	  way	  as	  their	  cytoplasmic	  counterpart	  and	  how	  does	  it	  influence	  the	  MKL1-­‐
FLNA	   complex?	   Taken	   together,	   functions	   and	   existence	   of	   nuclear	   actin	   have	   been	   a	  
mystery	  for	  many	  years.	  We	  found	  that	  FLNA	  is	  required	  for	  an	  association	  between	  F-­‐actin	  
and	  MKL1,	  which	  suggests	  that	  FLNA	  may	  mediate	  an	  association	  between	  polymerized	  actin	  
and	  MKL1,	   thereby	   transduces	   the	   signal	  of	  polymerized	  actin	   to	   SRF	  activation.	   Since	   the	  
MKL1-­‐FLNA	  complex	  is	  formed	  in	  the	  nucleus	  in	  melanoma	  cells,	  nuclear	  actin	  characteristics	  
are	   of	   great	   interest	   for	   our	   research.	   To	   further	   address	   questions	   about	   nuclear	   actin,	  
Baarlink	  and	  colleagues	  investigated	  MKL1	  regulation	  in	  the	  nucleus.	  Evidence	  was	  provided	  
that	   serum	   stimulation	   is	   able	   to	   rapidly	   and	   transiently	   induce	   formation	   of	   F-­‐actin	  
structures	  in	  a	  fibroblast	  nucleus	  (Baarlink	  C.	  et	  al,	  2013).	  These	  findings	  mesh	  excellent	  with	  
our	  data	  of	  an	  essential	  role	  of	  F-­‐actin	  for	  the	  FLNA-­‐MKL1	  interaction.	  However,	  and	  this	  is	  
crucial,	   Baarlinks	   group	   needed	   a	   stimulation	   agent	   for	   their	   nuclear	   F-­‐actin	   outburst	   the	  
same	  way	  we	  needed	  LPA	  for	  MKL1-­‐FLNA	  complex	  formation	  in	  the	  equivalent	  fibroblast	  cell	  
line.	  According	  to	  Baarlink	  C.	  and	  colleagues	  the	  nuclear	  F-­‐actin	  structures	  are	  dependent	  to	  
the	   formin	   mDia.	   The	   Rho	   family	   of	   GTPases	   orchestrates	   fundamental	   cell	   processes	  
through	   remodeling	   of	   the	   cytoskeleton	   after	   being	   activated	   by	   external	   stimuli	   like	   LPA.	  
The	   largest	   family	  of	  Rho-­‐GTPase	  effectors	   are	   formins	   (Jegou	  A.,	   Carlier	  MF.	   et	   al,	   2013).	  
mDia1	   is	   regulating	   myosin	   activity	   through	   feedback	   mechanisms,	   while	   mDia2	   is	  
stimulating	   the	   production	   of	   filopodia.	   They	   are	   able	   to	   stimulate	   nuclear	   actin	   filament	  
polymerization,	  accelerate	  the	  elongation	  and	  last	  but	  not	   least	  stabilize	  them	  (Baarlink	  C.,	  
Grosse	  R.,	  2014)	  	  
Since	  our	  results	  demonstrate	  that	  FLNA	  expressing	  melanoma	  cells	  lead	  to	  significant	  longer	  
formation	   and	   higher	   number	   of	   filopodia	   then	   their	   FLNA	   deficient	   counterpart,	   a	   result	  
that	  is	  also	  obtained	  through	  mDia2	  activity,	  nuclear	  F-­‐actin	  composition	  driven	  by	  formins	  
might	  be	  the	  missing	  but	  plausible	  explanation	  for	  the	  new	  MKL1-­‐FLNA	  intense	  activity.	  This	  
is	   strengthened	   by	   our	   very	   own	   observations	   that	   only	   a	   very	   weak	   actin	   network	   was	  
visible	   in	   FLNA	   depleted	   melanoma	   cells.	   Consistent	   with	   that,	   luciferase	   activity	   rose	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significantly	  when	  mDia	  and	  FLNA	  were	  available,	  in	  particular	  compared	  to	  a	  setup	  with	  no	  
FLNA	  presence.	  	  
7.3.5	  Mechanistic	  summary	  of	  the	  MKL1-­‐FLNA	  association	  
In	  conclusion,	  we	  identified	  FLNA	  as	  a	  MKL1	  interacting	  protein	  and	  an	  important	  participant	  
in	  MKL1-­‐SRF-­‐mediated	  transcription.	  The	  novel	   interaction	  is	  required	  for	  MKL1	  dependent	  
gene	  expression,	  cell	  migration	  and	  invasion.	  Therefore,	  binding	  to	  FLNA	  represents	  a	  newly	  
identified	   mechanism	   that	   positively	   regulates	   MKL1	   activity,	   thus	   opposing	   the	   known	  
repressive	  complex	  of	  MKL1	  and	  G-­‐actin	  (Fig.	  11).	  
	  
Figure	   11:	  Model	   of	   the	  MKL1-­‐FLNA	   interaction	   in	   LPA	   stimulated	   fibroblasts	   (left)	   and	   the	   unstimulated	  
counterpart	  (right).	  MKL1	  exists	  in	  a	  repressive	  G-­‐actin	  complex	  (right)	  or	  an	  activating	  FLNA	  complex	  (left).	  
FLNA	   impairs	   MKL1-­‐phosphorylation,	   which	   is	   a	   prerequisite	   for	   G-­‐actin	   binding,	   thereby	   switching	   the	  
repressive	  MKL1-­‐G-­‐actin	   structure	   to	   a	  MKL1-­‐FLNA	   complex	   that	   transduces	   actin	   polymerization	   into	   SRF	  
activity.	  Adapted	  from	  Kircher	  P.,	  Hermmans	  C.,	  2015.	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7.4	  MKL1	  and	  FLNA:	  A	  highly	  dynamic	  duo	  leading	  to	  cancer?	  
MKL1s	  original	  naming	  as	  megakaryoblastic	  leukemia	  1	  already	  reveals	  a	  bond	  to	  neoplastic	  
cancer	   events.	   Following	   chromosomal	   translocation	   the	   emerging	   protein	   of	  MKL1	   and	   a	  
fusion	   partner	   is	   strictly	   nuclear	   localized	   because	   it	   is	   not	   subject	   to	   G-­‐actin	   mediated	  
nuclear	  export	  anymore	  (Mercher	  T.,	  Busson-­‐Le	  Coniat	  M.	  et	  al,	  2001;	  Descot	  A.,	  Rex-­‐Haffner	  
M.	  et	  al,	  2008).	  As	  a	  result,	  SRF	  transcriptional	  activity	  is	  strongly	  and	  permanently	  activated.	  	  
Consistent	  with	  MKL1s	  pioneer	  discovery,	  our	  investigations	  revealed	  that	  the	  interaction	  of	  
MKL1	   and	   FLNA	   regulates	   MKL1	   gene	   expression.	   This	   idea	   is	   supported	   by	   the	   strong	  
induction	  of	  proven	  MKL1	  target	  genes	  like	  SM22,	  CTGF,	  ITGA5,	  CNN1,	  MYH9,	  GLIPR1,	  TGF-­‐
beta	  and	  FHL2	   (Schmidt	  L.,	  Duncan	  K.	  et	  al,	  2012;	  Elberg	  G.,	  Chen	  L.,	  et	  al,	  2008;	  Cheng	  X.,	  
Yang	  Y.,	  et	  al	  2015)	  in	  FLNA	  expressing	  melanoma	  cells	  and	  their	  correlated	  low	  expression	  
levels	  in	  FLNA-­‐depleted	  cells.	  The	  synergetic	  effect	  of	  an	  available	  MKL1-­‐FLNA	  complex	  was	  
not	  only	  demonstrated	  by	  addressing	  a	  variety	  of	  target	  genes,	  but	  also	  could	  be	  shown	  by	  
reporter	   gene	   experiments	   which	   revealed	   a	   tight	   and	   sensitive	   connection	   between	   the	  
amount	   of	   present	   MKL1,	   FLNA	   and	   the	   measured	   SRF	   reporter	   activity.	   A	   step-­‐by-­‐step	  
increase	   of	   siFLNA	   concentration	   led	   to	   lower	   levels	   of	   SRF	   protein	   levels	   and	   double	  
knockdown	   of	   MKL1	   and	   FLNA	   reduced	   SRF	   protein	   levels	   even	   more	   then	   just	   single	  
knockdown	  of	  one	  of	   the	  two	  proteins.	  qRT-­‐PCR	  experiments	  which	  used	  a	  setup	   in	  FLNA-­‐
depleted	  melanoma	  cells	  with	  FLNA	  rescue	  combined	  with	  MKL1	  knockdown,	  provided	  more	  
evidence	   for	   a	   synergetic	   effect	   by	   displaying	   the	   highest	   levels	   of	   gene	   expression	  when	  
FLNA	  and	  MKL1	  were	  bot	  available.	  Furthermore,	  we	  were	  able	  to	  demonstrate	  that	  MKL1	  
deletion	  mutants	   that	   are	  unable	   to	  bind	   FLNA	  heavily	   decreased	   the	  expression	  of	  MKL1	  
target	  genes.	  	  
Melanoma	  is	  an	  aggressive	  skin	  malignancy,	  which	  is	  able	  to	  spread	  into	  other	  organs	  of	  the	  
body,	  including	  more	  than	  230000	  new	  cases	  and	  55000	  deaths	  per	  year	  (Eggermont	  et	  al.,	  
2014).	   It	   is	  developing	  from	  the	  pigment-­‐containing	  melanocytes	  and	  mostly	  occurs	  on	  the	  
legs	   in	   women	   while	   men	   are	   affected	   on	   the	   back	   at	   a	   high	   percentage	   (World	   Cancer	  
Report.,	   2014,	   Chapter	   5.14,	   WHO).	   The	   primary	   cause	   of	   melanoma	   is	   exposure	   to	  
ultraviolet	  light,	  influencing	  especially	  people	  with	  low	  levels	  of	  skin	  pigment	  and	  corrupting	  
our	  genetic	  information	  (Kanavy	  HE,	  Gerstenblith	  MR	  et	  al.,	  2011).	  Highly	  energetic	  and	  most	  
dangerous	   UVC	   lights	   are	   absorbed	   by	   the	   ozone	   layer,	   while	   the	   longer	   UV	  wavelengths	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UVA	  and	  UVB	  however	  do	  pass	  the	  atmosphere.	  Wavelengths	  of	  the	  intermediate	  UVB	  light	  
are	   long	  enough	   to	  pass	   through	   the	  ozone	   layer	  but	   still	  energetic	  enough	   to	  attack	  DNA	  
(Goodsell	  D.,	  2001).	  Each	  melanocyte	  experiences	  up	  to	  100	  of	  these	  reactions	  during	  every	  
second	  of	  sunlight	  exposure	  (Goodsell	  D.,	  2001),	  however	  most	  of	  them	  are	  corrected	  right	  
away.	  If	  the	  damage	  does	  not	  get	  eliminated,	  the	  genetic	  information	  may	  be	  permanently	  
mutated,	  resulting	  in	  transformation	  of	  regular	  melanocyte	  stem	  cells	  into	  cancer	  cells.	  	  
Previous	   studies	  have	   illustrated	   that	  FLNA	   interacts	  with	  many	  proteins	   related	   to	   cancer	  
progression	   (Kim	  H.,	  McCulloch	   CA.,	   2010;	   Leung	  R.,	  Wang	   Y.	   et	   al,	   2010),	   a	   circumstance	  
that	  involves	  growth,	  motility	  and	  invasive	  properties.	  Interestingly	  Zhang	  K.	  and	  colleagues	  
found	   that	   reduction	   of	   FLNA	   expression	   inhibited	   the	   ability	   of	   melanoma	   cells	   to	   form	  
colonies.	  They	  also	  postulated	  that	  knockdown	  of	  FLNA	  correlated	  with	  reduced	  melanoma	  
growth	  in	  tumor	  xenograft	  (Zhang	  K.,	  Zhu	  T.	  el	  al,	  2014).	  This	  way,	  appropriate	  FLNA	  levels	  
seem	  to	  be	  essential	   in	  tumor	  cells	  for	  motility	  and	  invasive	  purposes,	  to	  resist	  mechanical	  
stress	  and	  attachment	  to	  extracellular	  matrix	  (ECM)	  to	  form	  metastases.	  	  
Per	  definition,	  benign,	  non-­‐cancerous	  tumors	  in	  contrast	  to	  malignant	  ones	  are	  self-­‐limited	  
in	  its	  growth,	  which	  means	  they	  are	  not	  capable	  of	  invading	  into	  close-­‐by	  tissues.	  As	  one	  can	  
imagine,	   this	   invasive	   cell	   properties	   are	   of	   great	   interest	   in	   the	   field	   of	   today’s	   cancer	  
research.	  We	  found	  that	  the	  interaction	  between	  MKL1	  and	  FLNA	  controls	  MKL1	  dependent	  
cell	  motility	  and	  invasion.	  Similar	  to	  gen	  expression	  experiments,	  the	  MKL1	  deletion	  mutant	  
unable	   to	   bind	   FLNA	   exhibited	   strongly	   reduced	   motile	   and	   invasive	   properties	   in	  
comparison	  to	  wild-­‐type	  MKL1.	  Furthermore	  MKL1	  and	  FLNA	  knockdown	  led	  to	  a	  decreased	  
number	   of	   filopodia	   formation.	   Filopodia	   are	   known	   to	   be	   crucial	   for	  motility	   procedures	  
(Kim	  MC.,	  Whisler	  J.	  et	  al,	  2015).	  These	  investigations	  confirm	  that	  the	  interaction	  with	  FLNA	  
is	  needed	  for	  MKL1	  to	  execute	  its	  motile	  functions	  and	  invasive	  role	  in	  a	  synergetic	  way.	  It	  
delivers	  yet	  another	   important	  value	  that	  the	  MKL1-­‐FLNA	  interaction	  is	  essential	  for	  tumor	  
progression.	   Literature	   provides	   evidence	   that	   knockdown	   of	  MKL1	   in	   a	   variety	   of	   cancer	  
cells	   led	  to	   impaired	  cell	  migration	  (Muehlich	  S.,	  Hampl	  V.	  et	  al,	  2012;	  Medjkane	  S.,	  Perez-­‐
Sanchez	   C,	   et	   al,	   2009).	   Based	   on	   our	   own	   new	   results	   in	   melanoma	   and	   hepatocellular	  
carcinoma	  cells,	  we	  propose	  a	   synergetic	  model,	  where	   the	   interaction	  of	  MKL1	  and	  FLNA	  
results	  in	  a	  strong	  increase	  of	  motility	  events,	  compared	  to	  a	  condition	  where	  no	  MKL1-­‐FLNA	  
interaction	  is	  taking	  place,	  resulting	  in	  reduced	  cell	  mobility.	  Consistent	  with	  our	  data,	  Liao	  X.	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and	   colleagues	   recently	  postulated	   similar	   results	   in	   terms	  of	  migration	  by	   the	   interaction	  
between	   MKL1	   and	   the	   transcription	   factor,	   signal	   transducers	   and	   activators	   of	  
transcription	   (STAT3).	   The	   association	   also	   led	   to	   a	   synergetic	   increased	  wound	  healing	   in	  
breast	  cancer	  cells	  (Liao	  X.,	  Wang	  N.	  et	  al,	  2014).	  
Another	  interesting	  topic	  regarding	  FLNA	  and	  cancer	  development	  is	  DNA	  damage	  response.	  
It	  has	  been	  reported	  that	  FLNA	  holds	  a	  nuclear	  function	  by	  interacting	  with	  BRCA2,	  a	  critical	  
tumor	   suppressor	   protein	   involved	   in	   DNA	   damage	   repair	   (Yuan	   Y.,	   Shen	   Z.	   et	   al,	   2001).	  	  
Evidence	   was	   given	   that	   inhibition	   of	   FLNA	   led	   to	   reduction	   of	   DNA	   double	   strand	   break	  
repair	   in	   cancer	   cells,	   resulting	   in	   sensitization	   of	   cells	   to	   ionizing	   radiation.	   Furthermore	  
chemotherapy	   effectiveness	   improved	   through	   sensitizing	   cancer	   cells	   to	   cis-­‐platin	   and	  
bleomycin	   drug	   treatment	   in	   low	   level	   FLNA	   cancer	   cells	   by	   delaying	   the	   repair	   of	   DNA	  
double	  strand	  breaks.	  Bleomycin	  causes	  mainly	  double	  strand	  breaks,	  while	  cis-­‐platin	  binds	  
with	  DNA	  to	  form	  different	  types	  of	  platinium-­‐DNA	  adducts.	  These	  results	  indicate	  that	  FLNA	  
not	  only	  plays	  a	   significant	   role	   in	   repair	  of	  a	  variety	  of	  DNA	  damage	  but	  also	   that	   lack	  of	  
FLNA	  is	  a	  marker	  for	  a	  better	  outcome	  after	  DNA	  damage	  based	  treatment.	  In	  other	  words,	  
FLNA	   can	   be	   inhibited	   to	   sensitize	   FLNA	   positive	   cancer	   to	   therapeutic	   DNA	  damage.	   This	  
way,	  FLNA	  can	  be	  used	  as	  a	  biomarker	  and	  a	  target	  for	  DNA	  damage	  based	  cancer	  therapy	  
(Yue	  J.,	  Lu	  H.	  et	  al,	  2011).	  	  
As	   stated	   in	   the	   beginning,	   this	   thesis	   experiments	  were	   performed	  with	   full-­‐length-­‐FLNA	  
interacting	  MKL1	  in	  the	  nucleus,	  which	  afterwards	  releases	  its	  cancer	  progressing	  potential.	  
Therefore	   it	   is	   tempting	  to	  speculate	  that	  cleaved	  FLNA	  might	  not	  be	  able	  to	   induce	  MKL1	  
target	  gene	  expression,	  migration	  and	   invasion.	   It	  also	  has	  been	  postulated	  that	  that	  FLNA	  
cleavages	   comes	   in	  hand	  with	   reduced	  metastasis	   (Bedolla	  RG.,	  Wang	  Y.	   et	   al,	   2009).	   This	  
way	  and	  in	  addition	  to	  simply	  inhibiting	  FLNA	  expression,	  an	  alternative	  strategy	  to	  disrupt	  
the	   FLNA	   function	   could	   be	   induction	   of	   FLNA	   cleavage.	   Recently	   Planaguma	   J.	   and	  
colleagues	   provided	   a	   novel	   optical	   tool	   for	   tracking	   the	   cellular	   functions	   of	   FLNA	   in	   real	  
time	  (Planaguma	  J.,	  Minsaas	  L.	  et	  al,	  2012).	  The	  group	  developed	  a	  fluorescent	  FLNA-­‐EGFP	  
construct	  by	  inserting	  the	  EGFP-­‐tag	  inside	  the	  flexible	  hinge	  1	  region	  of	  FLNA	  between	  two	  
calpain	  cleavage	  sites.	  Therefore,	  this	  tool	  might	  be	  promising	  as	  an	   instrument	  for	  stating	  
FLNA	  as	  a	  future	  biomarker	  and	  presenting	  optical	  data	  of	  FLNA	  cleavage	  activity.	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Fascinatingly,	   and	   similar	   to	   FLNA	   knockdown	   effects,	   depletion	   of	   MKL1	   reduced	   cell	  
adhesion,	   invasion	   and	   motility,	   all	   typical	   Rho-­‐dependent	   cytoskeletal	   processes,	   in	  
melanoma	  and	  breast	   cancer	   cells	   (Medjkane	   S.,	   Perez-­‐Sanchez	  C.	   et	   al,	   2009).	  Moreover,	  
depletion	  of	  MKL1	  target	  genes	  MYH9	  and	  MYL9,	  which	  have	  been	  related	  to	  invasive	  tumor	  
presence	   previously,	   resulted	   in	   significantly	   reduced	   invasiveness,	   impaired	   lung	  
colonization	   and	   reduced	   formation	   of	   lung	   tumors,	   delivering	   evidence	   that	  MKL1	   target	  
genes	  have	  at	  least	  some	  influence	  on	  tumor	  progression	  (Medjkane	  S.,	  Perez-­‐Sanchez	  C.	  et	  
al,	  2009).	  	  
Another	   interesting	   approach,	   which	   links	  MKL1	   to	   cancer	   development,	   is	   suppressor	   of	  
cancer	   cell	   invasion	   (SCAI),	   a	   newly	   found	   protein	   that	   regulates	   invasive	   cell	   migration	  
(Brandt	  T.,	  Baarlink	  C.	  et	  al,	  2009).	  Similar	  to	  MKL1,	  SCAI	  is	  primary	  located	  nuclear	  in	  cancer	  
cells	   where	   it	   forms	   a	   complex	   with	   MKL1	   and	   SRF,	   this	   way	   effectively	   blocking	   MKL1	  
activity.	   Fittingly,	   lower	   SCAI	   levels	   are	   tightly	   correlated	   with	   increased	   invasive	   cell	  
migration	   and	   SCAI	   is	   down-­‐regulated	   in	   several	   human	   tumors.	   Brandt	   T.	   and	   colleagues	  
further	   stated	   that	   the	   integrin	   beta-­‐1	   is	   strongly	   up-­‐regulated	   after	   suppression	   of	   SCAI,	  
which	  correlates	  well	  with	  our	  very	  own	  findings	  about	  elevated	  integrin	  alpha-­‐5	  levels	  when	  
MKL1	   and	   FLNA	  both	  were	   available.	   This	   is	   even	  more	   interesting,	   since	   one	  of	   integrins	  
major	   task	   as	   a	   cell	   surface	   receptor	   is	   the	  mediation	   of	   adhesive	   interactions.	   Therefore	  
integrins	   have	   recently	   been	   suggested	   crucial	   for	   invasive	   cell	   migration	   and	   tumor	  
progression	  (DeMali	  K.,	  Wannerberg	  K.	  et	  al,	  2003;	  Brakebusch	  C.,	  Fassler	  R.	  et	  al,	  2002).	  	  	  
The	  present	  chapter	  gives	  an	  example	  about	  the	  similar	  roles	  of	  MKL1	  and	  FLNA	  in	  the	  field	  
of	   cancer	   development	   and	   especially	   metastasis.	   They	   both	   display	   strong	   impacts	   on	  
motility,	   invasion	   and	  oncogenic	   target	   gene	   expression	  with	   their	   respective	   appearance.	  
We	   conclude	   that	   activation	   of	   MKL1/FLNA	   signaling	   in	   tumor	   cells	   provide	   oncogenic	  
properties,	   similar	   to	   the	   effect	   obtained	   from	   a	   fusion	   protein	   consisting	   of	   MKL1	   and	  
RBM15	   in	   megakaryoblastic	   leukemia	   cells	   (Mercher	   T.,	   Busson-­‐Le	   Coniat	  M.	   et	   al,	   2001;	  
Descot	   A.,	   Rex-­‐Haffner	   M.	   et	   al,	   2008):	   Constitutive	   nuclear	   localization	   combined	   with	  
strong	  induction	  of	  MKL1	  target	  genes,	  accompanied	  with	  tumor	  progression.	  	  
Around	   90%	   of	   all	   cancer	   deaths	   emerge	   from	   the	   metastatic	   spread	   of	   primary	   tumors	  
(Christofori	  G.,	  2006),	  but	  of	  all	  mechanisms	   involved	   in	  carcinogenesis,	  areal	   invasion	  and	  
metastasis	   formation	   are	   clinically	   most	   relevant,	   however	   sadly	   least	   understood.	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Expanding	   the	   current	   knowledge,	   we	   for	   the	   first	   time	   provide	   evidence	   that	   the	  MKL1-­‐
FLNA	   complex	   performs	   a	   symbiotic	   effect,	   which	   surpasses	   the	   one,	   each	   of	   the	   two	  
interaction	  partner	  showcases	  in	  singularity.	  This	  way,	  the	  MKL1-­‐FLNA	  complex	  might	  be	  an	  
extraordinary	   target	   for	   future	   pharmacotherapeutic	   approaches.	   A	   possible	   idea	   to	  
suppress	   the	  complex	  would	  be	  dummy	  binding	  agents	  which	  target	  aa	  301-­‐310	  on	  MKL1,	  
respectively	   repeat	   4	   or	   16	   on	   FLNA,	   thus	   inhibiting	   successfully	   complex	   formation.	   Our	  
experiments	   reveal	   a	   nuclear	   complex	   localization	   and	   it	   might	   be	   tempting	   to	   speculate	  
about	  reduced	  cancerogenic	  properties	  if	  the	  complex	  is	  relocated	  to	  the	  cytoplasm	  or	  drugs	  
even	  blocking	  a	  complex	  formation,	  thus	  modeling	  the	  MKL1	  pathway	  in	  a	  therapeutic	  way.	  
	  
7.5	  The	  many	  faces	  of	  MKL1	  and	  FLNA:	  Final	  thoughts	  and	  a	  link	  to	  
neuronal	  diseases	  
The	  present	  work	   showcases	  data	  of	   a	   novel	   complex,	   formed	  of	   two	  proteins,	  which	   are	  
both	  heavily	  involved	  in	  cellular	  motility	  procedures	  and	  target	  gene	  expression	  when	  active.	  
All	  carried	  out	  investigations,	  which	  resulted	  in	  a	  visible	  interaction,	  soaring	  levels	  of	  target	  
gene	  activation,	  reporter	  gene	  activity,	  cellular	  migration	  and	  invasion	  required	  a	  matching	  
high	  concentration	  of	  MKL1	  and	  FLNA.	  	  
This	   increased	  MKL1/SRF	  activity	  was	  not	  measurable	  under	  physiological	  conditions	   in	  un-­‐
stimulated	   3T3	   fibroblast	   cells,	   which	   led	   to	   our	   theory	   about	   complex	   formation	   under	  
pathophysiological	  conditions	  like	  in	  melanoma	  and	  hepatocellular	  carcinoma	  cells	  or	  during	  
wound	   healing,	   where	   strong	   MKL1-­‐dependent	   motility	   and	   overexpression	   of	   MKL1/SRF	  
target	   genes	   were	   detectable.	   This	   oncogenic	   potential	   of	   MKL1-­‐FLNA	   already	   being	  
discussed	  in	  detail,	  we	  now	  want	  to	  have	  a	  look	  at	  FLNA	  and	  MKL1	  mutations.	  
Consistent	  with	  our	  experiments	   stating	  a	   synergetic	   reduction	  of	  migratory	  courses	  when	  
MKL1	   and	   FLNA	   are	   both	   depleted,	   it	   is	   known	   that	   FLNA	   mutations	   prevent	   neuronal	  
migration	   during	   fetal	   development	   and	   cause	   human	   periventricular	   nodular	   heterotopia	  
(PVNH)	  due	  to	  FLNA	  depletion	  (Zhou	  A.,	  Hartwig	  J.	  et	  al,	  2010).	  Diversity	  and	  elasticity,	  which	  
is	   provided	   by	   FLNA	   as	   a	   gelation	   factor	   and	   orthogonal	   actin	   cross-­‐linker,	   is	   required	   for	  
modulating	   cell	   shape,	  which	   again	   is	   key	   for	   complex	  movement	   and	   crawling.	   In	   cortex	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development,	  most	  neurons	  essentially	  travel	  from	  the	  ventricular	  zone	  to	  the	  cortical	  plate.	  	  
FLNA	   is	   precisely	   regulated	   in	   the	   ventricular	   zone	   what	   appears	   to	   orchestra	   neuronal	  
migration	   (Yagi	   H.,	  Oka	   Y.	   et	   al,	   2016).	   FLNA	   on	   its	   own	   is	   conducted	   by	   FLNA-­‐interacting	  
protein	   (FILIP),	   which	   induces	   FLNA	   degradation	   thus	   clipping	   neurons	   in	   the	   ventricular	  
zone,	   preventing	   their	   journey	   and	   leading	   to	   abnormal	   appearance,	   which	   is	   the	   case	   in	  
PVNH.	  Clinical	  symptoms	  are	  epileptic	  seizures	  and	  vascular	  complications	  (Zhou	  A.,	  Hartwig	  
J.	  et	  al,	  2010).	  
Fascinatingly,	   MKL1	   respectively	   SRF	   mutations	   led	   to	   similar	   observations	   (Knöll	   B,	  
Nordheim	  A.,	  2009).	   SRF	  and	   its	   co-­‐activator	  MKL1	   regulate	  neuronal	   cell	  migration,	  guide	  
axons	   development,	   synapse	   function	   and	   last	   but	   not	   least,	   performance	   in	   learning	   and	  
memory.	  MKL1-­‐deletion	   resulted	   in	   aberrant	   brain	   development.	   In	   contrast	   to	   wild-­‐type	  
axons	   with	   multiple	   finger-­‐like	   filopodia	   structures	   consisting	   of	   bundled	   F-­‐actin,	   MKL1-­‐
deficient	  axons	  develop	  fewer	  filopodia	  (Knöll	  B,	  Nordheim	  A.,	  2009).	  	  
Similar	   to	   their	   potential	   as	   pharmacological	   targets	   in	   cancer	   treatment,	   neurological	  
disorders	   represent	   a	   field	   for	   therapeutic	   MKL1-­‐FLNA	   modulation.	   In	   contrast	   to	   cancer	  
treatment	  where	  complex	  formation	  blocking	  seems	  logical,	  MKL1	  or	  FLNA	  stimulation	  might	  
be	  the	  method	  of	  choice	   in	  this	  neuronal	  case,	  granting	  for	  example	  re-­‐growth	  of	   lesioned	  
axons.	  On	  the	  other	  hand,	  enhanced	  SRF	  and	  FLNA	  activity	  might	  also	  accelerate	  disease:	  in	  
Alzheimers	  disease,	  SRF	  led	  to	  speeded	  up	  progression	  of	  cerebral	  amyloid	  plagues	  (Bell	  R.,	  
et	  al,	  2009)	  and	  FLNA	  was	  identified	  as	  a	  requirement	  for	  amyloid	  toxic	  signaling	  (Wang	  H.,	  
Bakshi	   K.	   et	   al,	   2012).	   	   Furthermore	   our	   very	   own	   findings	   state	   that	  MKL1	   and	   FLNA	   in	  
advanced	   levels	  do	  push	   tumor	  metastasis.	   In	   conclusion,	   interfering	  with	  MKL1	  and	  FLNA	  
activity,	  in	  this	  case	  in	  brain	  pathology,	  might	  be	  a	  double-­‐edged	  sword,	  potentially	  resulting	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μg	   	   	   	   micro	  gram	  
μL	   	   	   	   micro	  Liter	  
μM	   	   	   	   micro	  Molar	  
aa	   	   	   	   amino	  acids	  
AB	   	   	   	   AntiBody	  
ABP	   	   	   	   Actin	  Binding	  Protein	  
AMKL	   	   	   	   Acute	  Mega	  Karyoblastic	  Leukemia	  
APS	   	   	   	   AmmoniumPeroxodiSulfate	  
bp	   	   	   	   base	  pairs	  
BRCA1/2	   	   	   BReast	  CAncer	  1/2	  
BSA	   	   	   	   Bovine	  Serum	  Albumin	  
cDNA	   	   	   	   copy	  DNA	  
CTGF	   	   	   	   Connective	  Tissue	  Growth	  Factor	  
DAPI	   	   	   	   4`,	  6-­‐DiAmindino-­‐2-­‐PhenylIndole	  
DLC1	   	   	   	   Deleted	  in	  Liver	  Cancer	  1	  
DMEM	  	   	   	   Dulbecco`s	  Modified	  Eagle	  Medium	  
DNA	   	   	   	   Deoxyribo	  Nucleic	  Acid	  
E.coli	   	   	   	   Escherichia	  coli	   	  
ECM	   	   	   	   ExtraCellular	  Matrix	  
ERK	   	   	   	   Extracellular	  signal-­‐Regulated	  Kinase	  
F-­‐actin	  	   	   	   Filamentous	  actin	  
FCS	   	   	   	   Fetal	  Calf	  Serum	  
FLNA	   	   	   	   FiLamiN	  A	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FOXC1	  	   	   	   FOrkhead	  boX	  C1	  
G-­‐actin	  	   	   	   Globular	  actin	  
GDP	   	   	   	   GuanosinDiPhosphat	  
GEF	   	   	   	   Guanosin	  Exchange	  Factor	  
GPCR	   	   	   	   G	  Protein-­‐Coupled	  Receptor	  
GTP	   	   	   	   GuanosinTriPhosphat	  
h	   	   	   	   hour(s)	  
HA	   	   	   	   HemAgglutine	  
HSP90	   	   	   	   Heat	  Shock	  Protein	  90	  
IB	   	   	   	   ImmunoBlot	  
IF	   	   	   	   ImmunoFluorescence	  
IP	   	   	   	   ImmunoPrecipitation	  
ITGA5	   	   	   	   InTeGrin	  Alpha	  5	  
kDa	   	   	   	   kilo	  Dalton	  
LPA	   	   	   	   LysoPhospatidic	  Acid	  
M	   	   	   	   Molar	  
mA	   	   	   	   milli	  Ampere	  
MEM	   	   	   	   Minimal	  essential	  Medium	  
mg	   	   	   	   milli	  gramm	  
min	   	   	   	   minute(s)	  
MKL1	  	   	   	   	   MegaKaryoblastic	  Leukemia	  protein1	  
MKL2	   	   	   	   MegaKaryoblastic	  Leukemia	  protein2	  
mL	   	   	   	   milliLiter	  
mm	   	   	   	   millimeter	  
mRNA	   	   	   	   messenger	  RNA	  
MRTF	   	   	   	   Myocardin-­‐Related	  Transcription	  Factor	  
NES	   	   	   	   Nuclear	  Export	  Signal	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nm	   	   	   	   nao	  meter	  
P-­‐MKL1	   	   	   phosphorylated	  MKL1	  
PAGE	   	   	   	   PolyAcrylamide	  Gel	  Electrophoresis	  
PBS	   	   	   	   Phosphate	  Buffered	  Saline	  
PCR	   	   	   	   Polymerase	  Chain	  Reaction	  
PI	   	   	   	   complete	  Protease	  Inhibitor	  cocktail	  
PVDF	   	   	   	   PolyVinyliDene	  Fluoride	  
RNA	  	   	   	   	   RiboNucleic	  Acid	  
rpm	   	   	   	   rounds	  per	  minute	  
RT	   	   	   	   Room	  Temperature	  
RT-­‐PCR	  	   	   	   Real-­‐Time	  Polymerase	  Chain	  Reaction	  
s	   	   	   	   seconds	  
SDS	   	   	   	   Sodium	  Dodecyl	  Sulfate	  
siRNA	   	   	   	   small-­‐interfering	  RiboNucleic	  Acid	  
SRE	   	   	   	   Serum	  Response	  Element	  
SRF	   	   	   	   Serum	  Response	  Factor	  
TBST	   	   	   	   Tris-­‐Buffered	  Saline	  Tween	  20	  
TCF	   	   	   	   Ternary	  Complex	  Factors	  
TEMED	  	   	   	   TEtraMethylEthylethyleneDiamine	  
TRIS	   	   	   	   TRIS(hyrdoxymethyl)aminomethane	  
WT	   	   	   	   WildType	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